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Chapter 1 
 
Multivalency and the glycoside cluster effect 
 2 
1.1 General aspects of multivalency 
 
In order to enhance the binding efficiency and selectivity of the designed ligands, chemists usually 
try to optimise the complementary matching (in terms of size and nature of binding forces) between 
the interacting species. However, quite recently they started to take advantage of a new powerful 
concept, multivalency, which is the ability of a particle (or molecule) to bind another particle (or  
molecule) via multiple simultaneous noncovalent interactions (Fig. 1). 
 
Fig. 1 Example of monovalent vs multivalent complexes. Taken from ref. 1 
 
 The valency is therefore the number of ligating functionalities of the same or similar types 
connected to each of these entities. Multivalent interactions usually result in high specificity and 
thermodynamic and kinetic stability (much higher than those arising from a simple monovalent 
interaction). Nature exploits multivalency to convert relatively weak interactions (e.g. carbohydrate-
protein interactions) into strong and specific recognition events. In the biomimetic approach to Drug 
Design, multivalency has also been exploited to successfully obtain inhibitors of some of these 
pathogens, allowing to develop therapeutic agents able to neutralise bacterial toxins or to prevent 
viral or bacterial infections. In the last decade, also Supramolecular Chemistry became more and 
more interested in applying the multivalency concept to the recognition of biological important 
molecules and to nanotechnology. Multivalency, in fact, has different and attractive features 
common to the supramolecular concept of self-assembly, such as reversibility, self-sorting and self-
repairing and the possibility to reach high thermodynamic and kinetic stability.2 Virtually any of the 
noncovalent interactions can be used to form multivalent complexes. Moreover, supramolecular 
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systems, sometimes simpler than the natural ones, can help the understanding and quantitative 
description of the multivalent effect.3 A multivalent ligand (Fig. 2) consists of a main core, called 
scaffold, bearing several covalent connections, linkers or spacers, to the peripheral ligating 
(binding) units.  
 
Fig. 2 Different topologies of multivalent ligands. a) 1-D linear arrangement, b) 2-D cyclic/macrocyclic; c) 3-D cavity 
containing scaffolds (cyclodextrins/calixarenes); d) polymers/peptoids; e) nanoparticles/dendrimers/liposomes; f) 2-D 
self-assembled monolayers (SAM) on Au/quartz. Taken from ref. 1 
 
Any multivalent scaffold can in principle be used, from those having low valency such as benzene 
derivatives, monosaccharides, transition metal complexes, azamacrocycles, cyclodextrins or 
calixarenes (Fig. 2a-c) to high valency ones such as dendrimers, polymers, peptoids, proteins, 
micelles, liposomes, and self-assembled monolayers (SAMs) on nanoparticles or plane surfaces 
(Fig. 2d-f).  
Often, the concept of cooperativity, generally intended as the influence of the binding of one ligand 
on the receptor’s affinity toward further binding, is associated with multivalency14. However, as 
elegantly pointed out by Ercolani,4 cooperativity in multivalent systems is extremely scarce. 
Moreover, although cooperativity can be easily and rigorously assessed by using Hill or Scatchard 
plots for the binding of monovalent ligands to a multivalent receptor (the most famous case being 
the binding of four O2 molecules to tetrameric haemoglobin), much more difficult is to prove its 
existence when a multivalent ligand interacts with a multivalent receptor.  
In general, to describe multivalent binding, an approach based on the additivity of the free 
energies5,6 can be used. The standard binding free energy for multivalent binding ΔG°multi is 
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ΔG°multi = nΔG°mono + ΔG°interaction 
where ΔG°mono is the standard binding free energy of the corresponding monovalent interaction, n is 
the valency of the complex and ΔG°interaction is the balance between favourable and unfavourable 
effects of tethering. 
A rather qualitative but often useful parameter, β, has been introduced by Whitesides et al.,14 as  
β = Kmulti/Kmono, 
where Kmulti and Kmono are the association constants for the multivalent and monovalent complexes, 
respectively. The parameter β, named enhancement factor, has been often used in the literature to 
compare the efficiency of ligands having different topology and/or valency: molecules with high β 
values are efficient ligands/inhibitors. Sometimes, if the valency n of the complex is know, this 
enhancement factor can be normalised to n, giving rise to the parameter β/n. Similarly a relative 
potency (r.p.) has been defined as IC50multi/IC50mono which is often also normalised to the valency n 
giving rise to r.p./n, relative potency per  ligating unit.  
More rigorous approaches have been proposed to quantitatively describe the multivalent binding 
process. Kitov and Bundle,6 for instance, developed a model where the standard free energy of 
multivalent interaction, ΔG°avidity, is a function of three terms ΔG°inter, ΔG°intra (binding free energies 
for the first intermolecular and the second intramolecular process, respectively, see Fig. 3) and a 
statistical term ΔS°avidity, namely avidity entropy, calculated on the basis of the topology of the 
complex. The avidity entropy can grow rapidly with the valency of the complex, always favouring 
binding, which explains why multivalency can overcome the loss of conformational entropy. By a 
nonlinear fitting of the measured binding energies for a series of multivalent ligands, ΔG°inter and 
ΔG°intra can be determined, thus allowing to design and maximise the avidity of multivalent ligands.  
 
Fig. 3 Intermolecular and intramolecular processes for the formation of a multivalent complex or of an intermolecular 
aggregate. Taken from ref. 1 
 
Very important is also the choice of the spacer which links the scaffold to the ligating units. It 
should be of the proper length to allow the simultaneous binding of all the ligating groups, without 
generating enthalphic unfavourable strains (enthalpically diminished binding). 
Finally, the kinetics of multivalent interactions is usually characterised by a step-wise dissociation 
pathway having extremely low dissociation rates. This also explains why the use of very high 
concentration of monovalent competing species is necessary to avoid rebinding of the partially 
dissociated multivalent complex. 
 
1.1. Glycobiology and the glycoside cluster effect 
 
Glycobiology7 is an interdisciplinary science, crossing the fields of chemistry, biology and 
medicine studying all the aspects of the structure, biosynthesis and functions of glycans widely 
distributed in nature. A very broad spectrum of functions have been revealed to glycans, besides the 
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mount importance in glycobiology. 
well-known, energetic and structural role they have. In fact, it is now clear that carbohydrates are 
involved in many important cellular processes regarding interactions with different chemical or 
biological species as, for example, viruses, bacteria, proteins, nucleic acids, hormones and other 
cells (Fig. 4).8 In almost all such processes a carbohydrate ligand usually binds to a protein 
receptor.9,10 Therefore there is an increasing interest in the synthesis of new neoglycoconjugates or 
high affinity mimics of native saccharides which could interfere in these processes; such 
compounds have potential therapeutic value in the treatment of viral, parasitic, mycoplasmal and 
bacterial infections, and of a wide range of human tumours. The study and understanding of 
protein–carbohydrate interactions, is therefore of para
 
Fig. 4. Adapted from F. Stoddart’s web page 
http://www.chem.ucla.edu/dept/Faculty/stoddart/research/multivalency.htm 
 
A reason for the difficulty in understanding completely the role of carbohydrates in all the 
physiological and pathological events of cell communication and trafficking lies in the structural 
complexity of oligosaccharides. While the other two classes of biopolymer, nucleic acids and 
proteins, have a linear arrangement of repeating units, carbohydrate building blocks have multiple 
points of attachment, leading to highly branched and stereochemically differentiated structures.11 
This structural complexity is further increased by post–synthetic modifications: hydroxyl groups 
can be sulphated, phosphorylated, acetylated, or oxidized to generate distinct biological activities4. 
All these elaborations of the sugars especially on the cell surface will equip the cells with a peculiar 
set of epitopes like a signature, distinguishing cell types from another. The mapping of the glycan 
profiles will at least provide an insight into the cell’s individual activity pattern of the enzymatic 
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machinery for the production of words in the sugar code (glycocode)11,12. In analogy to genomics 
and proteomics this work to map glycan determinants has been named glycomics13. 
A second difficulty in studying carbohydrate-protein interactions is that binding affinities are weak, 
with dissociation constants  in the milli-micromolar range;9 however, the efficiency and selectivity 
of the in vivo control of events mediated by protein–carbohydrate binding requires significantly 
greater affinity. Nature overcomes this limitation by combining multiple simultaneous interactions 
between two or more carbohydrates of the glycoproteins organised in domains on the cell surface - 
“glycocalix” - and a corresponding multimeric protein (Fig. 4). This particular type of multivalent 
effect14 has been also named “glycoside cluster effect”.9,15 These multivalent interactions have 
several mechanistic and functional advantages over their monovalent counterparts, the most 
relevant one probably being the ability to increase the specificity of binding.  
 
1.3 The carbohydrate binding proteins: the lectins 
 
There are several examples in nature of proteins which noncovalently interact with carbohydrates: 
the carbohydrate binding proteins (CBP). Important examples are carbohydrate-specific enzymes 
and anti-carbohydrate antibodies. However, recently, another class of such proteins, the 
lectins,10,16,17 raised the interest of many bio-organic research groups. Lectins, in fact, bind mono- 
and oligosaccharides reversibly and with high specificity, but are devoid of catalytic activity, and in 
contrast to antibodies, are not the products of an immune response. Lectins contain typically two or 
more carbohydrate-combining sites and therefore bind to cell membrane oligosaccharide by 
exploiting the multivalent effect. When reacting with cells, for example erythrocytes, they bind not 
only the sugars of a single cell, but eventually cause  cross-linking of the cells and their subsequent 
precipitation, a phenomenon referred to as cell agglutination. Lectins also form cross-links between 
polysaccharide or glycoprotein molecules in solution and induce their precipitation. Both the 
agglutination and precipitation reactions of lectins are inhibited by the sugar ligands for which the 
lectins are specific. Lectins are found in most organisms, ranging from viruses and bacteria to plants 
and animals. They represent a heterogeneous group of oligomeric proteins that vary widely in size, 
structure, molecular organization, as well as in the constitution of their combining sites. Although 
lectins were first described at the beginning of the 20th century, their started to catch remarkable 
attention in the 1960s, when it was demonstrated their role on cell surfaces during physiological and 
pathological processes, from cell differentiation to cancer.18 The study of lectins and their role in 
cell recognition processes, as well as the application of these proteins for the study of carbohydrates 
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in solution and on cell surfaces, are giving important contributions to the advancement of 
glycobiology.19  
Lectins are divided, according to their origin, in microbial, plant or animal16 lectins. Initially they 
were classified, into five groups, depending on the specificity to the monosaccharide for which they 
exhibit the highest affinity:  
i). D-mannose,  
ii). D-galactose/N-acetyl-D-galactosamine,  
iii). N-acetyl-D-glucosamine,  
iv). L-fucose,  
v). N-acetylneuraminic acid. 
Relevant for the biological activities of lectins is the fact that of the numerous monosaccharides 
found in nature, only those listed above are typical constituents of surfaces of eukaryotic cells. 
The classification of lectins according to their monosaccharide specificity, however, masks the fact 
that they often exhibit an exquisite specificity for di-, tri-, and tetrasaccharides (with association 
constants up to 1000-fold higher as compared with the monosaccharide) and that certain lectins 
interact only with oligosaccharides. Moreover, lectins of the same specificity group may differ 
markedly in their affinities for different oligosaccharides. From the functional point of view, 
binding of oligosaccharides is of special significance since, as mentioned earlier, they are most 
likely the natural ligands of lectins. 
However, also thanks to the high-resolution X-ray crystallography of lectins and their complex with 
carbohydrates it was possible to identify the carbohydrate recognition domain (CRD): therefore, the 
more accepted current classification of lectins is based on the homology of their CRD and they are 
divided in C-type, I-type, S-type, P-type, pentraxins, wild-type and so on.. 
C-type lectins are, for example, calcium dependent lectins while I-type show an immunoglobulin-
like CRD.  
Animal lectins can be divided, according to the classification reported in Table 1, into 5 different 
families.  Very important animal lectins are the galectins. They  share a cation-independent binding 
capacity to β-galactosides and show the conservation of a series of amino acid residues with 
relevance for the topology of the CRD. The former designation S-type lectins should be abandoned 
due to a lack of precision. Members of other lectin families are also soluble without addition of 
detergent and Cys residues (sulfhydryl groups) are not essential for the activity of several galectins, 
as shown by site-directed mutagenesis and the natural occurrence of galectins without a Cys 
residue.16 
 
 Family 
 
Structural motif 
 
Carbohydrate ligand 
C-type CRD conserved variable (mannose, galactose, fucose, 
heparin tetrasaccharide) 
I-type immunoglobulin-like CRD variable (Man,GlcNAc,, HNK-1 epitope, 
hyaluronic acid, a2,3/a2,6-sialyllactose) 
Galectins (S-type) CRD conserved β-galactoside 
Pentraxine pentameric subunit 
arrangement 
4,6-cyclic acetal of β-galactose, galactose, 
sulfated and phosphorylated 
monosaccharides 
P-type CRD conserved mannose-6-phosphate-containing 
glycoproteins 
 
Table 1. Current categories for classification of various animal lectins. 
 
Immunohistochemical fingerprinting had revealed, among galectin three subgroups (Fig. 5), that is, 
homodimeric proto-type (Gal-1), chimera-type (Gal-3), and tandem-repeat-type (Gal-4) proteins,  
an unfavourable relationship of galectin expression to prognosis in several tumor systems, for 
example in colon cancer for galectin-1, galectin-3, and galectin-4.20 
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Gal-3 
Gal-1 
Gal-4 
Fig. 5: The three different topologies of galectins: Gal-1 is binding to a membrane glycoprotein. 
1.4 Inhition of biological processes by polyglycosylated ligands 
 
This discovery of functional lectin–carbohydrate interactions and the possibility to inhibit them by 
using small polyglycosylated molecules offer enormous potential to the design of new drugs which 
could interfere with several pathological events (Fig. 6) such as intoxication by plant/bacterial 
toxins, viral and bacterial infections and tumor progression. 
  
 
Fig. 6: Examples of multivalent ligands and their potential uses  
 
If nature has circumvented the tight binding limitation through multivalency, it seems reasonable 
that multivalent ligands should bind with high affinity as well. On this basis many polyglycosylated 
molecules have been prepared and studied as multivalent ligands for a wide range of lectins. Most 
of these ligands show enhancements in activity compared to the corresponding monovalent ligand 
indicating that multivalency, i.e. the “glycoside cluster effect”, is involved. 
 
Several model systems have been developed to study multivalent carbohydrate-protein 
interactions.21 The low valency model systems present less than 20 carbohydrate ligands while the 
high valency model systems (glycoproteins, glycosylated monolayers/nanoparticles) possess a 
larger number (often hundreds) of carbohydrate ligands and will be not considered in this brief 
survey. 
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Model systems with low valency have been important for defining the geometric and structural 
requirements for tight binding to polyvalent receptors22. While these models are reasonably well 
defined and readily modified using synthetic organic chemistry, it is often necessary to prepare a 
large number of compounds in order to identify polyvalent ligands that achieve significant binding 
enhancements.23 Most of the polyvalent systems with low valency have been designed using 
detailed structural information of the carbohydrate binding protein. This approach, that is obviously 
limited to systems for which crystallographic or NMR structural data are available, significantly 
reduces the time required to develop a polyvalent system having ligands with the appropriate 
geometry and spacer length. Kiessling and co-workers24 generated a series of ligands, possessing 
structural diversity, to explore the effects of architecture on the inhibition and clustering of a model 
protein, the lectin concavalin A (Con A); the structural parameters that were varied include scaffold 
shape, size, valency, and density of binding elements. The authors found that ligands with certain 
architectures are effective inhibitors: specifically, high molecular weight, polydisperse polyvalent 
ligands are effective inhibitors for Con A binding, whereas linear oligomeric ligands have structural 
properties that favour clustering. The shape of a multivalent ligand also influences specific aspects 
of receptor clustering.  
In the following paragraphs few examples of multivalent synthetic ligand will be described,  
divided by type of scaffold used. 
Clusters. Glycoclusters represent a large group of model systems that present a low number of 
carbohydrate ligands on a small molecular template. These low valency model systems have been 
extremely important in determining the optimal binding geometries and ligand to ligand distances 
for a particular multivalent protein; the success or failure of a particular model system depends on 
the nature of the scaffold and the length of the tether between the scaffold and the carbohydrate. 
Generally the conformational flexibility and the ligand to ligand spacing in multivalent interactions 
are very important in this type of compounds; moreover it is very difficult to design the appropriate 
polyvalent ligand for a particular system. Concerning the importance of maximize the interactions 
between the receptor and the ligand it is important to project and design a molecule that 
incorporates structural information of the multiple target sites. Recently Fan25 prepared a 
pentavalent ligand  of Escherichia coli heat-labile enterotoxin (LT) by a modular structure-based 
design. In this modular approach, the large pentavalent ligand is divided into three modules to 
mimic the symmetrical arrangement of the five B-subunits of the LT: a semirigid “core”, a 
pentaazamacrocycle (15-N-5) that adopt a 5-fold symmetric structure and provides the basis for the 
generation of structural complementarity for the overall pentavalent ligand to LT, “linkers” of 
different length that project in the direction of the receptor binding sites, and “fingers” (galactose) 
that fit into the binding sites. The success of this design depends critically on the possibility to 
change the length of the ligand by assembling a different number of linker units (n in Fig. 7): the 
result is an IC50 value of 0.56 μM versus a value of 0.01 μM for the natural receptor. 
 
 
Fig. 7 Example of glycocluster for the inibition of pentameric lectins 
 
Bundle et al.26 recently prepared a decavalent sugar cluster for the inhibition of the binding of 
Shiga-like toxin, a member of the AB5 family of bacterial toxins; these toxins consist of five 
identical carbohydrate-binding subunits (B) arranged around a core subunit (A) in a star-like 
fashion. The authors used D-glucose as scaffold for the attachment of ligands (trisaccharide Gal – 
Gal – Glc) and varied the length of the spacer arm to achieve optimal binding. The most successful 
inhibitor, named STARFISH, had an IC50 of 4x10-10 mol/l. This value is comparable to the 
estimated affinity of the natural (monovalent) ganglioside (GB3) – toxin interaction (Kd = 10-9 
mol/l) and is 106 more potent than the single trisaccharide ligand (β ~ 106). 
 
Fig. 8: Polar and equatorial view of the crystal structure of the complex between STARFISH and the two B5 units of 
Shiga-like toxin. 
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The authors obtained a crystal structure of the toxin-inhibitor complex and found that each 
STARFISH ligand bound two toxin pentamers (Fig. 8). 
 
Cyclodextrins. Cyclodextrins are cyclic oligosaccharides containing α-(1,4)-linked glucopyranosyl 
units. These structures present a hydrophobic interior that is capable of binding small organic 
molecules and a hydrophilic exterior. Hydroxyl groups on the exterior of the cyclodextrins can be 
modified so that ligands are presented on a single face of the structure with control over ligand to 
ligand spacing. Although several synthetic methods for the preparation of glycosylated 
cyclodextrins have been reported27, few of these conjugates have been evaluated in terms of 
activity. Nishimura prepared a series of perglycosylated cyclodextrins and showed that a hexavalent 
N-acetylglucosamine conjugate inhibited the agglutination of human erytrocytes at a 240-fold lower 
concentration than its monomeric counterpart28. Defaye prepared a cyclodextrins derivatized with 
dendridic mannosides and showed that the hexavalent conjugate inhibited the binding of Con A to 
yeast mannan with an IC50 of 8 μmol/l, a 100-fold increase in potency over α-methyl mannoside29. 
Moreover, recently Mazzaglia and Darcy30 prepared some nano-aggregates of amphiphilic β-
cyclodextrins with alkylthio chains of differents length at the primary side and  glycosylthio-oligo-
(ethyleneglycol) units at the secondary side (Fig. 9).  
 
 
 
Fig. 9: Examples of perglycosylated amphiphilic cyclodextrins from ref. 30 
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These particular nanoparticles and vesicles targeted by galactosyl moieties showed multivalent 
effects in their binding to lectins.  
 
Calixarenes. Calix[n]renes31 (Fig. 10) are synthetic macrocycles derived from the condensation of 
phenol and formaldehyde.  
 
Fig. 10: General formulas of calix[n]arenes. 
 
The shape, size and conformational properties of these molecules can be fine-tuned by varying the 
procedures used for their synthesis. Calix[4]arenes can therefore be fixed in four different structures 
named cone, partial cone, 1,3-alternate and 1,2 alternate (Fig. 11) which show very different 
molecular recognition properties. Like cyclodextrins, these scaffolds are able to bind hydrophobic 
organic molecules and can be modified with carbohydrate ligands on one of the two rims of the 
molecule with control over ligand to ligand spacing. Calixarenes are particularly attractive as 
glycoconjugate scaffolds and the derivatives functionalized with carbohydrates at the upper or 
lower rim are named glycocalixarenes.1, 32 Furthermore, the calix[n]arenes blocked in the cone 
conformation can, to some extent, mimic a small portion of the cell surface presenting a series of 
glycosylated residues, projected all in the same direction, on the exterior of a lipophilic backbone 
(calixarene structure).  
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Fig. 11: The four limiting conformations of calix[4]arenes 
 
These glycoconjugates have attracted attention also because they can be potentially used also for 
site-directed drug delivery. Aoyama, for example, prepared a resorcarene presenting eight 
galactoside (Fig. 12a) and showed that this glycoconjugate can selectively deliver a fluorescent dye 
to the surface of rat hepatoma cells33. Ungaro and co-workers showed that the tetraglycosylureido 
calix[4]arene (Fig. 10b) is able to efficiently and selectively bind to Concavalin A and to complex 
small organic and anionic guest.34  
 
Fig. 12: a) Polyglycosylated resorcarenes and b) glycosylthioureidocalix[4]arenes. 
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The tetrasialosides35 and the corresponding tetra-N-acetylgalactosides36 synthesised by Roy and co-
workers, through the conjugation of sugar units to a spacer present at the lower rim of 
calix[4]arenes, are able to efficiently crosslink and agglutinate carbohydrate binding protein specific 
for the saccharides present on the macrocycle. Calix[4]- and calix[8]arene glycoclusters were also 
prepared by Consoli et al.. Glycocalixarenes exposing N-acetylglucosamine (GlcNAc) units were 
successfully tested as ligands of the wheat germ agglutin, a GlcNAc binding protein, and as 
inhibitors of agglutination of human erytrocytes.37 More recently, a divalent glycocalixarene (Fig. 
13) bearing two pseudo-GM1 sugar units at the upper rim showed a remarkable enhancement factor 
(β = 2000 per sugar units) in the binding of pentameric Cholera Toxin B5 (CTB5). The binding of 
the glycocalix to CTB5 (Kd = 48 nM) is even slightly better than that of the natural oligosaccharide 
GM1 (Kd = 219 nM).38 
 
Fig. 13: The GM1 oligosaccharide, its ps-GM1 mimic and a divalent glycocalixarene for CTB5 binding. 
 
A small library of calix[n]arenes bearing lactosylthioureido moieties at the upper rim and having 
different valency and conformation have been shown to strongly inhibit the adhesion of galectins to 
the oligosaccharide of tumor cells.39 Quite interestingly the inhibition depends not only on the 
valency of the glycoconjugate but also on its structure. The tetravalent calix[4]arene in the cone 
structure is selective for Gal3 while its stereoisomer in the 1,3-alternate conformation inhibits both 
Gal1 and Gal4.  
Dendrimers. At the borderline between systems with low valency and systems with high valency, 
one can find the dendrimer-based multivalent ligands. The term “dendrimer” derives from a greek 
word that means tree. In fact, dendrimers are macromolecular compounds that comprise a series of 
branches around an inner core just like in a tree40 (Fig. 14).  
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Fig. 14: Example of dendrimer 
 
Dendrimers can be synthesised utilising two different approaches: a) starting from the central core 
and building up the branches toward the periphery (divergent synthesis), or b) joining the preformed 
branches to the inner core (convergent synthesis). Dendrimers are largely used for the study of 
biological systems because of their size and their ease of preparation and functionalization. 
Dendrimers that incorporate carbohydrates into their structures are named “glycodendrimers” and 
can be divided into three main categories: a) glycodendrimers that simply have saccharide residues 
on their outer surface, b) glycodendrimers containing a sugar unit as the central core where all 
branches are attached, and c) glycodendrimers with carbohydrates constituting the branches. 
Bernardi and Pieters, have recently prepared a series of glycodendrimers based on the 3,5-di-(2-
aminoethoxy)-benzoic acid branching unit for inhibition of pentavalent cholera toxin41. The 
tetravalent compound was shown to be 440-fold more potent than its monovalent counterpart. More 
recently, it has been shown that the octavalent glycodendrimers of Fig. 15, bearing galactose42 units 
or GM1 oligosaccarides43 in the periphery, have spectacular relative potency (per sugar units) of 
2500 and 47500, respectively. 
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Fig. 15: The octavalent dendrimers bearing galactose or GM1 oligosaccharides at the periphery. 
 
Dendrimers bearing 8 or 16 sialic acid at the periphery  (Fig. 16a) as inhibitors of human 
erythrocyte hemagglutination by Influenza viruses have been recently designed and synthesised.44 
Stoddart and coworkers developed a series of dendrimers having from 3 to 36 α-mannose units as 
carbohydrates and found the most pronounced binding to Concanavalin A for the 9-mer and 18-
mer.45 Other interesting examples of glycodendrimers are those derived from polyamidoamine 
(PAMAM), that are constituted by a polyamide core (Fig. 16).46  
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a)  b)  
 
Fig. 16: Examples of glycosylated dendrimers bearing a) sialic acid and b) mannose units at the periphery 
 
An interesting self-assembling dendrimer has recently been developed by Thoma and co-workers, 
They have synthesize some glycodendrimers able to self-assemble into nanoparticles and thus 
behaving as polyvalent ligands47. If the self-assembly is a dynamic process, natural polyvalent 
receptor could serve as templates optimizing size and shape of their own polyvalent inhibitors. 
Generally, dendrimers are useful scaffolds for the design of polyvalent ligands for two reasons. 
First, they allow to obtain a valency between that of glycoclusters and model systems that present 
very large numbers of carbohydrates. Secondly, synthetic chemistry allows a wide flexibility in 
adjusting the valency, size and even shape of the molecule. However, despite this flexibility in 
design, they sometimes fail to display large enhancement factors in the binding to polyvalent 
proteins. Many authors reason that the poor binding enhancements observed reflect an incorrect 
spacing or geometry of the carbohydrates presented on these scaffolds.  
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2.1 Introduction 
 
Pseudomonas Aeruginosa (PA), a Gram-negative bacterium, is an opportunistic pathogen that 
causes a variety of diseases, including respiratory tract infections in patients suffering from cystic 
fibrosis. Cystic fibrosis (CF) is a genetic disease developed by mutations in the gene encoding the 
CF transmembrane conductance regulator (CFTR). CFTR regulates ion transporter across the lung 
epithelia, and patients with CF suffer impaired ion transport and a depletion of airway surface liquid 
volume. The poor lung hydration leads to the deterioration of lung hygiene as much secretions 
become refractory to mucociliary clearance. Despite the particularly physiotherapy and antibiotics, 
the median age for survival is about 37 years. The cystic fibrosis patients gets several combination 
of physiotheraphy, postural drainage and antibiotics, that help them to remove mucus from lungs, 
improve their ability to breathe, and treat chronic lung infections. Therapeutic treatment of 
Pseudomonas Aeruginosa bacteria is still very difficult because they exhibit high intrinsic resistance 
against a variety of different antibiotics. The vilurence is associated with their ability to adhere to 
host cell surface, to form a stable biofilms in the human lung and to secrete hydrolytic enzymes and 
toxic compounds. The P. aeruginosa covers the lipopolysaccharides (LPSs) that protect the cells 
thus avoiding the diffusion of antibiotics. The host polysaccharides act as specific targets for the 
pathogen binding and are involved in the establishment of infection. The bacterium host selectivity 
depends on the carbohydrate specificity of its lectins and adhesins, which is part of its virulence 
factors. Several virulence factors are produced by P. aeruginosa, among which the two lectins, 
LecA (PA-IL) and LecB (PA-IIL), that exert different cytotoxic effects on respiratory epithelial 
cells and are believed to be the mediators of biofilm formation in the airway mucosa. In cystic 
fibrosis patients, the bacteria exist mainly as biofilms, adopting an aerobic metabolism and 
encapsulating themselves in extracellular matrix, which protects them from different antibiotics1. 
Lectins (see also chapter 1) are specific carbohydrate-binding proteins different from enzymes and 
antibodies. They are found in a wide range of organisms as viruses, bacteria, plants and animals, 
and are believed to play an important role in cell-cell interactions. Lectins play also an important 
role in human infections. It was demonstrated that a P. aeruginosa-induced otitis externa diffusa as 
well as respiratory tract infections can be strongly depressed by application of a solution containing 
LecA and LecB-specific sugars which inhibit adhesion of these bacteria on the cell LPSs. 
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2.2 Biochemical properties of the Lectins PA-IL and PA-IIL 
 
The lectin PA-IL (51 kDa) is a multimeric protein composed of four subunits of 121 amino acids 
and binds D-galactose and its derivatives2. Lectin PA-IIL (47 kDa) which is also multimeric, is 
composed of four subunits of 114 amino acids and specifically binds L-fucose together with few 
other monosaccharides3. Both PA lectins were shown to be located mainly in the cytoplasm of 
planktonic cells4. After their purification from the planktonic cell extracts5, they behave as Ca++-
dependent tetrameric plant lectins, displaying haemagglutinating activity and relative resistance to 
heating, proteolysis and extreme pH. Biochemical studies also indicated the additional presence of 
Mg2+ ions in PA-IL and Mg2+ and Zn2+ ions in PA-IIL. These lectins were demonstrated to act 
directly in vitro and in vivo as cytotoxic compounds. When looking more particularly at respiratory 
epithelial cells, PA-IL was shown to be strongly cytotoxic for these cells. The PA-IL gene was 
isolated from P. aeruginosa ATCC 27853 genomic library6, whereas the PA-IIL gene was 
identified in the P. aeruginosa PAO1 genomic sequence thanks to the sequence of its 33 N-terminal 
amino acids3. The genes also referred to as lecA and lecB, are widely separated (about 867.5 kb) on 
the P. aeruginosa chromosome. Both mature proteins lack the initiator methionine and display 
acidic characters, but PA-IIL differs from PA-IL in lacking cysteine, methionine and histidine. 
 
2.3 Affinity and specifity in Carbohydrate binding of the P. aeruginosa lectins 
 
The PA-IL lectin has medium affinity for D-galactose with an association constant (Ka) of 3.4 x 104 
M-1 as reported from equilibrium dialysis study7. Among monosaccharides, the specificity is strictly 
for galactose, but there is also binding at lower affinity with N-acetyl-D-galactosamine. Affinity 
enhancements where observed when a hydrophobic group is present on the sugar anomeric position, 
either in α or β configuration and the tightest binding was obtained with phenyl- β-thiogalactoside8 
(see tab. 1). Among the disaccharides, only those containing a terminal α-D-galactose residue are 
recognised like αGal1-3Gal, αGal1-4Gal, and αGal1-6Gal that display the highest affinity for the 
lectin8,9. 
The PA-IL lectin binds several glycoproteins9 and glycosphingolipids8,10 amongst which the 
glycoconjugates with terminal non-substituted αGal1-4Gal disaccharide, i.e., the human P1 and Pk 
blood group antigens, present on either red blood cell glycosphingolipidis and αGal1-3Gal 
disaccharide, the human blood group antigen and the xeno-antigen present on non-human tissues.  
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Carbohydrate specificity of PA-IL and PA-IIL 
 
Table 1 Table selected from A. Imberty et al. Microbs and Infection 6 (2004) 221-228 
 
a Taken as reference value of 1.0 for an IC50 of 0.25 nM for inhibition of PA-IIL-binding to human group H and Leb active 
glycoprotein. 
b Taken as reference value of 1.0 for an IC50 of 40 nM for inhibition of PA-IL-binding to hydatid cyst glycoprotein. 
 
The lectin PA-IIL has high affinity for L-fucose with association constant (Ka)11 of 1.6 x 106 M-1 in 
the hemagglutination inhibition test. Among monosaccharides it shows the strongest affinity for p-
nitrophenyl-α-L-fucose, followed in order by L-fucose > L-galactose > D-arabinose > D-fructose > 
D-mannose while D-galactose is not bound significantly. 
The ability of different complex oligosaccharides to inhibit the binding of PA-IIL to human blood 
group H and to Leb active glycoprotein was also measured12. The Lea pentasaccharide and Lex 
trisaccharide (not shown in tab. 1) are the most potent inhibitors with 5 and 30 times higher activity 
than L-fucose respectively. These polysaccharides are isomeric structures that differ in the linkage 
of the galactose to the GlcNAc residue. It seems that the orientation of the GlcNAc N-acetyl group 
plays a major role in the binding.  
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2.4 Crystal structure of the PA-IL and PA-IIL lectins 
 
In the literature several examples of PA-IL crystal structures have been reported: the native lectin 
with one calcium ion per monomer13, the calcium-free lectin and the lectin with both calcium ion 
and bound galactose14.In all these cases the PA-IL has a quaternary structure with a tetramer 
arranged around a pseudo C222 axis of symmetry. 
 
A B 
  
 
Fig.1 PA-IL Picture from A. Imberty et al. Microbs and Infection 6 (2004) 221-228 
X-Ray crystal structure of PA-IL lectin with calcium ion in its (A) tetrameric and (B) monomeric arrangement. 
 
For the PA-IIL lectin there are two crystallographic studies12 15 the first one concerns the native 
lectin and the calcium-free protein, while the second study reports the X-ray crystal structure of the 
complexes with three different monosaccharides L-fucose, D-mannose, and D-fructopyranose. 
For PA-IIL a tetrameric association also occurs around a pseudo C222 axis of symmetry, resulting 
in a spherically formed quaternary structure (see fig. 2), like the PA-IL, but more compact. 
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A B 
  
 
Fig.2 PA-IIL Picture from A. Imberty et al. Microbs and Infection 6 (2004) 221-228 
 
X-Ray crystal structure of PA-IIL lectin with calcium ions in its (A) tetrameric and (B) monomeric arrangement. 
 
In both lectins the monosaccharide-binding is mediated by calcium ion. The sugar-binding site of 
PA-IL involves one calcium ion, whereas that of PA-IIL involves two calcium ions. In the complex 
between PA-IL and galactose14 one carbohydrate residue is inserted in each monomer, sitting on the 
calcium atom. The coordination sphere of the calcium ion directly involves the atoms O3 and O4 of 
the galactose (see Fig. 3). There are also six direct hydrogen bonds between the protein and the 
carbohydrate hydroxyl groups and there is one additional interaction mediated by a water molecule. 
Moreover, weak contacts between the apolar face of the galactose residue and some hydrophobic 
amino acid residues were observed. 
In the PA-IIL/fucose complex12 there is a peculiar situation since the fucose residue is locked on the 
two calcium ions. In the picture (Fig. 3) one can observe three hydroxyl groups of the fucose 
binding to those calcium ions indeed: O2 with the first calcium, O4 with the second one and O3 
with both of them. Besides these interactions, hydrogen bonds between three hydroxyl groups of the 
monosaccharide and carboxylic groups of the calcium-binding site can be observed. The pyranose 
oxygen of the fucose is involved in an hydrogen bond with the main peptide chain. In conclusion 
there are seven hydrogen bonds between the sugar and the protein with an additional hydrogen bond 
mediated by a water molecule. In position 6 of the fucose, the methyl group is important because it 
is located in a hydrophobic pocket of the lectin. In the literature, X-ray crystal structures of the PA-
IIL complexes with fructose and mannose15 have been also reported. The fructose in its D-
configuration uses a 2C5 chair conformation which is similar to the 1C4 chair of the L-fucose and has 
the same distribution of equatorial and axial hydroxyl groups. Considering that fructose binds the 
lectin using the same conformation of fucose but has no methyl group at the C6 position, the lower 
affinity to PA-IIL for fructose compared to fucose could be explained by the lacking of 
 30 
hydrophobic interactions. Mannose is different from fucose in its 4C1 chair conformation and in 
axial configuration at O2. Fucose and Mannose binds isosterically but adopt different orientations 
of their rings in the binding site, with O2, O3, and O4 of fucose being sterically equivalent to O4, 
O3 and O2 of mannose. 
 
                                              A                                                                            B 
 
 
Fig. 3 Picture from A. Imberty et al. Microbs and Infection 6 (2004) 221-228 
 
Binding sites of the X-ray crystal structures of PA-IL/galactose and PA-IIL/fucose complexes. 
 
(A) Stick representation of the amino acids involved in binding. Ca2+ coordination bonds are shown as solid orange 
lines; hydrogen bonds as dashed green lines. Colour coding: red, oxygen; blue, nitrogen; black, carbon; pink, Ca2+. (B) 
Electrostatic surface representation ( colour-coding from violet for negative to orange for positive) of the protein-
binding site, with Ca2+ as large magenta spheres and monosaccharides as stick models. 
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2.5 Roles of PA-IL and PA-IIL in infection 
 
Today, the exact biological roles of the two Pseudomonas Aeruginosa lectins have not yet been 
completely understood, but hypotheses have been considered. It is sure that PA-IL and PA-IIL are 
two lectins which bind specific glycans and that display multivalent effects. Most of their activity is 
stored intracellularly, although small but significant fractions are present on the cytoplasmic 
membrane, on the outer membrane and in periplasmic space16. The higher intracellular activities of 
the lectins are only released from the bacteria following their lysis. The distribution may change, in 
fact recent studies have reported that the PA-IIL is present in higher amount on the bacterial outer 
membrane15. These protein are therefore very important, because they play an important role in the 
interaction of the bacteria with the environment.  
The cell surface of the intact bacteria was shown to strongly agglutinate human erythrocytes and 
therefore may be involved in the bacterial adhesion to host cells16. It has been demonstrated that 
these lectins could have a role also in inducing agglutination of other bacteria or uni- and 
oligocellular eukaryotic organisms6. 
The role of bacterial-lectin interactions with host glycans is well established in symbiosis and 
pathogenicity17. The Pseudomonas Aeruginosa is a saprophytic bacterium which can become an 
aggressive pathogen if in contact with damaged and inflamed tissues like burn wounds and lungs of 
cystic fibrosis patients because in these cases the host cell surfaces present altered glycosylations. In 
several studies of the CF the important point is the mutations in the cystic fibrosis transmembrane 
conductance regulator (CFTR) gene which results in altered ion movements and also influences the 
N-glycosylation of the CFTR protein and other cell surface glycoproteins. The fucosylation 
increase, the sialylation decrease with higher levels of Lewisx and Lewisa epitopes were 
demonstrated to correlate with PA specific binding18. In addition, both the mucus (with mainly 
mucins, glycoproteins containing 70-80 % carbohydrates) covering the airway epithelia of CF 
patients and their salivary mucins that show higher levels of sialylated and sulphated Lewis x 
oligosaccharides19, attract P. Aeruginosa20. One can correlate these data with the biochemical and 
modelling studies and prove that PA-IIL has high affinity for oligosaccharides of the Lewis series12. 
The studies on the crystal structure, and on the biochemical properties of PA-IL and PA-IIL, 
together with the discover of their high affinity ligands opened the way to design new carbohydrate 
compounds for an efficient inhibition of bacterial adhesion and biofilm formation derived from 
Pseudomonas Aeruginosa infection. 
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2.6 Glycopeptide dendrimer libraries for lectin P.A. inhibition 
 
One of the main pharmaceutical strategies aimed at avoiding PA infection and removing or 
reducing the formation of biofilms originating from these bacterial strain is to find efficient 
inhibitors of PA-IL and PA-IIL. For this purpose, multivalent ligands (see chapter 1) have already 
demonstrated to be superior Different multivalent inhibitors based on the multiple display of 
glycosides, in particularly mannose and galactose21, and having a scaffold based on dendrimers22, 
oligosaccharides23, or glycopeptides24 are known. Moreover in the literature, no synthetic 
multivalent ligands were reported for fucose-specific lectins. Among all the different multivalent 
scaffold which can be used, dendrimers have been deeply studied. The field of dendrimer25 
chemistry has undergone a rapid development and has evolved from the discovery and the 
establishment of efficient synthetic procedures to the characterization of dendrimer properties and 
the design of functional dendrimers26. Also combinatorial chemistry has recently developed very 
rapidly with the aim at discovering synthetic compounds useful in biomedical applications where 
combinatorial chemistry was used. The Reymond’s group recently linked combinatorial to 
dendrimer chemistry and reported the synthesis of peptide dendrimer27 combinatorial libraries28 
together with their use in the discovery of synthetic enzyme models and in drug delivery29. The use 
of neoglycopeptide dendrimer combinatorial libraries was also applied to the discovery of lectin 
inhibitors30. 
In particular this method was exemplified by the selection of a strong ligand for fucose-specific 
lectins UEA-I from the plant Ulex europeaeus31 and for PA-IIL. The advantage of using of peptide 
dendrimer libraries is two-fold. First solid phase peptide synthesis (SPPS) can be used, ensuring 
high yields and purity of the products; moreover, identification of the most active members of the 
library can be easily obtained simply by sequencing its amino acids and without the use of any tag. 
Solid phase peptide synthesis was therefore used to prepare a library of peptide dendrimer 
containing alternating α-amino acids with the branching diamino acids (Lys). At the end of the 
peptide synthesis, L-fucose units were conjugated to the four terminal amino groups thus obtaining 
tetravalent glycopeptides dendrimers of up to 37 amino acids in 11 coupling steps (scheme 1). 
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Scheme 1 Combinatorial Library of Neoglycopeptide Dendrimer (56 = 15 625 sequence) 
 
Picture from Org. Lett., vol. 9, No. 8, 2007 
 
For the synthesis of the solid supported combinatorial libraries the “split-and-mix” metod32was used 
, which allows the simultaneous preparation of a large number of compounds in very few steps33. 
This synthesis is carried out on a solid phase support consisting of millions of microscopic beads, 
and results in the so-called one-bead-one-compound (OBOC) libraries in which each of the beads 
carries only one of the possible compounds. 
A large library (15 625-member) with a second-generation dendrimer was prepared on tentagel 
beads (0.5 g, 0.30 mmol/g diameter bead of 90 µm). Each dendrimer was funcionalized at the N-
terminus with L-fucose. The combinatorial library was carried out with amino acids placed in six 
variable positions to allow positive, negative, hydrophobic, small and polar or aromatic residues 
during all the sequence (Scheme 2). Each dendrimer was checked by amino acid analysis of 
randomly selected beads, providing the expected statistical distribution of amino acids at the 
variable positions. 
The library was assayed for binding to biotinylated UEA-I lectin and stained with an alkaline-
phosphatase-conjugated antibiotin antibody and 5-bromo-4-chloro-3-indolyl phosphate/ nitro blue 
tetrazolium (BCIP/NBT) as a chromogenic substrate as described for a related on-bead assay for 
wheatgerm hemaglutinin34. While the N-acetylated control library gave less than 1% of stained 
beads in the assay, over 90% of the beads in the fucosylated library were darkly stained. Addition of 
3 M fucose during the lectin binding step reduced staining to less than 2% of the beads. Darkly 
stained beads were manually picked, and their sequence was determined by amino acid analysis. A 
strong consensus for positively charged lysines at the terminal positions X6 and at position X2 was 
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observed and therefore the eight dendrimers of Table 2 were independently synthesised by SPPS, 
fucosylated and cleaved from the resin. 
 
 
 
Scheme 2 Combinatorial Library of Neoglycopeptide Dendrimer (56 = 15 625 sequence) 
 
Picture from Org. Lett., vol. 9, No. 8, 2007 
 
Dendrimer X6 X5 X4 X3 X2 X1 
FD1 Lys His Val His Gly Ala 
FD2 Lys Pro Leu Phe Lys Ile 
FD3 Lys His Leu Glu Lys Ile 
FD4 Lys Arg Asp Ser Arg Ala 
FD5 Lys Thr Ile Ser Arg Leu 
FD6 Lys Thr Leu His Lys Ala 
FD7 Lys Ala Ile His Lys Thr 
FD8 Lys Thr Val Ser Arg Ile 
 
Table 2 Sequences from the Dendrimer Combinatorial Library 
 
Every dendrimer from the library were tested in lectin binding by enzyme-linked lectin assay 
(ELLA) as described in literature35. This test measures the competition between the ligand and a 
biotinylated polymeric fucose reagent in the binding with the lectin. This test has identified the FD2 
dendrimer as the most potent (Tab. 3) ligand with an IC50 = 11 µM and a relative potency of 115 in 
reference to L-fucose. The other three dendrimers (FD1, FD3, and FD4) showed relative potencies 
in the range 20-40, which is similar on a per residue basis to the α-C-allyl fucoside (5). 
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To study the role played by the dendrimeric structure in these multivalent ligands, the terminal arm 
2G0 and the outer branch 2G1 (Fig 4) were also synthesized and tested. A gradual increase in 
relative potency per fucose unit was observed in the series 2G0 (r.p./n. = 4) → 2G1 (r.p./n. = 11) → 
FD2 (r.p /n. = 29). 
 
NH2
Fuc
Fuc
Fuc
Fuc
Fuc
(2G0)
Fuc
Fuc
(2G1)(FD2)
O
OH
OH
OH
OH
(1)
O
OH
OH
OH
(5)
FD2 = (Fuc-Lys-Pro-Leu)4-(Lys-Phe-Lys-Ile)2-Lys-His-Ile-NH2
2G1 = (Fuc-Lys-Pro-Leu)2-Lys-Phe-Lys-Ile-NH2
2G0 = Fuc-Lys-Pro-Leu-NH2  
 
Fig. 4 Structures of glycopeptide dendrimers FD2 and lower-generation analogues 2G1 and 2G0 
 
No. IC50 (µM) r. p.a nb r. p./nc 
1 1265±5 1 1 1 
5 261±13 5 1 5 
FD1 67±4 19 4 5 
FD2 11±0.35 115 4 29 
FD3 72±9 18 4 4 
FD4 31.5±9 40 4 10 
2G0 290±40 4 1 4 
2G1 56±6 23 2 11 
 
Tab. 3 IC50 in ELLA test against UEA-I lectin 
 
a r.p. = relative potency to fucose IC50 (fucose)/IC50 (ligand). b n = number of fucosyl units per dendrimer. c Relative 
potency per fucose residue.  
 
The high potency observed for the FD2 dendrimer seems therefore be due to the multivalent effect, 
while there is almost no increase in the r.p./n. values for  the other tetravalent dendrimers FD1, 
FD3, and FD4. The strong affinity of FD2 toward UEA-I is therefore deeply dependent on its 
structure and amino acid sequence. Besides the multivalent presentation of fucosyl units, FD2 
probably gives rise also to attractive secondary interactions of its peptide backbone with the lectins. 
In fact there could possibly be electrostatic interactions between the 6-fold positively charged 
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dendrimer and the negatively charges found close to the fucose binding site in UEA-I which can 
improve the binding. Also inhibition lectin PA-IIL test with FD2 gave a high result of IC50 of 
0.14±0.035µM that corresponds to a 80 fold relative potency. As for UEA-I, also in PA-IIL 
negatively charged residues are found close to the fucose binding site36. 
 
2.7 Synthesis of new fucosylated peptide dendrimers with high proteolytic stability 
 
Results obtained by the library of dendrimers have shown that the best inhibitor of PA-IIL are 
tetravalent dendrimers featuring positively charged amino acids (Lys) at the outer layers having a 
terminal C-fucoside residue mediating the binding to the lectin. The aim of my project, carried out 
during a six-months leave at the University of Berne in the group of Prof. J. L. Reymond, was to 
developed peptide dendrimers showing high proteolytic stability. In fact, in order to study and use 
the fucosylated peptide dendrimers in in vivo applications, a high stability to enzyme is to be seek. 
All the peptide dendrimers previously synthesized in Berne were based on L-amino acids and 
therefore, theoretically highly unstable in the presence of proteolytic enzymes. Given the structure 
of the most potent L-amino acid base peptide dendrimer FD2 we have planned to synthesize its 
counterpart based on D-amino acids which, being not recognised by natural proteases, should be 
much more stable. Therefore during my stay in Berne I resynthesized the FD2 L-dendrimer, named 
Ile-GAR- L, a related L-dendrimer but having a L-Leu as the first amino acid, and therefore named 
Leu-GAR-L (see Fig. 4) and the D-dendrimer, Leu-GAR- D, having only as branching L-Lys and 
all D-amino acids instead of L-amino acids. Therefore, my research work in Berne started with the 
synthesis of C-fucosyl-acetic acid building block from L-fucose via the known C-allyl fucoside 3 
(see scheme 3). A C-fucosyl derivative was chosen instead of an O-fucosyl one since the latter are 
know to be easily cleaved by glycosidases. 
The C-fucosyl-acetic acid (4) group was obtained by L-fucose (1) in a three steps procedure as 
reported in literature (Scheme 1)37. L-fucose (1) was acetylated with acetic anhydride in pyridine to 
give 2 in quantitative yield. In this step the complete removal of the toxic pyridine, which is used as 
solvent, was obtained performing several washes of the organic phase with a saturated aqueous 
solution of copper sulphate. This salt forms a water soluble complex with pyridine which is dark 
blue. So the organic phase was washed with the CuSO4 aqueous solution until the colour of the 
water layer becomes light blue. After evaporation of the solvent, compound 2 was obtained pure 
without further purification. The peracetylated L-fucose (2) was subsequently alkylated in the 
anomeric position with allyl trimethyl silane, boron trifluoride and trimethyl silyl triflate. In this 
step two parameters are very important: the time of the reaction which must be sufficiently long to 
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ensure a complete conversion and the temperature that needs to be maintained between 0 and -18° 
C for all the time of the reaction. In this way we could obtain only the α-allyl compound pure. The 
final step was the conversion of the allyl group of 3 in the corresponding acetic acid moiety. The 
reaction was performed at room temperature in aqueous mixture of CCl4 and acetonitrile with 
ruthenium(III) chloride and sodium meta periodate under vigorous stirring. After work-up and 
trituration of the crude product with ethyl ether very pure compound 4 was obtained and used 
without further purification. The C-fucosyl-acetic acid was therefore synthesized from L-fucose in 
84% overall yield. 
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rt, overnight
(a) (b)
(a) 1) (CH3)3SiCH2CH=CH2  0°C, 5 min. 2) BF3-OEt2 TMSOTf  0°C 5h, -18°C overnight, 0°C 5h, CH3CN dry
(b) NaIO4  RuCl3, CCl4/CH3CN/H2O overnight
O
OAc
OAc
OAc
OH
O
O
OAc
OAc
OAc
O
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OH
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Scheme 3 Synthesis of C-fucosyl acetic acid 4 
 
The dendrimer synthesis was performed through the Solid Phase Peptide Synthesis (SPPS) manual 
procedure, in plastic syringes. Nova Syn TGS RAM resin was used as solid support.(scheme 4) The 
F-moc protected resin (see scheme 5), after swelling with dichlorometane, was deprotected with a 
solution of piperidine/DMF 20/80 (a scheme 4). The deprotection was checked with 
Trinitrobenzenesulfonic Acid (TNBS) (b scheme 4) which is a reagent used in qualitative tests for 
free amine. In fact, one can see at the microscope the beads red coloured if the amine is free and 
colourless when the amine is still protected. 
The resin was then coupled with the amino acid using PyBOP and di-isopropyl-ethylamine (DIEA) 
(c). Generally, in the synthesis of first generation dendrimers the reaction time is 1 h and 30 min, 
but one needs 3 h reaction time after the first generation. After each coupling the resin was checked 
again with the TNBS test. If the TNBS test indicated the presence of some free amino groups, the 
coupling was repeated. In any case after each coupling, the remaining free amino groups were 
capped with acetic anhydride/CH2Cl2 (c1). The Fmoc protecting groups of each amino acid were 
then removed with a solution of 20% piperidine in DMF and steps (c) and (c1) repeated until the 
desired peptide structure was obtained. At the end of the sequence the resin was coupled with 
fucose 4 in the presence of DIEA and HCTU (d) overnight. In this step a large excess of 
carbohydrate was used and the coupling was repeated two more times. It was observed that 
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conjugation of the sugar is hard to be quantitative and often dendrimer minus one fucose unit were 
obtained. The glycodendrimer was then deacetylated using a solution of MeOH/NH4/H2O (v/v 
8:1:1) for 24 h for two times (step 1 in scheme 4) The resin was then dried and the dendrimer 
cleaved from the resin with TFA/TIS/H2O (95:2.5:2.5) for 4 h (step 2 in scheme 4) The peptide was 
precipitated with methyl tert-butyl ether and dissolved in a water/acetonitrile mixture. 
 
Fmoc
N
H
a) Fmoc deprotection
b) Testing
c) AA coupling
c1) Capping
b) Testing
d) Protected Fucose coup.
H
N
Fuc
Fuc
Fuc
Fuc
1) CH3OH/H2O/NH4OH,8:1:1 (deacetylation) 2x24 h
2) TFA-TIS-H2O, 95:2.5:2.5 (cleavage) 3h and HPLC
    (eluent: A, H2O-TFA 0.1%; B, CH3CN-H2O 3:2, 
     TFA  0.1%).
NH2
Fuc
Fuc
Fuc
Fuc
SPPS of peptide dendrimer
a) Piperidin/DMF 20:80 (2x10 min.)
b) TNBS/DIEA, two drops of each
c) amino acid, PyBop, DIEA, NMP
c1) Ac2O/DCM 1:1, 10 min.
d) Fucose(prot.), HCTU, DIEA, NMP two times
NOVA Syn® TGS Ram loading 500 mg capacity 0.24 mmol/g
OMe
MeO
NH-Fmoc
O
O
H
N PEG
 
 
Scheme 4 Solid Phase Peptide Synthesis general procedure 
 
All dendrimers were purified by preparative HPLC with detection at λ= 214 nm on a chromolith 
performance RP-C18, 4.6 x 100 mm column flow rate 3 mL min,-1 eluent A: water and TFA 
(0.1%); eluent B: acetonitrile, water and TFA (3/2/0.1%). After purification, the structure of the 
dendrimer was confirmed by ESI-MS. Lectin binding was assessed with an Enzyme-Linked Lectin 
assay (ELLA). As reported above, this assay measures, through absorbance (read at 415 nm), the 
competition between the ligand and a biotinylated polymeric fucose reagent, toward the lectin (PA-
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IIL). The logarithm of the concentration of the dendrimer was plotted vs the % of inhibition. The 
sigmoidal curve was fitted and the concentration at 50% of inhibition (IC50) was determined.  
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ES-MS = 3535.0
Y =10% isolated after prep. HPLC
Leu - GAR- L
Ile - GAR- L  dendrimer with L-amino acid sequence and Ile as first
Leu - GAR- L  dendrimer with L-amino acid sequence and Leu as first
Leu - GAR- D dendrimer with D-amino acid sequence, L-Lys as branch and Leu as first
 
Fig. 4 Glycopeptide dendrimers synthesized in Berne 
 
The results of IC50 obtained by the ELLA test (see Tab. 4) indicate that Ile GAR-L and Leu GAR-L 
having all L-amino acids are the most potent ligands against PA-IIL lectin, with an IC50 = 0.14 µM 
and 0.15 µM respectively, which corresponds to a relative potency of 80 and 73 relative to L-
fucose. No differences, within experimental errors, between the two amino acid based dendrimers 
was observed, indicating that the presence of a L-Ile or a L-Leu as first amino acid is not 
significant. Concerning Leu-GAR-D dendrimer, ELLA test against PA-IIL lectin shown an IC50 = 
0.66 µM and a relative potency of 17 relative to L-fucose. As could be expected, Leu-GAR-D has a 
 40 
different IC50 value than its L-amino acid counterparts, but is only 4-fold less active. In any case, 
Leu-GAR-D is 17 times (ca 4 times per sugar units) more potent than the monovalent L-fucose, 
thus showing that also for this ligand, a multivalent effect is operating. 
 
No. IC50 (µM) r.pa. nb r.p./nc 
L-fucose 11 1 1 1 
Ile-GAR-L 0.14 ± 0.035 80 4 20 
Leu-GAR-L 0.15±0.082 73 4 18 
Leu-GAR-D 0.66±0.12 17 4 4.2 
 
Table 4. IC50  Values with PA-IIL lectin as measured by ELLA test 
 
a r.p. = relative potency to fucose = IC50 (fucose)/IC 50 (ligand).  b n. = number of fucosyl units per dendrimer.  
c Relative potency per fucose residue. 
 
After having demonstrated that Leu-GAR-D is able to inhibit PA-IIL, we undertook studies aimed 
at evaluating its proteolytic stability. All dendrimers were incubated with two proteins, Trypsin and 
Chymotrypsin, with human serum and bacteria PAO1 at 37 °C. The stability of each dendrimer was 
monitored by HPLC injection at 10, 30, 60 min and after 24 h. (see Tab 5). The dendrimers Ile-
GAR-L and Leu-GAR-L are, as expected, not stable under these proteolytic conditions. In the 
presence of the proteolytic Trypsin or Chymotrypsin, more than 95% of the dendrimer is 
decomposed after only 30 min. of incubation. These L-dendrimers are slightly more stable in the 
presence of human serum or bacteria PAO1, but also in these cases an extended decomposition can 
be observed. Especially in the presence of bacteria PAO1, after 1 h, 20-50% of the dendrimer is 
decomposed, and after 24 h no traces of the inhibitor could be found in the incubation liquor. 
Remarkably different is the situation observed with the D-peptide dendrimer Leu-GAR-D, since it 
is resistant to proteolytic conditions in human serum, PAO1 bacterial strains and even enzymes. In 
all cases also after prolonged incubation time Leu-GAR-D can be found completely integer.  
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Cond. Leu-GAR-L Ile-GAR-L Leu-GAR-D 
Trypsin 10 min 68  17  100  
Trypsin 30 min 6  1  100  
Trypsin 1h 1  0  100  
Trypsin 24 h 0  - 100  
Chymotrypsin 10 min 49  2  100  
Chymotrypsin 30 min 1  0  100  
Chymotrypsin 1h 0  0 100  
Chymotrypsin 24 h - - 100  
Serum 30 min 100  100  100  
Serum 4h 100  ~90  100  
Serum 24 h 57  49  Not determ. 
PAO1 10 min 92  100  100  
PAO1 30 min 90  65  100  
PAO1 1h 78  54  100  
PAO1 24 h 0  0  not determ. 
 
Tab.5 Percentage (%) of integer fucosylated peptide dendrimer detected by HPLC after the delay of time indicated in 
different proteolytic conditions (T = 37° C). 
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2.8 Conclusions 
 
The neoglycopeptide dendrimers are a new class of synthetic macromolecules that can be prepared 
by standard peptide coupling chemistry with an efficient solid phase peptide synthesis. Every The 
experiments reported in this chapter show that ligands for fucose-binding lectins can be selected by 
affinity screening of combinatorial libraries of such dendritic ligands. A new approach to dendrimer 
property tuning is demonstrated by combinatorial variation of dendrimer branch length and 
multivalency level, using a large self-encoded glycopeptides dendrimer library. The preparation of a 
different arm-length combinatorial dendrimer library is an important extension of the self-encoded 
dendrimer library principle, that allow to prepare a large combinatorial libraries using the exact 
same number of synthetic operations, and relying as before on the simple amino acid analysis for 
sequence determination. After the screening of a large number of dendrimers Reymond’s group has 
identified a potent tetravalent C-fucosyl peptide dendrimer FD2 with 100-fold higher potency than 
fucose for binding to the lectins UEA-I and PA-IIL. This is the first example of a multivalent ligand 
of these lectins. During the research activity carried out at Bern University, three glycopeptide 
dendrimers bearing L-Fuc at the periphery were synthesised. They strongly inhibit the adhesion of 
glycoproteins to LecB of Pseudomanos Aeruginosa, showing promises for their therapeutical 
applications against the formations of biofilms. Remarkablys, the Leu-GAR-D dendrimer, 
composed of D-amino acids, is stable to proteolysis, without loosing its activity. Further 
optimization of FD2 and Leu-GAR-D are in progress to increase binding affinity toward PA-IIL 
with regards to the possible therapeutic relevance of lectin ligands as inhibitors of biofilm formation 
in the Pseudomonas aeruginosa pathogen. 
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2.9 Experimental section 
 
Materials and reagents. Amino acids were used as the following derivatives: Fmoc-Ala-OH, moc 
Asp(Ot-Bu)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-His(Boc)-OH, Fmoc-Leu-OH, Fmoc-Phe- OH, Fmoc-
Ser(t-Bu)-OH, Fmoc-Thr(t-Bu)-OH, Fmoc-Ile-OH, Fmoc-Gly-OH, Fmoc-Tyr(t- Bu)-OH, Fmoc 
Pro-OH, Fmoc-Lys(Boc)-OH, Fmoc-Lys(Fmoc)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Val-OH and 
FmocDapFmoc-OH. NovaSyn® TGR (loading: 0.18-0.29 mmol/g), and Rink amide NovaGel 
(loading: 0.63 mmol/g), was purchased from Novabiochem (Switzerland). Lectin UEA-I was 
purchased from Sigma and lectin PA-IIL was provided through collaborations. All solvents used 
were of analytical grade. Analytical RP-HPLC was performed in Waters (996 Photo diode array 
detector) chromatography system using a chromolith performance RP-C18, 4.6 x 100 mm, flow rate 
3 mL.min-1 column. Compounds were detected by UV absorption at 214 nm. Preparative RPHPLC 
was performed with HPLC-grade acetonitrile and MilliQ deionized water in a Waters prepak 
cartridge 500 g (RP-C18 20 mm, 300 Å pore size) installed on a Waters Prep LC4000 system from 
Millipore (flow rate 100 mL.min-1, gradient 1 or 1.25 %.min-1 CH3CN). MS spectra were provided 
by the Service of Mass Spectrometry of the Department of Chemistry and Biochemistry, University 
of Bern. 
 
2-(Tri-O-acetyl-α-L-fucopyranosyl)acetic acid (4). The known 3-(Tri-O-acetyl-α- L - 
fucopyranosyl)-1-propene 3, prepared as described in Uchiyama, T.;Woltering, T. J.;Wong,W.; Lin, 
C.-C.; Kajimoto, T.; Takebayashi, M.; Weitz-Schmidt, G.; Asakura, T.; Noda, M.;Wong, C.-H. 
Bioorg. Med. Chem. 1996, 7, 1149-1165, (3.8 g, 12.0 mmol) was dissolved in H2O/CCl4/CH3CN 
(30:14:14, v/ v, 116mL). Sodium(meta)periodate (10.1 g, 48.0 mmol, 4.0 eq) and RuCl3 (0.1 g, 0.48 
mmol, 0.04 eq) were added. The resulting solution was stirred at r.t. for 4 h and partitioned between 
water (50 mL) and dichloromethane (100 mL). The aqueous phase was extracted with 
dichloromethane (2×50 mL) and the combined organic phases were washed with water (2×50 mL), 
extracted with saturated aqueous NaHCO3 (2×50 mL). The aqueous phase was then acidified to pH 
4 by addition of conc. HCl and reextracted in dichloromethane. The organic phase was washed with 
brine (100mL), then dried over MgSO4. The solvent was removed under reduced pressure to give 4 
as a white foamy solid (2.6 g, 67%). 1H NMR (400 MHz, [d]chloroform): δ = 1.17 (d, J = 6.4 Hz, 3 
H, H-6), 2.01, 2.04, 2.15 (each: s, 3H, OAc), 2.66 (dd, J = 15.5, 5.6 Hz, 1 H, H-1’a), 2.76 (dd, J = 
15.5, 8.8 Hz, 1 H, H-1’b), 4.04 (dq, J = 2.0, 6.4 Hz, 1 H, H-5), 4.70 (dt, J = 9.0, 5.5 Hz, 1 H, H-1), 
5.16 (dd, J = 9.7, 3.3 Hz, 1 H, H-3), 5.28 (dd, J = 3.3, 2.2 Hz, 1 H, H-4), 5.38 (dd, J = 9.8, 5.5 Hz, 1 
H, H-2). 13C NMR (75 MHz, [d]chloroform): δ = 16.0; 20.8; 33.0; 67.2; 67.6; 68.6; 69.5; 70.3; 
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169.8; 170.2; 170.6; 175.5. ESI-MS: m/z 355.09 ([M + Na]+). HRMS (ESI-MS): calc. for 
[C14H20O9+Na]: 355.1005; found: 355.1014. 
 
Dendrimer synthesis, general procedure. Peptide syntheses were performed manually in a glass 
reactor or plastic syringes (5 or 10 mL). The resin NovaSyn® TGR (loading: 0.18-0.29 mmol/g) 
was acylated with each amino acid or diamino acid (3 eq) in the presence of BOP or PyBOP (3 eq) 
and DIEA (5 eq) for 1 h and 30 min, 3 h after the first generation. After each coupling the resin was 
successively washed with NMP, MeOH, and CH2Cl2 (3× with each solvent), then checked for free 
amino groups with the TNBS test. If the TNBS test indicated the presence of free amino groups, the 
coupling was repeated. After each coupling the potential remaining free amino groups were capped 
with acetic anhydride/CH2Cl2 for 10 min. The Fmoc protecting groups were removed with a 
solution of 20% piperidine in DMF (2×10 min) and the solvent was removed by filtration. In the 
end of the sequence the resin was capped with carbohydrate 4 (5 eq) in the precence of DIC (5 eq) 
and HOBt (5 eq) or DIEA (5 eq) and HCTU (3 eq) in NMP overnight. The carbohydrate was 
deacetylated with a solution of MeOH/NH4/H2O (v/v 8:1:1) for 24 h. The resin was dried and the 
cleavage was carried out with TFA/TIS/H2O (95:2.5:2.5) for 4 h. The peptide was precipitated with 
methyl tert-butyl ether then dissolved in a water/acetonitrile mixture. All dendrimers were purified 
by preparative HPLC with detection at λ = 214 nm. Eluent A: water and TFA (0.1%); eluent B: 
acetonitrile, water and TFA (3/2/0.1%). Dendrimers were obtained as colorless foamy solids after 
cleavage from the resin and preparative RP-HPLC purification. 
 
Dendrimer GAR 1-5-1: (Fuc-α-CH2CO-Lys-Pro-Leu)4(Lys-Phe-Lys-Ile)2Lys-His-Ile-NH2 with 
L amino acid : (Yield = 8.0 %)  MS (ES+) calc for C172H290N35O43 [M+H]+: 3536.34, found: 
3536.0. Preparative RP-HPLC: (A/B = 80/20 to A/B = 40/60 in 50 min). Deletion side product with 
MS 3439.0 = [M+] – 97 (proline residue). 
 
Dendrimer GAR 1-20-1: (Fuc-α-CH2CO-Lys-Pro-Leu)4(Lys-Phe-Lys-Ile)2Lys-His-Leu-NH2 
with L-amino acid : (Yield = 10.0 %)  MS (ES+) calc for C172H290N35O43 [M+H]+: 3536.34, found: 
3536.0. Preparative RP-HPLC: (A/B = 80/20 to A/B = 40/60 in 50 min). Deletion side product with 
MS 3439.0 = [M+] – 97 (proline residue). 
 
Dendrimer GAR 1-13-1: (Fuc-α-CH2CO-Lys-Pro-Leu)4(Lys-Phe-Lys-Ile)2Lys-His-Leu-NH2 
with D-amino acid and only L-Lys as branching : (Yield = 12.0 %)  MS (ES+) calc for 
C172H290N35O43 [M+H]+: 3536.34, found: 3536.0. Preparative RP-HPLC: (A/B = 80/20 to A/B = 
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40/60 in 50 min). Deletion side product with MS 3347.0 = [M+] – 188 (minus one fucose residue 
dendrimer). 
 
Proteolytic stability test with PAO1 
Inocula of P. aeruginosa strains PAO1 were prepared from 5 ml overnight cultures grown in LB 
broth and the optical density (600 nm) was adjusted to 0.1 and aliquots of 20 µL were mixed with 
20 µL dendrimer solution (2 mM) in tris buffer (100mM, pH 7.5). The mixture was incubated at 
37˚C for 10 min, 30 and 60 min and the proteolysis was stopped by addition of 100 µL of H2O (1 % 
TFA). The solution was filtered and analyzed by RP-HPLC. Flowrate: 1.5 mL·min-1 (AD 80/20 to 
0/100 in 15 min). Conversions were calculated by comparing integrals of starting material left after 
the test with a blank.  
 
Proteolytic stability test with Human serum 
20 µL human serum to 20 µL of dendrimer solution, 2 mM in tris buffer (100mM, pH 7.5). The 
proteolysis was stopped by addition of 100 µL MeOH (1% TFA), filtered and then analyzed by RP-
HPLC. Flowrate: 1.5 mL·min-1 (AD 80/20 to 0/100 in 15 min). Conversions were calculated by 
comparing integrals of starting material left after the test with a blank.  
 
Proteolytic stability test in solution with Trypsin and Chymotrypsin 
The proteolysis was started by an addition of 5 µL of a freshly prepared stocksolution of the 
protease (2.4 mg/mL of trypsin and 1 mg/mL of chymotrypsin) to a mixture of 50 µL dendrimer 
solution (2 mM in tris buffer (100mM, pH 7.5)) and 45 µL of tris buffer (100mM, pH 7.5). The 
reaction mixture was analysed after 10, 30, 60 min and 48 hours by RP-HPLC. Flowrate: 1.5 
mL·min-1 (AD 80/20 to 0/100 in 15 min). Conversions were calculated by comparing integrals of 
starting material left after the test with a blank.  
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3.1 Magnetic Resonance Imaging (MRI) 
 
Magnetic resonance imaging (MRI), or Nuclear magnetic resonance imaging (NMRI), is primarily a 
medical imaging technique most commonly used in radiology to visualize the structure and function 
of the body1. It provides detailed images of the body in any plane. MRI provides much greater 
contrast between the different soft tissues of the body than computed tomography (CT) does, 
making it especially useful in neurological (brain), musculoskeletal, cardiovascular, and oncological 
(cancer) imaging. Unlike CT, it uses no ionizing radiation, but uses a powerful magnetic field to 
align the nuclear magnetization of (usually) hydrogen atoms in water in the body. MRI is a 
relatively new technology, which has been in use for little more than 35years (compared with over 
110 years for X-ray radiography). The first MR Image was published2 in 1973 and the first study 
performed on a human took place on July 3, 1977.  Magnetic resonance imaging was developed 
from knowledge gained in the study of nuclear magnetic resonance. In its early years the technique 
was referred to as nuclear magnetic resonance imaging (NMRI). However, as the word nuclear was 
associated in the public mind with ionizing radiation exposure it is generally now referred to simply 
as MRI. Scientists still use the term NMRI when discussing non-medical devices operating on the 
same principles. The term Magnetic Resonance Tomography (MRT) is also sometimes used. One of 
the contributors to modern MRI, Paul Lauterbur, originally named the technique zeugmatography, a 
Greek term meaning "that which is used for joining"2. The term referred to the interaction between 
the static, radiofrequency, and gradient magnetic fields necessary to create an image, but this term 
was not adopted. The MRI technique is based on the possibility of generating images through the 
spatial localization of the water protons in the tissues1  Compared to a traditional NMR experiment 
the spatial information is decoded through the application of magnetic field gradients in such a way 
that the proton resonance becomes dependent on the position (Fig.1). 
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Fig. 1. Signals and spectra obtained from three water samples in different positions along the x axis without and with 
the application of a field gradient along the x axis. In the presence of the gradient the signals of the three samples are 
resolved and the separation between the signals is dependent on their spatial separation in the x direction and on the 
intensity of the field gradient. 
MRI gives the maps of local chemico-physical properties such as the proton density, the 
longitudinal (T1 ) and transverse (T2) relaxation times, which become images once the relation 
between these parameters and the anatomy and pathology of the tissues has been established. The 
quality of an image depends on the degree of contrast which can be obtained and, in this case, it 
derives from the differences in the water concentration and in the relaxation times of the protons in 
the different biochemical environments3. Careful design of the imaging pulse sequence allows one 
contrast mechanism to be emphasized while the others are minimized. The ability to choose 
different contrast mechanisms gives MRI tremendous flexibility. In the brain, T1-weighting causes 
the nerve connections of white matter to appear white, and the congregations of neurons of gray 
matter to appear gray, while cerebrospinal fluid (CSF) appears dark. The contrast of white matter, 
Without gradient With gradient 
Signal 
Time 
Spectrum 
Frequency 
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gray matter and cerebrospinal fluid is reversed using T2  imaging, whereas proton-density-weighted 
imaging provides little contrast in healthy subjects. Additionally, functional parameters such as 
cerebral blood flow (CBF), cerebral blood volume (CBV) or blood oxygenation can affect T1, T2  
and so can be encoded with suitable pulse sequences. The body is mainly composed of water 
molecules which each contain two hydrogen nuclei or protons. When a person goes inside the 
powerful magnetic field of the scanner these protons align with the direction of the field. A second 
radiofrequency electromagnetic field is then briefly turned on causing the protons to absorb some of 
its energy. When this field is turned off the protons release this energy at a radiofrequency which 
can be detected by the scanner. The position of protons in the body can be determined by applying 
additional magnetic fields during the scan which allows an image of the body to be built up. These 
are created by turning gradients coils on and off which creates the familiar knocking sounds during 
an MR scan. Diseased tissue, such as tumors, can be detected because the protons in different 
tissues return to their equilibrium state at different rates. By changing the parameters on the scanner 
this effect is used to create contrast between different types of body tissue. 
 
Fig. 2 MRI Scanner (courtesy from NASA) 
  
A B 
Fig. 3 MRI image of a brain of the Schlerosis multiple patient; A) without contrast agent, B) with contrast agent  
from web: /www.sclerosi-multipla.com 
 54 
3.2 Gd (III) complexes as contrast agents for MRI 
In some situations it is not possible to generate enough image contrast to adequately show the 
anatomy or pathology of interest by adjusting the imaging parameters alone, in which case a 
contrast agent may be administered. This can be as simple as water, taken orally, for imaging the 
stomach and small bowel. However, most contrast agents(CA)  used in MRI are selected for their 
specific magnetic properties. Paramagnetic substances are usually used for increasing and 
controlling the magnetic relaxation of water protons4 
 
 
 
 
 
 
Fig. 4: MR image in the presence of a contrast agent 
 Most studies have been performed on complexes of Gd (III) since this metal ion with a S ground 
state electronic structure couples a large magnetic moment with a long electron spin relaxation time 
(≈ 10-9 s at the magnetic field strengths for MRI applications) two properties that ensure an 
optimum efficiency for nuclear spin relaxation of the interacting nuclei. 
 Other general requirements of CA for MRI are low toxicity, rapid excretion after administration, 
good water solubility and low osmotic potential of the solutions clinically used. Moreover, since the 
free metal ions are toxic they must be coordinated by a strong binding ligand that occupies most of 
the available coordination sites. Eventually, the preferred metal complexes, in addition to showing 
high thermodynamic ( and possibly kinetic) stability, should present at least one water molecule in 
the inner coordination sphere, in rapid exchange with the bulk solvent, in order to affect strongly the 
relaxation of all solvent protons. The anionic complexes Gd( DTPA)2- ( MAGNEQUISTR , 
Schering AG, Germany) and Gd(DOTA)- (DOTAREMR , Guerbert SA, France) were the first 
complexes entered into clinical practice and they represent the reference compounds for the 
development and evaluation of new agents. Gd(DTPA-BMA) (OMNISCANR, Nycomed Imaging 
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AS, Norway) and GdHPDO3A (PROHANCER, Bracco, Italy), have been introduced with the aim 
of providing systems with reduced osmotic potential for applications requiring high doses of CA. 
Fig. 5 reports the schematic structure of the four ligands and the thermodynamic stability constants 
of their Gd (III) complexes measured at 25 °C  and µ = 0.1. 
 
 
Fig 5 Schematic representation of the four ligands whose Gd(III) complexes are currently used as CA for MRI. 
Thermodynamic stabilities of the complexes in water at 25 °C and µ = 0.1 M are reported. ( Adapted from ref 5) 
It may be surprising to find out that a complex like Gd( DTPA-BMA), whose stability constant is 
more than five orders of magnitude lower than Gd( DTPA)2- is considered safe enough for its 
clinical use. However, it has been pointed out that the toxicity6 in vivo  of Gd(III) complexes with 
polyaminocarboxylate logands does not correspond to the overall thermodinamic stability. Rather, 
the lack of displacement of Gd(III) by endogenous Ca(II) and the selectivity towards Ln(III) ions 
introduced by the two amide substuituents are effective in setting off the net loss in the overall 
thermodynamic stability. 
These agents catalytically shorten the relaxation time  of nearby water molecules , thereby 
enhancing the contrast with background tissues. In 1999, approximatively 30% of all MRI scans 
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used a contrast agent, most of which were based on gadolinium complexes. By now, this number 
has probably increased to between 40 and 50 %. 
This utility has prompted research on improved Gd-based contrast agent, about which several 
reviews have recently been published.5 7 8 9 10 11 12 13 14 15 16 17 18 19 20  
Current MRI agents require gram quantities of Gd in order to obtain satisfactory contrast in the 
resulting image. With such large doses required for reasonable image enhancement, current contrast 
agents (CA) are limited to targeting sites where they can be expected to accumulate in high 
concentrations, such as the blood stream. Ideally, second generation agents will be site-specific; 
much higher relaxivities will be required to account for the decrease in concentration that 
accompanies increased tissue specificity. The image-enhancing capability of a contrast agent is 
directly proportional to its relaxation of neighbouring water molecules by the paramagnetic ion; that 
is, to the relaxation rate increase either longitudinal (1/T1) or transverse (1/T2). This effect includes 
both inner-sphere contributions (from water molecules directly coordinated to the Gd) and out-
sphere contributions (from nearby, H-bonded waters). The latter are usually relatively small and are 
usually neglected. The overall paramagnetic relaxation enhancement referred to by a 1mM 
concentration of a given Gd(III) chelate is called its proton relaxivity (r1p), whose unity is mM-1s-1 
For Gd(III) complexes, the inner sphere relaxivity  primarily results from a dipolar contribution 
(through-space interaction due to the random fluctuations of the electronic field) and can be 
described  by the Solomon-Bloembergen-Morgan theory21. According to the SBM theory to 
increase the relaxivity, r1p, of a Gd contrast agent, one has to design a ligand that will enable the 
complex to have a greater number of inner sphere water molecules, q ; an optimally short water 
residence time τM ; and a slow tumbling rate, 1/τR (Fig. 6) , while maintaining sufficient 
thermodynamic stability. This is quite a challenge ! The water residence time, τM , is probably the 
least understood and most important parameter that affects relaxivity. Indeed it has been 
demonstrated that the relaxivity of a gadolinium complex will increase upon slowing down its 
molecular tumbling ( increasing its molecular weight) insofar as its water residence time is close to 
optimal.22 23 24 25 
 
5-20
2 -25 
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Fig. 6 Parameters influencing  relaxivity 
( taken from : http://www.cchem.berkeley.edu/knrgrp/mri.html) 
In order to evaluate the relaxation parameters it is necessary to study the dependence of the 
relaxivity upon magnetic field. This is made possible through an instrumentation called field-
cycling  NMR relaxometer . The technique, called Nuclear Magnetic Relaxation Dispersion 
(NMRD) gives the so called dispersion profile by measuring,  over a large frequency interval (0.01-
50 MHz),  the longitudinal relaxation time ( T1) of water molecules in a solution containing the 
paramagnetic complex (Fig. 7).The quantitative analysis of the dispersion profile allows a more 
accurate evaluation of all parameters which determine relaxivity.  
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Fig. 7 Typical NMRD profiles of low molecular weight Gd(III) complexes 
(adapted  from ref. 18) 
Considering the aforementioned properties, current commercial poly(amino-carboxylate) complexes 
(Fig. 7)  have several disadvantages. They have only one coordinated water molecule and fast 
tumbling rates due to their small size. Attempts to increase their relaxivities by grafting them on 
macromolecules (slowing τR) have led to mixed success due to the accompanying particularly slow 
water exchange rates1 26 27, 1/τM, typically 0.5-5x10-6 s-1 . These water exchange rates are several 
orders of magnitude slower than the rate for Gd(H2O)83+ and far below levels necessary to achieve 
high relaxivity (τM ≈ 20 ns at 20 MHz). Because the fundamental properties of current commercial 
contrast agents are far from optimal, their resulting relaxivities are very low (≈ 5 nM-1s-1), just a few 
percentage points of what is theoretically possible. Recent attempts to increase their water exchange 
rates by destabilizing their nine-coordinate ground state have resulted in less stable complexes26 27. 
 
3.3 DOTA and its Lanthanide Complexes 
We will give here some details on  1,4, 7,10-tetraazacyclododecane-N,N’, N’’,N’’’-tetraacetic acid 
(DOTA)  and its Gd (III) complex (Gadoterate),  since our contrast agents are based on this 
macrocycle.   
Gadoterate has been the first macrocyclic gadolinium complex which entered the market 
((DOTAREMR , Guerbert SA, France). DOTA is considered a derivative of a macrocyclic 
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tetramine, called cyclen,  which can be synthesized through different routes28 29 30 31 32 33 34. The 
first one is illustrated in scheme 1 in which the cyclization of the tosylates 1 and 2 is performed in 
high yields, since the hydrocarbon segments between the heteroatoms are short, and relatively equal 
segnments of the target macrocycle are condensed. After detosilation of 3 the cyclen 4 is obtained. 
For the production of cyclen on a large scale, the tetramerization of N-benzylaziridine 6 seems to be 
preferential (Scheme 2). Tetrabenzylcyclen 7 has been prepared in nearly quantitative yield by 
refluxing a mixture of 6 and p-toluenesulfonic acid in alcohol for 6 hours. Debenzylation of 7 can 
be carried out by treatment with 10% Pd-C under hydrogen. Cyclen 4 is obtained in high yield. 
Alkylation with chloro- or bromoacetic acid leads to the ligand DOTA 9, which is subsequently 
complexed with gadolinium chloride or gadolinium oxide to yield Gd-DOTA 533 (Scheme 3).  
                      
 
Scheme 1. Synthesis of cyclen by cyclization Scheme 2. Synthesis of Cyclen by tetramerization 
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Scheme 3 Synthesis of gadoterate (Gd-DOTA) from cyclen 
Due to the macrocyclic nature of the ligand the Gd (III) complex is endowed with high 
thermodynamic and kinetic stability in vivo35 36. The formulations of Dotarem (Gd-DOTA) consist 
of gadoterate as its N-methylglucamine salt in concentration of 0.5 and 1.0 mol/l.  The latter 
solution displays relatively high osmolarity (  4.02 osmol/kg water ) and viscosity (11.3 cP)37. 
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Several   cyclen-based macrocyclic ligands similar  to  DOTA have been synthesized, in order to 
improve the relaxivity properties of their gadolinium complexes or for other  purposes. A list is 
reported in Scheme 4. 
 
Scheme 4 Some representative examples of DOTA analogues 
(from ref 18) 
DOTA, having four carboxylate groups, forms with Gd(III) a negatively charged complex  having 
one coordinated water molecule. The structure and dynamics in solution of the Lanthanide 
complexes of DOTA depends on many factors which has been elucidated (Fig. 8) through the 
combined use of several techniques (mainly 2D NMR)16. 
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As briefly pointed out in the previous sections of this chapter,  the research in the field of contrast 
agents (CA)  for Magnetic Resonance Imaging has taken two main directions: 
1) design and synthesis of kinetically stable lanthanide complexes in which the number of 
coordinated water molecules is higher and their exchange rates is increased compared to the 
known CAs, in order to enhance relaxivity (especially at the higher magnetic field strengths 
of  current and future clinical MRI scanners); 
2) attach to the selected gadolinium complexes recognition motives in order to deliver the 
paramagnetic complex to a specific organ or a biological target (site-specific MRI).  
Along the first line interesting new results have been recently reported by the group of  K. N. 
Raymond38, who synthesized a series of hydroxypyridone-based Gd(III) complexes (Fig. 9) which 
show significantly improved properties compared to the commercial agents. 
 
Fig. 8 Schematic representation of the structures and dynamics of [Ln(DOTA)]- complexws, looking down along 
the Ln-water O bond. The water ,olacule is omitted for clarity. 
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Fig.9: Structures of hydroxypyridone-based Gd(III) complexes 
The X ray crystal structure of  the gadolinium (III) complex of one of these ligands, called Tren-
tris HOPO shows  that it is  8-coordinate.The organic ligand is coordinated in an hexadentate 
fashion through the hydroxypyridone O-atoms and two water molecules complete the coordination 
sphere (Fig. 10). The relaxivity appears to be 2.5 times as high as that of [Gd (DTPA)]- . 
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Fig. 10 (taken from : http://www.cchem.berkeley.edu/knrgrp/mri.html) 
Although the organic ligand is only hexadentate, the thermodynamic stability of the complex is 
good (log β110= 20.3), which may be ascribed to some degree of preorganization and stability due to 
internal hydrogen bonds.  
 
                                                    A                                              B 
Fig. 11 
More recently the same group reported39  two other examples (A and B Fig 11) of  water soluble 
tris-hydroxypiridonate Gd(III) complexes in which the TREN cap has been replaced by a 
trazacyclononane (TACN) derivative. These two complexes shows an increased hydration number 
(q=3), a fast water exchange and a slow electronic relaxation which results in one of the highest 
relaxivity observed for a low molecular weight CA (r1p = 13.1 and 12.5 mM-1 s-1 for A and B 
respectively at 20 MHz and 298 K, whereas this value is around 4-5 mM-1 s-1 for commercial agents 
in the same conditions. Concerning point 2, several examples of targeting using non sugar DOTA-
conjugates will be given below (3.4),  whereas the carbohydrate-based site specific MRI contrast 
agents will be discussed  in more details in Chapter 4.   
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3.4 Site-specific MRI. 
 
Typical clinical MRI contrast agents such as Gd-DTPA or Gd-DOTA are small molecules that 
distribute evenly through-out the extracellular space. These agents are well suited for vascular 
imaging applications, such as angiography and perfusion imaging. However, there is an increasing 
interest in achieving high MRI contrast and resolution especially in those regions or organs affected 
by diseases. New contrast agents are therefore needed which could reach this selectivity goal. The 
strategy,  which has been named targeted or site-specific MRI tries to reach this goal via 
molecular imaging of the pathologic (or physiologic) biomarkers (Fig. 12) which can lead to early 
recognition of diseases, better therapeutic management, and improved monitoring for 
recurrence.40,41,42 Although biomolecules are much too small (nm size) and in far too low of a 
concentration (pM range) to be directly imaged by MRI - which has a typical resolution of µm and 
detection limit of µM - by selective accumulation of site-directed contrast agents on molecular 
epitopes of pathologic or biomarkers it would be possible to visualise specific organs or tissues.  
 
Target Biomolecule
H
H
O
Gd3+
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Fig. 12: Schematic representation of site-specific contrast agent in molecular imaging. 
 
The design of site-specific contrast agents (also named molecular imaging contrast agent) implies 
the conjugation of a Gd(III) chelate to a proper ligand which shows selectivity for the biomarker of 
interest, generally genes or proteins which are linked directly or indirectly to human diseases. In 
this way, thanks to the selective ligand-receptor interaction, the Gd-chelate can be targeted directly 
and specifically, thus allowing the imaging of a receptor-rich tissue. Imaging of proteins or protein 
functions is more feasible, given the much larger number of such targets per cell compared with the 
number of DNA or mRNA targets per cell.43 
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Following this design, several molecular imaging contrast agents conjugated to monoclonal 
antibodies (mAb), antibody fragments (Fab), (recombinant) proteins, peptides, peptidomimetics, 
sugars and small molecules44 were synthesised and tested. 
Historically, the first example of in vivo MRI of cell surface molecular targets in solid tumors with 
site-specific contrast agents was obtained in 1985 when a Gd-DTPA chelate was conjugated to a 
mAb.45 It was however recognised that one of the major problems associated to this contrast agent 
was the low sensitivity of MR detection. That is also the reason why the use of dendrimers, 
polymerised vesicles, liposomes or polypeptides carrying hundreds of Gd-chelates or nanoparticles 
resulting in a massive accumulation of paramagnetic probes in close proximity to the receptor is a 
strategy pursued by different research groups.42,46  
By coupling Gd-chelates to lipoprotein HDL and LDL it was possible to image atherosclerosis 
plaques since these contrast agents appear to accumulate in the resident macrophages of the 
plaque.47 Moreover, since LDL receptors are over expressed in many type of malignant tumors, 
magnetically labelled LDL was also used to assess the expression of this receptor in vitro on 
melanoma cells.48 
Other examples of site-specific contrast agents were obtained by coupling a fibrin-avid small 
peptide to a Gd-DTPA complex. In this way, it was possible to induce a substantial image 
enhancement of advanced atherosclerosis plaques which are rich in fibrin and thrombus.49 Even 
more remarkable enhancement were obtained using paramagnetic perfluorocarbon nanoparticles 
coupled with antifibrin antibodies.50  
On the other hands, early atherosclerosis is associated with increased angiogenesis in the vessel 
wall for which the αVβ3-integrins are general markers. Therefore αVβ3-integrin-targeted 
paramagnetic perfluorocarbon nanoparticles were used to specifically detect and characterise early 
stage atherosclerosis.51 Moreover, since αVβ3-integrins and selectins are highly expressed at tumor 
vasculatures, paramagnetic polymerised vescicles were coupled to proper αVβ3-integrin antibodies 
to target tumor angiogenesis.52 Another ligand very specific for the αVβ3-integrins, a cyclic peptide 
containing the RGD sequence of amino acids, was also incorporated into liposomes containing a 
Gd-DTPA attached to two stearyl chains and a fluorescent rhodamine lipid. This bimodal targeted 
liposomal contrast agent is able to detect angiogenic endothelium in mouse tumor both at 
anatomical level in vivo by MRI, and at subcellular level ex vivo by fluorescence microscopy (Fig. 
13).53 
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Fig. 13. Bimodal liposomal contrast agent is used to identify angiogenic endothelium in mouse tumor. Picture taken 
from ref. 53 
 
Bile acid moieties such as cholic acid, cholylglycine, and cholyltaurine were also conjugated to 
DTPA or DOTA chelating groups and their Gd(III) complexes showed high biliary elimination as 
well as good tolerabilities. Noticeably, the conjugate 1 seems to play a peculiar role in addressing 
the Na+/taurocholate transport system.54  
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Rather studied is also the folate receptor targeting. In fact, folate receptors are overexpressed by 
several types of cancer cells including ovarian, breast, colorectal and nasopharyngeal carcinomas in 
adults as well as pediatric tumors, and show high affinity (Kd ~ 1010 M) for the folate ligand. The 
uptake of a Gd polyamidoamine (PAMAM) folate dendrimer in ovarian cancers was observed55,56 
while more recently, the specific accumulation to an ovarian tumor of a folic acid conjugate 2 with 
a high relaxivity dimeric Gd-chelate was obtained.57,58 
Another candidate receptor for MRI is the so-called peripheral benzodiazepine receptor (PBR), 
overexpression of which has been observed in certain cancers.59 The Gd-complex of 3 yielded a 
contrast enhancement of 1.7 : 1 in the localization of glioblastoma (brain cancer) cells.  
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Synthesis and properties of 
polyglycosylated-DOTA ligands 
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4.1 Sugar-Gd.chelate conjugates as MRI contrast agents. 
 
Few examples of contrast agents with appended sugar units at the periphery have been reported in 
the literature. 
A functional MRI agents was reported by Meade and co-workers who developed a Gd-DOTA 
derivative capped by a β-galactosyl residue (I). The sugar, blocks the close approach of water 
molecules to the metal centre and therefore limits the contrast enhancement to outer-sphere 
relaxation. However, in the presence of β-galactosidase enzyme, galactose is cleaved causing a 
transition from a weak to a strong relaxivity state.1 This “smart contrast agent” may find application 
in monitoring several processes which this enzyme is involved in.2 More recently a similar 
approach was used to detect oncologically relevant enzyme β-glucoronidase.3 Enzymatic hydrolysis 
of the β-glucoronic acid from (II) allowed to switch on relaxivity of the Gd chelate demonstrating 
the potential of this approach for imaging cancer cells via changes in enzyme levels. 
 
 
Other site-specific MRI contrast agents may have potential for molecular imaging of tumor related 
cell surface receptors. Gd-DTPA-B(sLex)A, for example, is a Gd-DTPA based MRI contrast agent 
(III) specific for the E-selectin receptor obtained by conjugation to a Sialyl LewisX mimic.4 
Although this contrast agent has only been applied in inflammatory models it is potentially useful 
for staining the tumor vasculature where the cell surface receptors (E-selectins) are expressed. 
With the idea to exploit the cluster glycoside effect5 and to target carbohydrate binding proteins 
(lectins)6 biomarkers of many inflammatory and tumor processes, recently few glycoclusters 
functionalised with DOTA or DTPA have been synthesised.  
A tetragalactosylated DOTA derivative (IV)7 and a tetra-galactosylated DTPA analogues (V)8 for 
the targeting of hepatic asyaloglycoprotein receptor were reported. Cell internalization and animal 
studies on both 153Sm3+ and Gd3+ complexes were carried out with γ-scintigraphy and MRI, 
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respectively. In vitro studies showed superior activity of the multivalent derivatives (IV-V) 
compared to monovalent ones in the uptake of their radiolabelled Sm (III) complexes by hepatocyte 
carcinoma cells line Hep G2 containing the asialoglycoprotein receptor. Also in vivo biodistribution 
of the radiolabelled polygalactosylated derivative (IV) looked promising with interesting specificity 
for the liver uptake and superior activity especially when compared to the polyglucosylated 
counterparts.  
N
N
N
N
S
O
OH
OH
OH OH
O
NH
N
S
O
OH
OH
OH OH
O
NH
NH
O
N
S
O
OH
OH
OH
OH
O
NH
N
S
O
OH
OH
OH OH
O
NH
NH
O
NH
O
NH
O
O
OH
OH
O
OH
O
IV
S
O
OH
OH
OH OH
O
NH
N
S
O
OH
OH
OH OH
ONH
NH
O
NH
O
S
O
OH
OH
OH
OH
O
NH
N
S
OOH
OH
OH OH
O
NH
NH
O
NH
O
N
O
OH
N N
OH O
OH O
V
 
However, despite this specific liver uptake of the radiolabelled galactose-bearing multivalent 
compounds, the animal MRI assessment of the corresponding Gd3+ chelates showed liver-to-kidney 
contrast effects which are not significantly better than those shown by aglycono-Gd-DTPA. This 
has been attributed by the authors to a quick wash-out from the liver of these hydrophilic 
complexes, before they can be sufficiently concentrated within the hepatocytes via receptor-
mediated endocytosis.9 
Dendritic DTPA (VI) or DOTA (VII) Gd complexes bearing 12 glycosyl units at the periphery 
were also independently prepared by Takahashi10 and Parker and Aime.11 While VI was only 
prepared and characterised, the glucosyl complex VII was also studied in details and compared 
directly with ProHance, at the same doses, in preliminary imaging experiments with mice. The Gd 
complex (VII) gave rise to a longer-lived signal enhancement, maintaining a 50-60% overall 
increase over the period 5 to 45 min post-injection and a significant gain compared to the 
enhancement of ProHance. Unluckily, a study carried out with a galactosyl anologue of VII to seek 
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liver targeting based on the recognition of one or multiple β-galactosyl residues by 
asialoglycoprotein receptor, gave no significant enhancement in this organ.  
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4.2 Methods of ligand conjugation to chelating units. 
 
Different strategies for the conjugation of the sugar units to the moiety devoted to Gd(III) 
complexation have been used. They can be grouped in three different categories: i) covalent 
methods; ii) biotin/(strept)avidin coupling; iii) noncovalent approach.  
The covalent methods, which can be considered the most classical and used strategies, aim at 
forming a covalent bond between the ligand and the chelating unit possibly separating them with a 
linker of proper length. The reaction which are mostly used are those forming amide bonds also 
because Gd(III) chelating units such as DOTA or DTPA presents carboxylic acid groups which 
might be used for this purpose. Quite common is the use of coupling reagents such as HATU, 
HBTU or PyBOP which have shown to be so successful in peptide synthesis. In general, very 
efficient reactions should be chosen like those between amino groups and iso(thio)cyanates in order 
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to form (thio)urea bonds. The selection of very efficient reactions is particularly crucial when the 
synthesis of multivalent ligands has to be carried out. This is also the reason why, in the latest years, 
an important success has been obtained by the “Click Chemistry” methodology which exploits the 
1,3-dipolar cycloaddition reaction also know as Huisgen reaction. 
The 1-3 –dipolar cycloaddition reactions have been the subject of intensive research, most notably 
by Rolf Huisgen, whose work led to formulation of the general concepts of 1,3-dipolar 
cycloadditions12. This cycloaddition chemistry found many of applications in organic synthesis and 
has been the subject of several reviews. In a few years since its discovery, the Cu-catalyzed azide-
alkyne 1,3-dipolar cycloaddition (CuAAC) has been established as one of the most reliable 
procedure for the covalent assembly of complex molecules. It has enabled a number of applications 
in synthesis, medicinal chemistry, molecular biology and materials science. The 1,2,3-triazole finds 
several application because it has many advantageous properties: a) high chemical stability, it is 
inertness to severe hydrolytic, oxidizing, reducing conditions and at high temperature, b) a strong 
dipole moment (5.2-5.6 D), c) aromatic character, d) good hydrogen-bond-accepting ability13 14. 
The 1,2,3-triazole reaction has been thoroughly investigated by Huisgen and co-workers in 1950s to 
1970s15,16. This reaction is thermodynamically favoured (∆H° = -45 to -55 Kcal/mol) due to the 
high potential-energy content of the two reaction components, and the kinetic-energy barrier is 
relatively high (ca. 26 Kcal/mol for methyl azide and propyne17), so the reaction is very slow at 
room temperature for unactivated reactants. The uncatalyzed thermal cycloaddition of azides to 
alkynes requires prolonged heating and one can obtain a mixture of 1,4- and 1,5-disubstituted 
regioisomers. Today the efficient route, CuAAC leads only to 1,4-disubstituted-1,2,3-triazoles at 
room temperature in good yields. In this reaction one can use different Cu(I) sources: copper(I) salts 
(CuI, CuBr) and coordination complexes like [Cu(CH3CN)4]PF6,18 (EtO)3P x CuI,19 and 
[Cu(PPh3)3]Br20 21 can be used. The latter catalyst is very efficient in organic solvent where the 
cuprous salts have limited solubility. However the Cu(I) is thermodinamically unstable and can be 
easily oxidized to inactive Cu(II). Aqueous alcohols like methanol, ethanol, tert-butanol, THF and 
DMSO can be used as solvent. The discovery that catalytic Cu(I) increases the reaction rate and 
controls the regioselectivity to give the 1,4-di-substituted triazole group while suppressing the 
formation of the 1,5-regioisomer was made independently in recent years by Sharpless22, Meldal23 
and their co-workers. 
 
The biotin/(strept)avidin approach is quite often used for the conjugation of different types of labels 
to antibodies2. It exploits the extraordinary high avidin-biotin binding affinity (Kd = 10-15 M) that 
results in a practically irreversible binding under physiological conditions. It offers also the 
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advantage that the biotinylated (or avidin conjugated) Gd complex can be also administered after 
the avidin conjugated (or biotinylated) antibody has reached his molecular target thus preventing 
any negative influence of the contrast agent on the recognition process between the antibody and 
the target (Fig. I). 
 
Fig. I: The two-step labelling scheme with receptor pretargeting by biotinylated 
antibody and avidin-based Gd contrast agent. From ref. 2. 
 
Biotin-avidin (streptavidin) linker system will, however, have limited application in vivo because 
both avidin and streptavidin are foreign proteins and may induce host immune response. This 
significantly limits the successful applications of this technique in vivo especially when repetitive 
imaging is required. 
 
The noncovalent approach, exploits the possibility of generating a stable supramolecular complex 
between the Gd-complexes and the ligand, without carrying out a real chemical reaction thus 
avoiding purification steps. A nice example of this supramolecular approach was obtained by 
mixing a cyclodextrin-grafted chitosan with a Gd-DTPA derivative bearing either an hydrophobic 
bis-phenyl-cyclohexyl-phosphate or a lithocholic acid residue (Fig. IV). Thanks to hydrophobic 
interactions between the lipophilic residues of the Gd complexes and the cyclodextrin cavities, 
stable adducts, showing important relaxivity values, were observed. This system thus appears 
promising as carrier for the in vivo vehiculation of Gd(III) complexes.24 
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Fig. II: The noncovalent approach for the preparation of stable adducts between a biopolymer and a 
contrast agent. In the figure the chitosan-cyclodextrin conjugate and two different lipophilic Gd-DTPA 
complexes are represented (from ref. 24). 
 
Another possibility, exploited in this noncovalent approach, is to assemble the Gd chelate and the 
ligand in a supramolecular structure like a liposome, a micelle or a nanoparticle25. 
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4.3 Synthesis of site specific contrast agents using a calix[4]arene scaffold 
 
The first goal of  this project was the synthesis of polyglycosylated site specific contrast agent based 
on the calixarene scaffold and featuring four units of the same saccharide at the upper rim for 
polyvalent interactions with the lectins and the 1,4,7,10- tetraazacyclododecane-N,N’,N’’,N’’’-
tetraacetic acid (DOTA) at the lower rim for gadolinium complexation (Fig. 1 B) 
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Taking advantage of the previous experience of glycosylation reactions on calixarene scaffolds 
carried out in our research group26 27 28 29 30 31, we planned to conjugate the sugars at the upper rim 
of the calix using thiourea bonds. The coupling reaction between p-amino calixarenes and 
peracetylated-β-glycosyl isothiocyanates is, in fact, always nearly quantitative. Moreover in this 
coupling reaction the same stereochemistry at the sugar anomeric position is maintained. This 
conjugation method is also quite convenient since different β-glycosyl isothiocyanates are 
commercially available, although we usually prefer to synthesise then by ourselves. 
Target Biomolecule 
SITE-SPECIFIC MRI 
CONTRAST AGENT 
H 
H
O
Gd
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We originally planned to synthesize compounds of type A (Fig.1) following a convergent strategy 
preparing separately the calix[4]arene having four amino groups at the upper rim and one carboxy 
unit at the lower rim (by reducing the nitroderivative 5) the mono functionalized DOTA derivative 
12 and the peracetylated-β-glycosyl isothiocyanates (C). The DOTA derivative 12 and the 
saccharide unit (C) were also synthesised. 
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The synthesis of the lower rim monofunctionalized-p-nitro calix[4]arene (5) has been carried out in 
four steps, from p-tert-butyl calix[4]arene (1). In the first step, cesium fluoride  and a stechiometric 
amount of ethyl bromo-acetate in dry DMF under nitrogen atmosphere were used to obtain a 
selective monoalkylation at lower rim (scheme 1). The cesium fluoride being a weak base, can 
deprotonate only one of the phenolic hydroxyl group. It has been demonstrated, in fact, that there is 
a wide difference between the first and the second pKa values in calix[4]arenes32 When the first 
phenolic hydroxyl group is deprotonated, the resulting phenolate can be stabilized by two H-bonds 
from the adjacent phenolic OH’s. The reaction time is quite important. The reaction was monitored 
by TLC and after 24 hs the starting material disappeared and a new spot of the target compound 
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appeared. The reaction was quenched immediately after traces of a new spot corresponding to the 
1,3-dialkylated compound appeared. After acidic extraction, the crude material was purified by 
flash-chromatography to get compound 2 with 60% yield. The 1H-NMR spectrum of compound 2 
(fig. 2) showed the characteristic peaks of compound having only one symmetry plane. Particularly 
diagnostic of the mono functionalization are the signals of the hydroxyl groups which give rise to 
two singlets at δ = 10.23 ppm and at δ = 9.25 ppm in the integration ratio 1:2. Rather typical of the 
monosubstitution are also the two doublets for the axial methylene protons at 4.48 ppm and 4.30 
ppm. The singlet at δ = 4.89 ppm, the quadruplet at δ = 4.41 ppm and the triplet at δ = 1.41 ppm 
show the presence on calixarene of only one ethyl acetate group. 
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Fig. 2 1H NMR Spectrum (CDCl3, 300 MHz, 298 K) of the compound 2. 
 
Compound 2 was then submitted to exhaustive alkylation ,by stirring it in the presence of sodium 
hydride and five equivalents of iodo-propane to get the corresponding triproproxy-monoester 3 
(Scheme 2). After the work-up, recrystallization with acetonitrile allowed to isolate the pure 
product. The size of the annulus of calix[4]arenes is too small to allow a propoxy group to pass 
inside and therefore different fixed conformations are formed depending on the synthetic procedure 
used33. In the 1H-NMR spectrum (Fig. 3) the typical signals of the propoxy groups were observed, 
while no hydroxyl signal could be detected. However, there are signals (▼) which can be attributed 
to the corresponding acid compound 4. This was also confirmed by ESI-MS that showed three 
different peaks: one peak at m/z 884.3 of the ion [M + Na]+ corresponding to the monoester 
derivative 3 and two peaks at m/z 877.5 and 855.5 respectively of the ions [M - H + 2 Na]+ and [M 
+ Na]+ of the carboxylic acid compound 4. Probably, due to the not completely dry conditions, the 
hydrolysis of the ethyl ester also took place. However, we did not proceed in the elimination of 
monoacid 4 from the reaction mixture, since in the following step the hydrolysis of the ester group 
was anyhow required. 
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Fig. 3 1H NMR spectrum (CDCl3, 300 MHz, 298 K) of the compound 3. (▼) signals of the monoacid compound 4. 
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Therefore the mixture of acid and ester was stirred at reflux with potassium hydroxide in THF and 
water, overnight. 
 
Fig. 4 1H NMR spectrum (CDCl3, 300 MHz, 298 K) of the compound 4 
 
After the work-up of the reaction, the crude product was triturated in methanol to obtained the 
mono acid in 83 % yield. In the 1H-NMR spectrum (Fig. 4) it is possible to see the disappearance of 
the characteristic signals of the ester, the quadruplet to δ = 4.41 ppm and the triplet to δ = 0.98 ppm. 
Again, the 1H-NMR spectrum is quite characteristic of a compound fixed in the cone conformation 
and having one symmetry plane. There are two singlets at 7.15 and 7.13 ppm which are 
respectively, the aromatic protons of the phenolic unit bringing the acetic acid moiety and that 
diametrically opposite; two doublets with J meta (2.4 Hz) at δ = 6.59 and 6.48 ppm correspond to 
the protons of the others two aromatic rings. The chemical shift difference between the two groups 
of signals suggests that the calixarene is in flattened cone conformation: in particular the ring with 
the acetic acid group and the opposite one are more opened, shielding the protons of the other two 
rings which are in a nearly parallel disposition. The two low field doublets at δ = 4.45 ppm and δ = 
4.22 ppm are originated by the axial protons of the ArCH2Ar groups whereas the two high field 
doublets at δ = 3.22 and 3.15 ppm are generated by the equatorial ArCH2Ar protons. This chemicals 
shift difference is quite peculiar indicating mono substitution at lower rim. To carry out the 
following nitration of the upper rim, classical conditions developed for the ipso-nitration of 
calixarenes were used. 
Compound 4 was stirred at room temperature with a mixture of concentrated nitric acid and glacial 
acetic acid for three days. The reaction was monitored by mass spectrometry since it is not very 
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easy to separate the product of partial nitration from the final tetra-nitro compound by TLC. After 
this time we obtained the tetra-nitro calyx[4]arene 5 in 81% yield without the need of further 
purification. In the 1H-NMR spectrum (Fig. 5) it is possible to see that there is no signal of the tert-
butyl groups at high field and the aromatic protons are shifted to lower field (δ = 8.01 ppm and δ = 
7.22 ppm) due to the presence of the electronwithdrawing NO2 groups. We also have tried this 
reaction in different nitration conditions, with trifluoroacetic acid and sodium nitrate, but we 
obtained compound 5 in only 35% yield. 
 
Fig. 5 1H NMR spectrum (CDCl3, 300 MHz, 298 K) of the compound 5. 
 
The synthesis of the monofunctionalised DOTA derivative 12 was carried out in several steps 
following procedures which are reported in the literature. We started from cyclization reaction 
between ethylene glycol ditosylate 7 and triethylene tetraamine tetratosylate34 6 (scheme 4) which 
yields tetratosylated cyclen. In this reaction is very important the heating time since if it is shorter 
than three hours a considerable amount of the acyclic mono condensation product is formed. After 
work-up, the crude reaction product was recrystallized from toluene to obtained a white solid 
powder of pure compound 8. This compound was characterized by 1H-NMR and shows the typical 
signals of the tosyl and of the methylene groups. 
 
 86 
N N
NN
Ts
TsTs
Ts
N NHTs
NHTsN
Ts
Ts
O
O
Ts
Ts
K2CO3
DMF dry
24h to rt
3h to 70 °C
+
(6) (7) (8)
NH HN
HNNH
(9)
H2SO4
130°C
 
Scheme 4 
 
We proceeded in the removal of the tosyl groups by using sulfuric acid at 130° C to obtained the 
corresponding cyclen (9) after trituration of the crude product in ethyl ether. For the work-up we 
followed the procedure reported in literature35. In the 1H-NMR spectrum we have observed the 
disappearance of the tosyl groups and the presence of only one peak at 2.67 ppm of the methylene 
protons. 
The cyclen (9) was subsequently reacted with three equivalent of tert-butyl bromoacetate (scheme 
5). to obtained the triester compound36 (10) in 62% yield after recrystallization from toluene which 
allows to eliminate a small amount of the tetra-alkylated cyclen. In the 1H-NMR spectrum of 10 it is 
possible to observe three singlets of the tert-butyl groups at δ = 1.46, 1.45, 1.44 ppm while at δ = 
3.28 and 3.36 ppm there are two characteristic signals of the NCH2CO groups (1:2 ratio). Moreover 
a broad signal at 10.00 ppm is evident which is attributed to the endocyclic amine proton. In the 
following step, we again alkylated the remaining secondary amine groups of cyclen using ethyl 
bromoacetate and potassium carbonate as base, in order to obtain an ester group orthogonal to the 
other three already present. Compound (11) was obtained in 92% yield after trituration with ethyl 
ether (scheme 5). 
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Scheme 5 
 
The 1H-NMR spectrum in CDCl3 confirms the presence of the compound (11): in fact one can 
observed at δ = 4.15 ppm and at 1.26 ppm the typical signals of the ethyl group, a quartet and a 
triplet respectively. 
For the synthesis of compound 11 we also, tried to follow a different procedure which was reported 
in literature which inverts the alkylation steps. This approach consists in the mono-alkylation of 
compound 9 with ethyl-bromoacetate, followed by trialkylation with tert-butyl bromoacetate. 
During this procedure, however, we encountered some difficulty since in the first step the reaction 
is not very selective and we observed a mixture of compounds (mono-, di-, tri- and tetraalkylated) 
which was very difficult to be separated by flash chromatography. Therefore this strategy was 
abandoned and we followed the one reported above (scheme 5) which gave good yields. 
The last steps to complete the synthesis and prepare a DOTA derivative 12 which could be easily 
attached to the calixarene carboxylic acid consisted in the selective amide formation between the 
ethyl ester (11) and ethylenediamine for 72 h (scheme 6). 
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 88 
In this reaction we used ethylendiamine as solvent in order to prevent the coupling of two molecules 
of compound 11 with both ends of the diamine. The reaction was stirred at room temperature for 
three days. After complete conversion of the starting material (monitored by TLC) we evaporated 
the solvent to obtained pure compound 12. The 1H-NMR spectrum (Fig. 6) in CDCl3 shows the 
disappearance of the ethyl ester signals and the appearance of a triplet at 8.76 ppm (NH amidic) and 
a quadruplet at 3.36 ppm plus a triplet at 2.90 ppm attributable to the methylene groups of ethylene 
diamine. Moreover, a singlet at 1.45 ppm of the tert-butyl groups and a broad signals of the 
endocyclic methylenes can be observed between 2 and 4 ppm. These signals are rather broad since 
the macrocycle possess a reduced conformational mobility at room temperature. 
 
 
Fig.6 1H NMR spectrum (CDCl3, 300 MHz, 298 K) of the compound 12 
 
Compound 12 was then coupled to the tetranitro-calixarene mono-carboxylic acid (5). The reaction 
was performed using hydroxy benzotriazole (HOBt) and dicyclohexylcarbodiimide DCC (scheme 
7) to form the active ester which was reacted in situ with a slight excess of the DOTA amine 
derivative (12). We tried to purify the compound from dicyclohexyl urea by crystallization using 
several solvents but without success and therefore we had to use the flash chromatography which 
gave compound (13) in very pure form. The 1H-NMR spectrum (fig. 7) shows two broad peaks at 
8.80 and 8.85 ppm for the amide groups, two singlet for the aromatic protons of the nucleus bearing 
the DOTA derivative and of the opposite one, while the protons of other two aromatic rings give 
rise to two doublets at 7.80 and 7.77 ppm. Again, very broad signals between 2 and 3 ppm were 
attributed to the methylene proton of cyclen. 
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The position of the aromatic signals suggests that the phenolic nucleus functionalized with the 
DOTA derivative and the one in opposite position are in a nearly parallel situation in the shielded 
zone created by the other two rings. The structure of compound (13) was also confirmed by mass 
spectrometry where the peak at m/z = 1407.6 corresponding to [M+Na]+ was observed 
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Fig. 7 1H NMR spectrum (CDCl3, 300 MHz, 298 K) of the compound 13 
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The reduction of the nitro groups in calixarene 13, was carried as reported in scheme 8. Compound 
13 was dissolved in methanol and then a catalytic amount of Pd/C was added. The mixture was 
stirred at room temperature under hydrogen (1 atm) in the Parr apparatus. The reaction was rather 
slow and still after one day of reaction we obtained only a partial reduction of our compound. We 
have assessed that the reaction needs five days to give the compound 14, completely reduced as 
ascertained by ESI-MS analysis. 
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Scheme 8 
 
Even if the 1H-NMR spectrum of compound 14 showed only very broad signals we nevertheless 
decided to proceed with the conjugation of the carbohydrate units using a procedure well 
consolidated in our group and reported in scheme 9. Compound 14 was solubilised in 
dichloromethane and then 1.5 equivalent for each amino group, of tetraacetyl D-galactosyl β-
isothiocyanate, was added using DIPEA as base in order to be sure that all the amino groups are 
deprotonated. After three days stopped the reaction evaporated the solvent and tried to purify the 
crude product by crystallization from ethyl ether, to eliminate the carbohydrate in excess. However, 
both the 1H-NMR spectrum, which shows very broad peaks for all the signals, and the ESI-MS 
spectrum, in which the molecular peak is not present, suggest that the coupling reaction was not 
successfully. The incomplete conjugation of the saccharides to the calixarene scaffold, might 
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probably originates from a not complete reduction of the p-nitrocalixarene 13 to the p-amino 
derivative 14. Moreover quite recently, in our group, it has been observed that amino calixarenes 
can be easily carbonatated to carbamic acids, also by atmospheric CO2.It might be that this effect 
had also concurred in the degradation of our p-amino calixarene derivative 14 preventing a 
complete conjugation of the sugar moieties. We tried to force the reaction conditions increasing the 
reaction time and the amount of reagents in the last two steps, but without any success, therefore we 
decided to change our of glycoconjugation strategy. 
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Scheme 9 
We devoted our attention to the 1,3-dipolar cycloaddition reactions of azides with alkynes to give 
1,2,3-triazoles37, which is a very efficient ligation technique, often referred as “Click Chemistry”38. 
This reaction, first proposed in 1960s was usually carried out at high temperature to give a 1:1 
mixture of two regioisomers, the 1,4 and 1,5 disubstituted triazole ring. Nowadays, with the use of 
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copper(I) as catalyst one can selectively obtain the 1,4-disostituted triazole39 in very high yields and 
excellent purity, often without the need of any purification. That is the main reason why this 
conjugation reaction is often used for multivalent ligands40. We therefore planned to use this 
strategy to conjugate the sugar units to the calixarene scaffold. 
Our first idea was to synthesise the tetra alkynyl calix[4]arene (21) and then to react it with the 2-
azido O-glycosyl tetraacetyl-D- galactose (23) using the “Click Chemistry”41. 
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Fig. 8 
 
For the synthesis of compound (21), we started from p-H calix[4]arene and functionalized it at the 
lower rim as reported in literature42 thus obtaining the desired monoester-tripropoxy derivative 17. 
We then functionalized compound 17 at the upper rim as reported in scheme 8. Bromination or 
iodination of calixarenes can be conveniently performed by direct substitution with the appropriate 
halogen and the halogenated macrocycles used for further functionalization. So we reacted 
compound 17 with silver acetate and, after 30 min., iodine was added and the suspension was 
stirred to 60°C for 1h. The reaction was monitored by TLC and after complete conversion of the 
starting material was quenched. We thus obtained the corresponding p-iodocalixarene 18 in high 
yield and without further purification.  
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Scheme 8 
 
The following step is a Pd-catalyzed cross-coupling reaction of the aryl halides with terminal 
alkynes, named Sonogashira coupling43 44. The reaction was performed under Argon atmosphere in 
degassed triethylamine since it has been was demonstrated that the oxygen promotes the coupling 
between two alkyne moieties. Although we used Pd(II), it is reduced in situ by Cu(I) to Pd(0) which 
is the active species in the catalytic cycle. This reaction is very sensitive to the presence of oxygen 
and to reaction conditions not completely dry, so that sometimes we also obtained as by-products 
partially substituted calixarenes which had to be eliminated by flash chromatography. The 1H-NMR 
spectrum (Fig. 9) showed beside the characteristic signal at δ = 0.2 ppm of the trimethylsilane 
groups, also some minor signals around 5.5 ppm which seems to indicate the presence of alkene 
protons. Moreover, also in the aromatic region and around the signals of the OCH2CO groups other 
signals shows the presence of minor compounds, which, however could not be eliminated by flash 
chromatography. 
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Figure 9 :1H NMR spectrum (300 MHz, CDCl3, 300 K) of compound 19 
 
In the following reaction, the tri-methylsilyl groups were removed with potassium fluoride in DMF 
at 60° C. The reaction was quenched after 24 h to give the compound 20 in 98% yield without 
further purifications. The compound 20 was characterized by mass spectrometry, where the 
molecular peak [M+Na]+ at m/z = 755.41 and two other peaks at m/z = 781.29 and at m/z = 807.47 
could be observed. Moreover the 1H-NMR spectrum (Fig 10) shows the absence of the signals of 
the trimethylsilyl groups and the appearance of the signals of the protons of the alkynes confirming 
the complete deprotection. However, still around 5.5 ppm some signals possibly due to vinylic 
protons could be observed. Looking to the  literature45, we found that in Sonogashira coupling there 
is often the possibility that trimethylsilyl acetylene reacts also with the alkyne bound to the aromatic 
group to form an addition product having a double bond as reported in scheme 9. This hypothesis is 
confirmed by the presence of the peaks at m/z = 781.29 and 807.47 in the mass spectrum which are 
attributed to the addition of one and two -C≡CH groups, respectively (Fig. 11). Luckily, at this 
stage the by-products could be eliminated by flash chromatography. The formation of the above 
mentioned by-products are probably facilitated by the fact that we have used an excess of trimethyl 
silyl acetylene and a long the reaction time, needed to substitute all the four iodine atoms at the 
upper rim of the calix[4]arene. 
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Fig. 10:1H NMR spectrum (300 MHz, CDCl3, 300 K) of compound 20 
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Scheme 9 Schematic representation of possible by-product (red colour) in Sonogashira coupling 
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Fig. 11 By-products from Sonogashira coupling : alkene groups in difunctionalised products might be in vicinal or 
distal positions 
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Fig. 12:1H NMR spectrum (300 MHz, CDCl3, 300 K) of compound 20 after purification by flash chromatography. 
The spectrum shows the absence of signals around 5.5 ppm and clean signals for the aromatic and methylene protons. 
 
The hydrolysis of the ester group in calixarene 20 was performed in THF/H2O solution with 
potassium hydroxide and after 12 h reflux we obtained the compound 21 with 80% yield without 
further purification. In the 1H-NMR spectrum we observed the disappearance of the signals of the 
ethyl group of the ester and a change in the aromatic region where two doublets respectively at δ = 
6.55 and 6.50 ppm (J = 1.8 Hz) were observed. Moreover at δ = 7.32 ppm there is a singlet of four 
protons corresponding to the hydrogen atoms in meta position of the ring with the carboxylic group 
and the opposite one. The mass spectrum confirms the ester hydrolysis, showing the peak at m/z = 
755.41 [M+Na]+ corresponding to compound 21. 
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In parallel, we synthesized the peracetylated 2-azido ethyl-O-galactoside (Fig. 8, compound 23) as 
reported in literature46 47 and according to scheme 10. D-galactose was peracetylated with acetic 
anhydride and sodium acetate to get the corresponding peracetylate compound in quantitative yield. 
The 2-bromoethanol was mixed at 0° C with boron trifluoride in dichloromethane. The reaction was 
stirred at room temperature over night and monitored by TLC. After disappearance of the starting 
material the reaction was quenched and only the β-anomer compound 22 was obtained in 98 % 
yield without further purification. The bromine atom was then replaced with azide in DMF at 60° C 
and under nitrogen atmosphere to get compound 23 in high yield (the same procedure was used for 
synthesizing the corresponding glucose derivative 23a in 95% yield) 
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Scheme 10 
 
Once obtained the sugar azide 23 and the tetra-acetylene calix[4]arene mono-acid 21, we started to 
study their conjugation through “Click Chemistry”. Compound 21 was dissolved in toluene and 
copper iodide and DIPEA were added. The reaction was stirred at room temperature in the dark 
since copper iodide is light sensitive. After 24 h, TLC analysis of a sample still showed mainly the 
presence of the starting material. Attributing the low reactivity to the presence of the carboxylic 
group, which could have sequestered the copper catalyst, we added another aliquot of copper iodide 
and left the reaction for an additional day in the same conditions. The compound 24 was isolated 
after work-up and trituration with ethyl ether. The 1H-NMR spectrum of 24 (Fig. 13) results rather 
complicated and very difficult to be interpreted. The presence of singlets between 1.96 and 2.15 
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ppm for the acetyl groups, of multiplets at 3.75-5.40 ppm together with two doublets around 3.40 
ppm for the equatorial methylene protons and the aromatic signals clearly indicate that the sugar 
units are conjugated to the calixarene scaffold. 
In the aromatic region, two doublets at 6.83 and 6.72 ppm and two singlets at 7.71 and 7.12 ppm, 
show the multiplicity expected for compound 24, although one signal is unexpectedly shifted at 
quite low fields. 
This unusual distribution of the aromatic signals could be probably due to a flattened cone 
conformation of the calix[4]arene induced by the formation of an intramolecular hydrogen bond 
between the carboxylic group and one oxygen atom bearing the propyl chain. Moreover, while for 
the triazole are expected at maximum three singlets, between 7.81 and 7.90 ppm there are, indeed, 
four signals. The spectrum is also quite broad and does not change significantly in DMSO-d6 even 
at high temperature. One of the reasons of the complicated NMR spectrum could be that products of 
partial conjugation might also be present: by increasing the degree of conjugation at the upper rim, 
increases also the steric crowding and tetra conjugation might be slowed down. This could also 
explain the unusually long reaction times needed for a “Click Chemistry” reaction. 
Another hypothesis made to explain the broadness and high multiplicity of the signals could be 
related to the presence of conjugation between the triazole and the phenol nuclei which slow the 
rate of rotation around arene-arene bonds. 
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Scheme 11  
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To perform the reaction between compounds 21 and 23 we also used Cu(II) sulfate mixed  
organic/water solution or copper (I) with a coordination complex (Cu(PPh3)3Br) which is particular 
effective in organic solvents, like dichloromethane solubility but we did not obtain improvements. 
(scheme 11 conditions a-c). 
 
 
Fig. 13 1H NMR spectrum (300 MHz, CDCl3, 300 K) of the compound 24 
 
The ESI mass spectrum (fig. 14) also confirms the presence of compound 24. The cluster of peaks 
around 1200 a. u. can be in fact explained as doubly charge ions of the desired product: m/z = 
1209.91 [M + 2Na]2+ ; 1220.8 [M + 3Na - H]2+ ; 1199.4 [M + Na + H]2+ ; 1188.5 [M + 2H]2+. 
Despite of all these attempts, the amount of tetra-conjugated product was always quite modest. The 
reactivity of the p-alkynyl calix[4]arene 21 in the “Click chemistry” conditions seems rather low 
and long reaction times and high temperature are required to obtain a significant conversion. All 
these data brings us to hypothesize that the reaction follows also the thermal route producing a 
mixture of 1,4- and 1,5- disubstituted, triazoles which makes it difficult the purification of the 
compounds and gives complicated NMR spectra. 
This low reactivity could derive from an increase of steric crowding at the upper rim of the 
macrocycle as soon as the number of triazole units increases. We have therefore decided to increase 
the distance between the triazoles and calixarene scaffold by introducing a linker (Fig. 15). 
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Fig. 14 ESI mass spectrum in CH3OH with positive ionization mode of compound 24  
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Fig. 15 new target with a linker between calix[4]arene and triazole 
 
In the compound 30 we planned to have a spacer of three atoms which should be enough to 
eliminate the steric crowding at the upper rim of the calixarene during the Click Chemistry reaction. 
The new synthetic strategy to obtain compound 30 is reported in scheme 12. 
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a) BrCH2COOEt, NaH, THF dry, T = 67°C, 1h 30'; (25), Y = 87%. b) HNO3 100%, CH2Cl2, 
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Scheme 12 
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The p-tert-butyl calix[4]arene, as reported in literature48 was deprotonated with a strong base such 
as sodium hydride, and then alkylated with α-bromo-ethyl acetate in dry THF. The reaction was 
stirred at 70° C for two hours. We slightly modified the procedure reported in literature. In fact we 
used 16 equivalents of NaH and 20 equivalents of α-bromo ethyl acetate instead of the 8 equivalents 
of each reagent. Compound 25 was obtained, after work-up and without further purification, in 87% 
yield. In the 1H-NMR spectrum Fig. 16 two doublets at δ = 4.85 ppm and 3.18 ppm (J = 13 Hz) are 
present, which are the signals characteristic of the methylene bridge protons in axial and equatorial 
positions respectively indicating only a cone conformation for the product. Beside the singlets at δ = 
6.77 ppm for the aromatic protons and at δ = 1.07 ppm for the tert-butyl-groups, it is possible to 
assign the singlet at δ = 4.8 ppm to the ArOCH2- groups and the quartet at δ = 4.2 ppm and the 
triplet at δ = 1.28 ppm to the ethyl ester group. 
 
 
Fig. 16 1H-NMR spectrum (CDCl3) of compound 25 
 
Compound 25 was then nitrated at the upper rim using a reaction which, due to the simultaneous 
removal of the tert-butyl groups is named ipso-nitration49. The corresponding tetra-nitro compound 
26 was isolated in 45% yield. The reaction was carried out in the same conditions as reported in the 
scheme 3 for compound 4. In this case, however, we observed, after crystallization from methanol 
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of the crude compound, a small amount of the corresponding methyl ester, originated from the 
transesterification reaction, which took place during crystallization in slightly acidic condition. The 
mixture of ethyl and methyl esters were therefore treated with refluxing ethanol and a catalytic 
amount of concentrated sulfuric acid for 24 hours, to obtained the pure tetra-ethyl ester. 
The reduction of the nitro groups to amine, (c, scheme 12) was carried out with a large excess of 
sodium borohydride and cobalt(II) dichloride hexahydrate at room temperature and overnight. 
Compound 27 was isolated in high yield but not in a very pure form. In fact in the 1H-NMR 
spectrum (Fig. 17) all the signals are rather broad, included the peak of residual CDCl3. We tried to 
record the spectrum in different solvents, like methanol-d4 and DMSO-d6 but we also observed very 
broad spectra as in CDCl3. Probably, the broad signals observed should be attributed to the presence 
of traces of cobalt which is paramagnetic. Although the spectrum is quite difficult to be interpreted 
and even if peaks are rather broad, all expected signals are present. A positive test with ninhydrin 
reagent on the TLC plate also confirms the presence of amino groups. 
 
Fig. 17 1H-NMR spectrum (300 MHz CDCl3) of compound 27 
 
This crude product 27 was therefore submitted to acylation reaction with α-chloro-acetyl chloride 
and N-ethyl-di-isopropyl amine. The mixture was stirred in dry dichloromethane at room 
temperature and under nitrogen atmosphere for 1h. After work-up the crude product was purified by 
flash chromatography to give the pure compound 28 (scheme 12) in 95 % yield. The 1H-NMR 
spectrum was registered in a mixture of CDCl3 and methanol-d4 to avoid the formation of intra-and 
 104
intermolecular H-bonds, which broadens the spectrum. We could observe the characteristic singlet 
at δ = 3.82 ppm for the proton of the C(O)CH2Cl group which confirms the success of the reaction. 
To synthesize the tetra-azido derivative 29, to be used in the final “Click Chemistry” step for 
conjugation of the sugar to the calixarene, we submitted compound 28 to the nucleophilic 
substitution of chlorine with azide group. The reaction was carried out under phase transfer-
catalysis, with tetra-butyl ammonium hydrogen sulfate, sodium azide, in a mixture of a sodium 
hydrogen carbonate saturated aqueous solution and methylene chloride (e, scheme 12). The mixture 
was vigorously stirred at room temperature for two days. 
It was rather difficult to monitor this reaction by TLC, since no chromatographic conditions could 
be found either on a direct or an inverse phase, to separate the two compounds. We therefore used 
Electrospray Mass Spectrometry (ESI-MS) to follow the reaction. The kinetics of this reaction is 
very slow; in literature it was reported the use of 12 equivalents of sodium azide but we had to use 
40 equivalents for each chloride to be substituted. After the work-up we could obtain a crude 
product which was purified by crystallization in ethanol to get compound 29 in 52% yield. The 
latter compound was characterized by ESI-MS (Fig. 18) where the sodiated molecular peak at m/z 
= 1183.66 [M+Na]+ was observed; in any case no peak of partially substituted compounds is 
present. The IR spectrum of this compound (Fig. 19) in a film on NaCl pellets shows the 
characteristic absorption at 2107 cm-1 which is typical of the azide group. On the other hand the 1H-
NMR spectrum was not very informative since not significant differences with the signals of the 
tetrachloro derivative 28 could be observed. 
 
Fig. 18 ESI-MS spectrum in CH3OH with positive ionization mode of compound 29. 
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Fig. 19 Infrared spectrum (film on NaCl pellets) of compound 29 
 
The following “Click Chemistry” was carried out between compound 29 and the commercially 
available peracetylated 2-propynil-β-D-glucose (31). The reaction was carried out in microwave 
apparatus. Compound 29, and an excess of peracetylated 2-propynil-β-D-glucose were mixed 
together with a catalytic amount of copper sulfate penta-hydrate and sodium ascorbate in DMF as 
solvent. The mixture was irradiated at 150 watt power (T = 80° C) for 20 minutes. After this time a 
TLC analysis indicated the complete conversion of the starting material. After quenching the 
reaction and work-up we could recover the unreacted sugar, used in excess, by trituration of the 
crude product in ethyl ether. We obtained quite pure the compound 30 in 84% yield without further 
purification. In parallel experiments under traditional heating, conditions we used the Cu(PPh3)3Br, 
a Cu(I) complex soluble in organic solvents50, in methylene chloride or CuI in toluene, but without 
success. In both conditions we only obtained mixtures of compounds partially conjugated, which 
were very difficult separated. 
The 1H-NMR spectrum (Fig. 20) shows at δ = 8.03 ppm the signal of triazole protons (4H); at δ = 
6.93 ppm the signal of the aromatic protons (8H). The sugar units give at δ = 5.04 ppm a triplet for 
H-4 which couples with H-3 (at δ = 5.24-5.21). H-3 is also coupled with H-2 (at δ = 4.95-4.70) 
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while the doublet for H-1 is superimposed to H-2. The four singlets at δ = 2.02, 1.99, 1.95, 1.94 are 
attributed to the protons of the acetyl groups of the sugar. The assignment of each of these signals 
was confirmed with the aid of a COSY spectrum (Fig. 21). 
 
Fig. 20 1H-NMR ( 300 MHz in CD3OD)spectrum of compound 30. 
 
  
Fig. 21 H-COSY spectrum (300 MHz in CD3OD) of compound 30 
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For reason of time, compound 30 could not be linked to DOTA. However, we plan to selectively 
hydrolyse one of the four ester groups at the lower rim, as reported in literature51 on similar 
tetraester derivatives, and to subsequently couple the resulting acid with DOTA-amine (12). 
Another possibility which could be explored is to hydrolyse all the four ethyl groups at the lower 
rim of the calix and to attach four DOTA-amine (12) units (Fig. 21b). 
The latter conjugate, once complexed with Gd(III), should present a high concentration of 
paramagnetic ions and should improve sensitivity for this class of site-specific contrast agents. 
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Fig. 21b compound 30 respectively one and four units of DOTA derivative 
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4.4 Synthesis of Gallic acid-DOTA conjugates 
 
In parallel to the synthesis of polyglycosylated calixarene-DOTA conjugates we also prepared two 
potential contrast agents based on gallic acid as scaffold and having exposed galactose or glucose 
units (Fig. 22). We choose gallic acid since it bears three hydroxy groups to which three units of the 
same carbohydrate can be attached. Again we planned to take advantage of “Click Chemistry” to 
conjugate saccharide units to the trifunctional scaffold and use the carboxylic function to bind the 
DOTA derivative. 
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Fig. 22  
 
Conjugation of sugar with “Click Chemistry” catalyzed by copper salts, should take place prior to 
the coupling of DOTA, since we verified that the functionalised azamacrocycle form extremely 
stable complexes with copper ions which are very difficult to dissociate. 
Starting from gallic acid we synthesised the common intermediate 33 (Scheme 13) which was 
subsequently conjugated to galactose or glucose  
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Scheme 13 Synthetic steps for conjugation of sugars on gallic acid. 
 
Gallic acid was first protected as methyl ester, following the procedure reported in literature52, 
which uses methanol and a catalytic amount of sulfuric acid at reflux to obtained compound 31 in 
90% yield. 
The alkylation of the hydroxy groups53 was carried out using with an excess of propargyl bromide 
and potassium carbonate. Compound 32, obtained in 96% yield, was then hydrolyzed53 with sodium 
hydroxide in a mixture of dioxane/methanol at room temperature. Compound 33 was obtained  in 
quantitative yield, without further purification. 
At the same time the galactose-(23a) and the glucose-O-2-azido (23b) ethyl derivatives (see 
scheme 10 chap. 4.1) were synthesised as reported in literature46, 47. 
The Click Chemistry reactions between gallic acid derivative 33 and azido sugars 23a and 23b were 
carried out using the classic conditions53 (Scheme 14); copper sulfate, sodium ascorbate in 
DMF/water as solvent in the dark and using conventional heating. 
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Scheme 14 Click Chemistry reaction on Gallic acid derivative. 
 
In both reactions with galactose or glucose we encountered some problems; the reagents are not 
very soluble in the reaction media so we had to used a high stirring speed. Moreover, after 24 h 
TLC analysis still showed the presence of the starting material and an extra half equivalent of sugar 
and catalyst had to be added. After two more days, the starting material disappeared and the 
reaction was quenched. We tried to eliminate the copper salts with several washings of the organic 
phase with a phosphate buffer (pH = 7.00) but without success. Both compounds were purified by 
flash chromatography and the glycoconjugates 34a and 34b were obtained in 56 and 58% yield 
respectively. 
These compounds were characterised by ESI-MS where we observed the doubly charged molecular 
peaks with two sodium ions [M +2Na]2+ at m/z = 1581. The structure of compounds 34 was verified 
by 13C and 1H-NMR spectra while all the signals in the proton NMR spectra where unequivocally 
assigned using 2D-COSY. For compound 34a in CDCl3 the broad singlet at δ = 7.86 ppm correlates 
with signals at 5.23 ppm indicating they are due to the triazole and the ArOCH2 protons. At δ = 7.47 
the broad singlet of the aromatic protons are clearly visible indicating that the coupling took place. 
The methyne and methylene protons of the sugar are visible between 3.92 and 5.19 ppm. whereas 
the four singlets between 1.88 and 2.13 ppm are diagnostic of the acetyl groups. The expected ratio 
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between the signals of the sugar units and the gallic and ArOCH2 units confirm the 
trifunctionalization. The coupling reaction between compounds 34a, or 34b and DOTA amino 
amide derivative 12 was carried out using O-Benzotriazole-N,N,N’,N-tetramethyl-uronium-
hexafluoro-phosphate (HBTU) and triethylamine in dry dichloromethane (scheme 15). In each case 
the reaction mixture was stirred at room temperature under nitrogen atmosphere for 24 h. After the 
work-up, the crude reaction product were purified by flash chromatography to obtained 35a and 
35b in 84% and 55% yield, respectively. 
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Scheme 15 Coupling reactions between gallic acid derivatives and DOTA amino-amide derivative 
 
The 1H-NMR spectrum of compound 35a registered in DMSO-d6 (Fig. 23) shows two broad 
singlets at δ = 7.92 and 8.11 ppm which are correlated with signals at 5.17 and 5.04 ppm indicating 
they are due to the triazole and the ArOCH2 protons. Moreover, at δ = 8.22 and 8.43 ppm there are 
two broads singlets of the two –NH protons. Between δ = 3.92 and 5.25 ppm we observe the 
methylene protons of the sugar and the signals of the NCH2CH2O chain between triazole and sugar. 
Finally, significant is the presence at δ = 1.43 and 1.44 ppm of two singlets which are attributed to 
the tert-butyl groups of the macrocycle. The structures (35a and 35b) were confirmed with electro-
spray analysis where we observed peak at m/z = 1089.6 [M+2Na]2+ and 2155.8 [M+Na]+. 
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ppm (f1)
2.03.04.05.06.07.08.0
Fig.23 1H-NMR spectrum in DMSO-d6 (300 Mhz) of compound 35a. 
 
The removal of the tert-butylic groups of both compounds 35a and 35b was performed (scheme 16) 
following the classical conditions reported in literature54, trifluoro acetic acid and triethyl-silane, in 
dichloromethane. The reactions were stirred at room temperature for 24 h, obtaining compounds 
36a and 36b in 92 and 78% yield respectively, after solvent evaporation. The 1H-NMR spectra 
showed the disappearance, in both compounds, of the signals of the tert-butyl groups around 1 ppm. 
Moreover we recorded the two-dimensional 1H-1H COSY in both compounds. 
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Scheme 16 Removal of the tert-butyl groups. 
 
The last step consisted in the removal of the acetyl groups from the saccharide units. A solution of 
sodium methoxide in methanol was added to compounds 36a and 36b and the suspension stirred at 
room temperature for 3 h. The pH was slowly brought at neutrality by addition of a AMBERLITE 
IR 120 H+ resin. After filtration of the resin, methanol was removed from the solution to give 
compound 37a and 37b in 98 and 81% yield respectively (scheme 17). The 1H-NMR spectrum in 
D2O showed the characteristic peaks of the triazole proton at low fields and all the other protons 
were identified by 1H-1H COSY analysis. 
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Scheme 17 Removal of the acetyl groups 
 
In collaboration with Aime’s group at the University of Torino we tested compounds 37a and 37b 
to estimate the complexation ability versus the gadolinium ion, the relaxometric properties of their 
Gd(III) complexes and to study the interaction all these polyglycosylated Gd complexes with two 
types of lectins, ConcanavalinA (ConA) and Peanut Agglutinin from Arachis hypogea (PNA). 
Herein we report our preliminary results (Tab.1). 
The gadolinium complexes show a relaxivity at 20 MHz and 25° C of 7.8 mM-1s-1 for the 
compound 37a and 8.5 mM-1s-1 for 37b (Tab 1), which are comparable to values found for 
analogous complexes having similar molecular weight (cfr. Aglycone 38 in tab 1). 
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Fig. 24 
The preliminary relaxometric studies carried out so far show that both compounds 37a and 37b 
form rather stable complexes with Gd(III) in water solution at different pH (results not shown) with 
a stability quite similar to those of other monoamide-Gd-DOTA. 
 
 Compound Relaxivity 
20 MHz, 25°C  
(mM-1s-1) 
PNA K ass  
(M-1) 
ConA Kass  
(M-1) 
Relaxivity of the 
ConcA adduct 
Galacto-gallic 
37a 
7.8 mM-1s-1 No interaction 9.8×105 M-1 15.5 mM-1s-1. 
Gluco-gallic 
37b 
8.5 mM-1s-1 No interaction 3.9×103 M-1 38.8 mM-1s-1 
Aglycone 
38 
5.06 mM-1s-1 Not measured No interaction _ 
 
Tab. 1 Preliminary results of relaxivity and complexation of compounds 37a, 37b and aglycone 38 
 
The interaction of the Gd-37a and Gd-37b complexes with plant lectins was also studied by 
observing the variation of the relaxivity of a 0.1 mM solution of Gd(III) complexes with increasing 
amount of proteins. 
ConA itself is paramagnetic, since it contains a Mn(II) ion. For this reason, the relaxivity of ConA 
alone was also measured at 20 MHz and 25°C resulting to be 7.1 mM-1 s-1, which is a rather high 
value and comparable to that of the Gd(III) complexes. During the titration experiments of Gd 
37a/b with ConA, this contribution to relaxivity had therefore to be subtracted. 
The curves for the galactose cluster complex Gd-37a and ConA or PNA are reported in fig. 24 
while those for the glucose cluster complex Gd-37b are reported in fig. 25  
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Fig. 24 Fig. 25 
 
 
While it is clear that neither Gd-37an or Gd-37b interact with the galactose-selective lectin (PNA), 
both Gd-complexes seem to interact rather strongly with the glucose-selective lectin (ConA). 
From these titration curves, the Kass and relaxivity of the Gd-37-ConA adduct could be calculated. 
While the relaxivity of the two adducts are quite similar, the affinity for ConA of the galactose-Gd-
37a complex is unexpectedly nearly 250-fold higher than that of the corresponding complex of 
glucose Gd-37b. Rather unexpected is also the fact that a galactose sugar cluster is bound so firmly 
to a glucose-selective lectin. In order to exclude that this strong binding is simply originated by a 
Gd-protein interaction, we also titrated the Gd-38 complex with ConA. The linear trend of this 
titration curve (not shown) however clearly indicates a complete absence of interaction. 
We are currently trying to confirm these Kass values using a different technique. However these 
preliminary results are quite encouraging, indicating that ligands 37a and 37b strongly complex 
Gd(III) ions with important relaxivities and are able, thanks to the presence of the sugar units, to 
interact with lectins. 
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4.5 Conclusions 
 
In this chapter of the thesis, our efforts to synthesize new potential Site-Directed Contrast Agents 
for MRI, which exploit the cluster glycoside effect, are described. We used the strategy of coupling 
a tetraazacyclododecane-N,N’,N’’,N’’’-tetraacetic acid (DOTA) to polyglycosylated calix[4]arene 
and gallic acid scaffolds. Several synthetic procedures were attempted to introduce glycosyl units 
on the calixarene macrocycles at the upper rim and it was finally found that the best one exploits the 
“Click Chemistry” approach through the formation of a triazole ring. Initially the calix[4]arene 
scaffold was adorned with four alkynyl groups at the upper rim and were coupled with sugar-azide 
derivatives, leading to useful intermediates but not to the final products. Subsequently, the 
complementary strategy of anchoring the azido group on the calixarene scaffold and the alkynyl 
moiety on the carbohydrate, was attempted. In this case it was found that the cycloaddition 
reactions leading to the simultaneous conjugation of four sugar units is very sensitive to the steric 
crowding which originates at the upper rim during the reaction. To obtain positive results in this 
conjugation method it was necessary to introduce a three-atom spacer between the macrocycle and 
the forming triazole units. In the case of the gallic acid scaffold the synthetic goal of having 
simultaneously on the same molecule a sugar clusters and a DOTA unit was completed. The Gd(III) 
complexes of these ligands were prepared and their stability and relaxivity properties studied in 
water solution, in collaboration with Prof. Aime’s group in Torino. They show good stability and 
remarkable relaxivities, comparable with those of other DOTA derivatives reported in literature. 
However, thanks to the multivalent display of galactose and glucose units the complexes strongly 
interact with plant lectins such as Concanavalin A (ConA) and PeaNut Agglutinin (PNA) showing 
good perspective in the development of new “Site-Directed Contrast Agents”. 
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4.6 Experimental section 
 
General Methods: all moisture sensitive reactions were carried out under nitrogen atmosphere. Dry 
solvents were prepared according to standard procedures and stored over molecular sieves.  
Melting points were determined under nitrogen sealed capillaries with an Electrothermal apparatus.  
1H and 13C NMR spectra were recorded at 300 and 75 MHz, respectively, on Bruker AC300 and 
Bruker 300 Avance spectrometers, at 300 K unless otherwise specified. The reported J values are 
referred to H,H coupling constants, unless other specifications. Chemical shifts are reported as δ 
values in ppm using the solvent residual peak as internal standard. IR spectra were recorded on a 
Perkin Elmer 298 apparatus.  
Mass spectra by chemical ionization (CI) and electrospray ionization (ESI) methods were recorded 
on a Finnigan Mat SSQ 710 spectrometer  and on a Micromass ZMD spectrometer, respectively.  
TLC were performed on silica gel Merck 60 F254 sheets and flash chromatography on 230-240 mesh 
Merck 60 silica gel. 
For reasons of clarity and in order to reduce space, the names calix[4]arene was used instead of the 
original IUPAC name: pentacyclo[19.3.1.1.1.1]octaosa-1(25),3,5,7(28),9,11,13(27),15,17,19(26),- 
21,23-dodecane. The nomenclature IUPAC applied to the calixarene is complicated; in fact to 
expose a  macrocycle very large denominations are required. Therefore  here is used the 
international nomenclature proposed by Gutsche, where the numeration of the positions on the 
macrocycle is denominated as in the scheme below. 
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The internal positions of the aromatic rings are referred to the main hydroxy substituent, that is 
named with ipso, and the following  are indicated as  ortho, meta and para. The substituent in para is 
posed before the name of the calixarene. 
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Synthesis of 25-(ethoxycarbonylmethoxy)-p-tert-butylcalix[4]arene 2 
 
                                                                                   
O OH
OH OH
O
OEt  
 
In the two-necked flask under nitrogen was dissolved cesium fluoride (840 mg; 5.5 mmol) in dry 
DMF (75 ml), then was added p-tert-butylcalix[4]arene (3 g; 4.62 mmol) and ethyl bromoacetate 
(5.12 ml 46 mmol). The reaction mixture was stirred under nitrogen at 40°C for 7 h and at room 
temperature for 60 h. 
The reaction was monitored by TLC (SiO2: eluent CH2Cl2/ether petroleum 3:1). When the starting 
material disappeared, the reaction was quenched with a 2M HCl solution (200 ml). The aqueous 
phase was extracted with CH2Cl2 (3 x 50 ml). The organic phase was washed with water (3 x 50 ml) 
and dried over sodium sulfate. The solvent was evaporated under reduced pressure to obtain a crude 
product  as white solid. The crude product  was purified by flash chromatography (SiO2 : gradient 
cyclohexane:ethyl acetate = 95:5, 9:1, 8:2 ) to obtain the product 2 as white solid. Yield: 50%. 1H 
NMR (300 MHz, CDCl3): δ(ppm) 10.23 (s, 1H, OH), 9.25 (s, 2H, OH), 7.09 (s, 2H, Ar), 7.05 (s, 
2H, Ar), 7.04 (d, 2H, J = 2,3 Hz, Ar), 6.98 (d, 2H, J = 2.3 Hz, Ar), 4.89 (s, 2H, OCH2CO), 4.48 (d, 
2H, J = 13.3 Hz, ArCH2axAr), 4.41 (q, 2H, J = 7.2 Hz, OCH2CH3), 4.30 (d, 2H, J = 13.3 Hz, 
ArCH2axAr), 3.43 (d, 4H, J = 13.3 Hz, ArCH2eqAr), 1.38 (t, 3H, J = 7.2 Hz, OCH2CH3), 1.23, 1.20, 
1.19 (s, 36H, C(CH3)3). 13C NMR: δ(ppm): 169.5 (s, CO), 149.9 and 148.2 (Ar ispo), (Ar), 72.0 
(OCH2COOEt), 61.9 (OCH2CH3), 34.2, 34.0, 33.9 (C(CH3)3), 33.0 and 32.5 (ArCH2Ar), 31.5, 31.4, 
31.2 (C(CH3)3), 14.2 (CH3). ESI-MS (+) C48H62O6 (734.45): m/z = 757.3 [M+Na]+.  m. p.: 275-276 
°C 
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Synthesis of 25-(ethoxycarbonylmethoxy)-26,27,28-tripropyloxy-p-tert-butylcalix[4]arene 3 
 
                                                                                   
O O
O O
O
OEt
 
 
Compound 2 (0.430 g, 0.58 mmol) and DMF dry (4 ml) were stirred in a two-necked round 
bottomed flask under nitrogen atmosphere. Then sodium hydride (55-65% in oil, 0.140 g, 2.9 
mmol) and iodopropane (0.493 g, 2.9 mmol) were added. The reaction mixture was stirred under 
nitrogen at room temperature for 24h. The reaction was monitored by TLC (SiO2: eluent ethyl 
acetate/hexane = 6:4). After disappearance of the starting material, the reaction was quenched with 
0.1M HCl (15 ml). The organic phase was extracted with dichloromethane (3 x 20 ml), dried over 
sodium sulfate and the solvent was evaporated under reduced pressure to obtain a crude product. 
This yellow solid was crystallized by acetonitrile to obtain a product 3 as white solid. Yield: 55%. 
1H NMR (300 MHz, CDCl3 ) δ(ppm) 6.91 (s, 2H, Ar), 6.89 (s, 2H, Ar), 6.70-6.63 (m, 4H, Ar), 4.83 
(d, 2H, J = 11.8 Hz,  OCH2CO), 4.62 (t, 2H, J = 12.9 Hz, ArCH2axAr), 4.40 (d, 2H, J = 12.6 Hz, 
ArCH2axAr), 4.10 (t, 2H, J = 6.8 Hz OCH2CH3CH3), 3.85-3.65 (m, 6H, OCH2CH2CH3, CH3CH2O), 
3.16 (d, 2H, J = 12.9 Hz, ArCH2eqAr), 3.11 (d, 2H, J = 12.6 Hz, ArCH2eqAr), 2.19-2.05 (m, 2H, 
OCH2CH2CH3), 2.05-1.88 (m, 4H, OCH2CH2CH3), 1.30 (t, 3H, OCH2CH3), 1.18 (s, 18H, C(CH3)3), 
0.98 (s, 18H, C(CH3)3), 1.10-0,90 (m, 12H, OCH2CH2CH3). 
13C NMR (75 MHz, CDCl3): δ(ppm): 170.9 (CO); 154.1; 153.5; 153.5 (Ar ipso); 144.9; 144.6; 
144.3 (Ar para); 134.6; 134.1; 133.3; 133.1 (Ar ortho); 125.5; 125.1; 124.9; 124.8 (Ar meta); 76.8 
(OCH2CH2CH3); 70.9 (OCH2CO); 60.2 (OCH2CH3); 33.8, 33.6 31.5, 31.4, 31.3, 30.9 (C(CH3)3, 
C(CH3)3 and ArCH2Ar); 23.3 23.2 (OCH2CH2CH3); 14.1; 10.4 10.0 (OCH2CH2CH3). 
ESI-MS (+) C57H80O6 (860.6): m/z = 883.9 [M+Na]+. m. p.: 189-191 °C 
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Synthesis of 25-(hydroxycarbonylmethoxy)-26,27,28-tripropyloxy-p-tert-butylcalix[4]arene 4 
 
                                                                                   
O
OH
O
O O
O
 
 
In a round-bottomed flask, 25-ethoxycarbonylmethoxy-26,27,28-tripropyloxy-p-tert-
butylcalix[4]arene 3 (1.22 g; 1.42 mmol) was dissolved in THF/H2O (60 ml, 5:1) and a solution of 
KOH (0.738 g; 13.2 mmol) in THF/H2O (5:1) was added. The reaction mixture was stirred at reflux 
for 48h. The reaction was monitored by TLC (SiO2: eluent, cyclohexane/ethyl acetate = 1:1). The 
reaction was quenched with 0.1M HCl until pH 3. the organic phase was extracted with CH2Cl2 (4 x 
30 ml) and dried over sodium sulfate. The solvent was evaporated under reduced pressure to obtain 
a yellow solid after trituration by methanol. Yield: 82.5%. 
1H NMR (300 MHz, CDCl3): δ(ppm): 7.15 (s, 2H, Ar), 7.13 (s, 2H, Ar), 6.59 (d, 2H, J = 2.4 Hz, 
Ar), 6.48 (d, 2H, J = 2.4 Hz, Ar), 4.64 (s, 2H, OCH2COO), 4.45 (d, 2H, J = 12 Hz, ArCH2axAr), 
4.22 (d, 2H, J = 12 Hz, ArCH2axAr), 3.78- 3.67 (m, 6H, J = 6.5 Hz, OCH2CH2CH3), 3.22 (d, 2H, J = 
12 Hz, ArCH2eqAr), 3.15 (d, 2H, J = 12 Hz, ArCH2eqAr), 1.93- 1.85 (m, 6H, J = 6,5 Hz, 
OCH2CH2CH3), 1.34 (s, 18H, C(CH3)3), 0.98 (t, 6H, 7.5 Hz, OCH2CH2CH3), 0.88 (t, 3H, 7.5 Hz, 
OCH2CH2CH3), 0.83 (s, 18H, C(CH3)3). 13C NMR (75 MHz, CDCl3): δ (ppm): 170.7 (CO), 154.1, 
151.8, 151.0 (Ar-CO), 147.0, 145.0, 144.8 (Ar-CC), 135.4, 135.0, 132.6, 131.6 (Ar-CCH2), 125.9, 
125.3, 125.1, 124.5 (Ar-CH), 78.2 and 77.6 (OCH2CH2CH3), 70.7 (OCH2CO), 34.2, 34.1, 33.6 
(C(CH3)3), 31.7, 31.6, 31.2, 31.0, 30.9, 29.7 (C(CH3)3 and ArCH2Ar), 23.1 and 22.4 
(OCH2CH2CH3), 10.3, 9.8 (OCH2CH2CH3). ESI-MS (+) C55H76O6 (832.56): m/z = 877.5 [M+2 
Na]+. m. p.: 226.6-228 °C. 
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Synthesis of 5,11,17,23-tetranitro-25-(hydroxycarbonylmethoxy)-26,27,28-tripropyloxy-
calix[4]arene 5 
 
                                                                                   
O
OH
O
O O
O
O2N O2N
NO2 NO2
 
 
In a round-bottomed flask, compound 4 (241 mg, 0.29 mmol) was dissolved in CH2Cl2 (4 ml) and 
glacial acetic acid (4 ml), the solution cooled to 0°C and added dropwise of 100% HNO3 (1.35 ml). 
The black coloured reaction mixture was stirred at room temperature for 72h. The reaction was 
monitored by TLC (SiO2: eluent cyclohexane/ethyl acetate 6/4) and then quenched at 0°C (ice bath) 
with water (20 ml). The organic layer was extracted with CHCl3 (3 x 20 ml), washed with water till 
neutral pH, dried over sodium sulfate and the solvent was evaporated under reduced pressure to 
obtain a yellow solid. Yield: 81%. 
1H NMR (300 MHz, CDCl3): δ(ppm): 8.01 (s, 4H, Ar), 7.25-7.20 (m, 4H, Ar), 4.87 (s, 2H, 
OCH2COO), 4.58 (d, 2H, J = 14.4 Hz, ArCH2axAr), 4.54 (d, 2H, J = 14.4 Hz, ArCH2axAr), 4.04 (t, 
2H, J = 7.8 Hz,), 3.90 (t, 2H, J = 7.8 Hz, OCH2CH2CH3), 3.53 (d, 2H, J = 14.4 Hz, ArCH2eqAr), 
3.44 (d, 2H, J = 14.4 Hz, ArCH2eqAr), 2.00-1.78 (m, 6H, OCH2CH2CH3), 1.05 (t, 6H, J = 7.2 Hz, 
OCH2CH2CH3), 0.94 (t, 3H, J = 7.5 Hz, OCH2CH2CH3). 13C NMR (75 MHz, CDCl3): δ(ppm): 
10.1-10.5 (OCH2CH2CH3); 23.38 and 23.4 (OCH2CH2CH3); 31.5 and 31.8 (ArCH2Ar); 71.3 
(OCH2CO); 79.1 (OCH2CH2CH3); 123.9, 124.2, 125.0, 125.4 (Ar meta); 134.2; 135.0; 135.8; 136.6 
(Ar ortho); 143.9 and 144.3 (Ar para); 160.2 and 162.5 (Ar ipso); 169.2 (CO). ESI-MS (+) 
C39H40N4O14 (788.25): m/z = 787.1 [M-H]- m. p.: 267- 268 °C. 
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Synthesis of N, N’, N’’, N’’’-tetratosyl-1,4,7,10-tetraazacyclododecane 8 
 
N N
NN
Ts
TsTs
Ts
 
 
In a two-necked flask under nitrogen atmosphere, a suspension of dry potassium carbonate (1.13 g; 
8.15 mmol) in dry DMF (50 ml) was added of compound 7 (3.0 g; 3.92 mmol). The suspension was 
stirred at room temperature under nitrogen for 15 min. Then the reaction mixture was added 
dropwise of a solution of triethylenetetramine tetratosylated 6 (1.45 g; 8.15 mmol) in dry DMF (20 
ml). The suspension was stirred at room temperature under nitrogen for 24h and heated at 70°C for 
3h. 
The solvent was then evaporated under reduced pressure and the brown solid was transferred in 
water and extracted with CH2Cl2 (3 x 50 ml). The combined organic layers were dried over sodium 
sulfate. The solvent was evaporated under reduced pressure to obtain a crude product  as brown 
liquid. This residue was crystallized from toluene to obtain a white solid. Yield: 67% 
1H NMR (300 MHz, CDCl3): δ(ppm): 7.68 (d, 8 H, Ar), 7.33 (d, 8 H, Ar), 3.42 (s, 16 H, NCH2), 
2.44 (s, 12 H, CH3). 13C NMR (75 MHz, CDCl3): δ(ppm): 143.9, 129.8, 127.6 (Ar), 52.3 (CH2), 
21.5 (CH3). ESI-MS (+) C36H44N4O8S4 (788.2): m/z = 811.2 [M+Na]+. m. p.: > 260 °C. 
 
Synthesis of 1,4,7,10-tetraazacyclododecane 9 
 
N N
NN
H
HH
H
 
 
To a sample of compound 8 (2.06 g; 2.61 mmol) in a round-bottomed flask was added concentrated 
sulfuric acid (5.5 ml). The black coloured suspension was stirred at 130°C under nitrogen 
atmosphere for 36h. The solution was then cooled in an iced bath and ether (15 ml) slowly added. 
The resulting precipitate was filtered, washed with ethyl ether and dried at a vacuum pump. The 
solid was then dissolved in water (50 ml) and the solution cooled with an iced bath. A concentrated 
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NaOH solution was added until a precipitate started to form (impurity). This precipitate was filtered 
off and the filtrate was extracted with chloroform (4 x 20 ml). The combined organic layers were 
dried over sodium sulfate. The solvent was evaporated under reduced pressure to obtain a white 
solid. Yield: 54% 
1H NMR (300 MHz, CDCl3): δ (ppm): 2.67 (s, 36H, NCH2CH2N). 13C NMR (75 MHz, CDCl3): δ 
(ppm): 45.9. ESI-MS (+) C8H20N4  (172.17): m/z = 174.0 [M+1]. m. p. 113-114 °C. 
 
Synthesis of N,N’,N’’-tris(butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane 10 
 
NH N
NN
t-BuOOC
COOt-Bu
COOt-Bu
 
 
In a two-necked flask, to a solution of compound 9 (40.6 mg, 0.23 mmol) in dry CH3CN (2.3 ml) 
was added under nitrogen atmosphere sodium hydrogen carbonate (65 mg, 0.77 mmol). This 
suspension was cooled to 0°C with an iced bath and tert-butylbromoacetate (0.126 ml, 0.77 mmol) 
added dropwise. The reaction mixture was stirred at room temperature for 48h and monitored by 
TLC (SiO2 eluent dichloromethane/methanol, 92:2). The inorganic salts were filtered off and the 
solvent evaporated under reduced pressure to obtain a crude yellow product. This solid was 
crystallized by toluene to obtain the product as a white solid. Yield: 62% 
1H NMR (300 MHz, CDCl3): δ (ppm): 10.0 (s, 1H, NH), 3.36 (s, 4H, CH2COO), 3.28 (s, 2H, 
CH2COO), 3.09- 2.87 (m, 16 H, NCH2), 1.46, 1.45, 1.44 (3s, 27 H, C(CH3)3). 13C NMR (300 MHz, 
CDCl3):δ (ppm): 170.4 and 169.5 (CO), 81.6 and 81.56 (C(CH3)3), 58.1 (NCH2CO), 51.2, 51.1, 
49.1 and 47.4 (NCH2CH2N), 28.1 (C(CH3)3). ESI-MS (+) C26H50N4O6 (514.37): m/z = 515.3 
[M+1]. m. p. 187.8-190 °C. 
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Synthesis of N-(ethoxycarbonylmethyl)-N’,N’’,N’’’-tris(butoxycarbonylmethyl)-1,4,7,10-
tetraazacyclododecane 11 
 
N N
NN
t-BuOOC
COOt-Bu
COOt-Bu
EtOOC  
 
In a two-necked flask under nitrogen atmosphere, a solution of compound 10 (0.38 mg; 0.75 mmol) 
in dry CH3CN (20 ml) was added of potassium carbonate (96.8 mg; 0.7 mmol) and ethyl 
bromoacetate (0.075 ml). The reaction mixture was stirred at room temperature for 72h and 
monitored by TLC (SiO2, eluent dichloromethane/methanol 94:6). After completion of the reaction, 
the solid phase was filtered off and the filtrate evaporated under reduced pressure to obtain a white 
product after trituration with ethyl ether.  
Yield: 92%. 1H NMR (300 MHz, CDCl3): δ (ppm): 4.14 (bq, 2H, COOCH2), 3.60-2.10 (bs, 24H, 
NCH2CO and NCH2CH2N), 1.45, 1.44 (s, 27H, C(CH3)3), 1.26 (t, J = 7.2 Hz, 3H, COOCH2CH3). 
13C NMR (75 MHz, CDCl3):δ (ppm): 173.4, 172.8, 172.7 (CO), 82.0 (C(CH3)3), 61.2 
(COCH2CH3), 55.5 54.6 (NCH2CO), 52.4 48.6 (NCH2CH2N), 27.7 (C(CH3)3), 13.9 (COCH2CH3). 
ESI-MS (+) C30H56N4O8 (600.41): m/z = 623.4 [M+Na]+. m. p. : 170-172 °C. 
 
Synthesis of N-[(2-amino-ethylamino)carbonylmethyl]-,N’,N’’,N’’’-
tris(buthoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane 12 
 
N N
NN
t-BuOOC
COOt-Bu
COOt-Bu
NH
O
H2N  
 
Compound 11 (0.4 g; 0.6 mmol) in neat ethylendiamine (3.5 ml) were stirred in a round-bottomed 
flask at room temperature for 72 h. Unreacted ethylendiamine was eliminated under reduced 
pressure to obtain a yellow oil. Yield: 79% 
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1H NMR (300 MHz, CDCl3): δ (ppm): 8.76 (t,1H, NH), 3.36 (q, 2H, NCH2CH2NCO), 2.90 (t, 2H, 
NCH2CH2NCO), 3.46- 2.16 (m, 30H, NCH2), 1.45 (s, 27H, C(CH3)3). 
13C NMR (75 MHz, CDCl3): δ (ppm): 172.3 172.2 (CO), 81.7, 81.6 (C(CH3)3), 55.9, 55.5, 55.4 
(NCH2CO), 51.3, 48.5 (NCH2CH2N), 40.1 and 36.6 (NHCH2CH2NH2), 27.9 (C(CH3)3). ESI-MS 
(+) C30H58N6O7 (614.44): m/z = 637.5 [M+Na]+. 
 
Synthesis of tetranitrocalix[4]arene-DOTA-tri-tert-butyl ester 13 
 
N
N
N
N
COOt-Bu
COOt-Bu
t-BuOOC
O
O
O O
O2N NO2
NO2 NO2
NH
NH
O
O
 
 
To a stirring solution of compound 12 (72.9 mg; 0.115 mmol) and 5 (100 mg; 0.127 mmol) and 
DCM (8 ml) in a two-necked flask under nitrogen atmosphere, was added HOBt (17.4 mg; 0.128 
mmol) and a solution of DCC (26.5 mg; 0.13 mmol) in DCM (2 ml). The reaction mixture was 
stirred at 0°C for 15 min and then allowed to return to room temperature and stirred for 24h. The 
reaction was monitored by TLC (SiO2, eluent dichloromethane/methanol 96:4). The salts were 
filtered off and the filtrate evaporated under reduced pressure. The residue was taken with ethyl 
acetate and washed  with brine and a saturated solution of potassium hydrogen carbonate. The 
solvent was evaporated under reduced pressure to obtain a crude product as orange solid. 
Compound 13 was obtained pure by flash-chromatography (SiO2, eluent dichloromethane/methanol 
96:4) tas an orange solid. Yield: 62% 
1H NMR (300 MHz, CDCl3): δ (ppm): 8.85 and 8.80 (2 bs, 1 H of each NH), 7.80 (d, 2H, J = 2.7 
Hz, Ar), 7.76 (d, 2H, J = 2.7 Hz, Ar), 7.36 (s, 2H, Ar), 7.29 (s, 2H, Ar), 4.87 (d, 2H, J = 14.4 Hz, 
ArCH2axAr), 4.84 (s, 2H, OCH2CO), 4.54 (d, 2H, J = 14.1 Hz, ArCH2axAr), 4.20-4.10 (m, 2H, 
OCHHCH2CH3), 4.05-3.95 (m, 2H, OCHHCH2CH3), 3.88 (t, 2H, J = 7.2 Hz, OCH2CH2CH3), 3.53 
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(d, 2H, J = 14.4 Hz, ArCH2eqAr), 3.35 (d, 2H, J = 14.1 Hz, ArCH2eqAr), 3.30 and 3.00-2.00 (bs, 
26H, NHCH2CH2NH, NCH2CH2N, NCH2CO), 2.00-1.85 (m, 6H, OCH2CH2CH3), 1.45 (s, 9H, 
C(CH3)3), 1.40 (s, 18H, C(CH3)3), 1.04 (t, 3H, J = 7.5 Hz, OCH2CH2CH3), 0.95 (t, 6H, J = 7.5 Hz, 
OCH2CH2CH3). 13C NMR (75 MHz, CDCl3): δ (ppm): 172.3, 171.5, 168.1 (CO), 162.5, 161.2, 
161.1 (Ar ipso), 142.7, 142.6, 142.5 (Ar para), 136.4, 135.8, 135.4, 135.0 (Ar ortho), 124.6, 124.0, 
123.5, 123.3 (Ar meta), 81.9, 81.8, (C(CH3)3), 77.8, 77.7, 73.8 (OCH2CH2CH3), 56.0, 55.6, 55.5, 
(NCH2CO), 52.2, 51.5, 48.7, 47.9 (NCH2CH2N), 39.1, 38.9 (NHCH2CH2NH), 31.8, 31.1 
(ArCH2Ar), 29.6, 27.9, 27.8 (C(CH3)3), 23.2, 23.1 (OCH2CH2CH3), 10.3, 9.9 (OCH2CH2CH3). ESI-
MS (+) C69H95N10O20 (1383.67): m/z = 1407.6 [M+Na]+. m. p. 186.5-189 °C. 
 
Synthesis of 2,3,4,6-tetra-O-acetyl-α-D-galactopyranosyl-bromide 
 
O
OAc
Br
OAc
AcO
OAc
 
 
To a solution of peracetylated D-galactose (1.62 g; 3.94 mmol) in dry DCM (16 ml) was added an 
HBr solution in glacial acetic acid (33% w/v, 11 ml). The yellow solution was stirred at room 
temperature for 18h. The solvent was evaporated under reduced pressure, to obtain a crude product 
as brown oil which was purified by TLC (SiO2, eluent: cycloexane/ ethyl acetate 1:1), to give a 
white foam. Yield: 97%. 
1H NMR (300 MHz, CDCl3): δ (ppm): 6.69 (d, 1H, J = 1.2 = 3.6 Hz, H-1), 5.51 (dd, 1H, J = 4.3 = 
3.6 Hz, J = 4.5 = 1.1 Hz, H-4), 5.40 (dd, 1H, J = 2.3 = 10.6 Hz, J = 2.1 = 3.6 Hz, H-2), 5.04 (dd, 1H, 
J = 3.2 = 10.6, Hz, J = 3.4 = 3.6 Hz, H-3), 4.51-4.46 (m, 1H, H-5), 4.18 (dd, 1H, J6,6 = 11.4 Hz, 
J6,5 = 6.4 Hz, H-6), 4.10 (dd, 1H, J = 6.6 = 11.4 Hz, J = 6.5 = 6.7 Hz, H-6’), 2.14, 2.10, 2.05, 2.00 
(4s, 3H, of each CH3CO). 13C NMR (75 MHz, CDCl3): δ (ppm): 170.1, 169.9, 169.7, 169.6 (4s, 
CO), 88.1 (d, C-1), 71.0 (d, C-5), 67.9 (d, C-3), 67.7 (d, C-2), 66.9 (d, C-4), 60.1 (t, C-6), 20.6, 
20.5, 20.4 (3q, CH3CO). m. p. 84-85°C. [α]D = + 266.8 (c = 0.5, CHCl3). 
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Synthesis of 2,3,4,6-tetra-O-acetyl-β-D-galactopyranosylazide 
 
O
OAc
OAc
AcO
OAc
N3
 
 
To a solution of 2,3,4,6-tetra-O-acetyl-α-D-galactopyranosyl-bromide (793 mg, 1.93 mmol) in 
DCM (15 ml) was added sodium azide (376 mg; 5.79 mmol), TBAHS (655 mg; 1.93 mmol) and a 
saturated solution of sodium hydrogen carbonate (15 ml). This suspension was stirred at room 
temperature for 5h monitoring it by TLC (SiO2, eluent: toluene/ethyl acetate 2:1). The reaction was 
diluted with dichloromethane, the organic phase was extracted and washed several times with a 
NaHCO3 aqueous solution, water, brine and dried over sodium sulfate. The solvent was evaporated 
under reduced pressure to obtain a pure white solid. Yield: 96%. 
1H NMR (300 MHz,CDCl3):δ(ppm): 5.33 (dd, 1H, J4,3=3.2 Hz, J4,5=0.7 Hz, H4); 5.07 (dd, 1H, J2,3= 
10.3 Hz, J2,1= 8.5 Hz, H2); 4.97 (dd, 1H, J3,2= 10.3 Hz, J3,4= 3.2 Hz, H3); 4.55 (d, 1H, J1,2=8.5 Hz, 
H1); 4.09-4.07 (m, 2H, H6, H6’); 3.96 (ddd, 1H, J5,6’= 7.1 Hz, J5,4= 0.6 Hz, H5); 2.07, 1.99, 1.96, 
1.90 ( 4s, 3H of each CH3CO). 13C NMR (75 MHZ,CDCl3): δ(ppm): 170.3-169.3 (4s,CO); 88.2 
(d,C1); 72.8 (d, C5) 70.7 (d, C3); 68.0 (d, C2); 66.8 (d, C4); 61.2 (t, C6); 20.7, 20.6, 20.5 (q,CH3CO). 
m. p.: 103-104 °C. [α]D = -14.0 (c=1, CHCl3). 
 
Synthesis of 2,3,4,6-tetra-O-acetyl-β-D-galactopyranosylamine 
 
O
OAc
OAc
AcO
OAc
NH2
 
 
To a solution of 2,3,4,6-tetra-O-acetyl-β-D-galactopyranosylazide (706 mg; 1,89 mmol) in 
acetonitrile (100 ml) was added a catalytic amount of Palladium hydroxide on carbon. The 
suspension was hydrogenated in a Parr apparatus under pressure (2 atm) for 6h. The reaction was 
monitored by TLC (SiO2, eluent: toluene/ethyl acetate 6:4). After disappearance of the starting 
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material, the reaction was quenched, palladium filtered off and the solvent evaporated under 
reduced pressure to obtain a yellow solid. Yield: 74%. 
1H NMR (300 MHz,CDCl3): δ(ppm): 5.37 (dd, 1H, J4,3=3.0 Hz, J4,5= 1.2 Hz, H4); 5.01 (dd, 1H, 
J3,2= 10.0 Hz, J3,4= 3.3 Hz, H3); 4.96 (dd, 1H, J2,3= 10.0 Hz, J2,1= 7.8 Hz, H2); 4.11 (d, 1H, J1,2= 7.8 
Hz, H1); 4.08-4.01 (m, 2H, H6, H6’); 3.85 (ddd, 1H, J5,6’= 6.8 Hz, J5,6= 6.5Hz, J5,4= 1.2 Hz, H5); 
2.09, 2.02, 1.99, 1.95 (4s, 3H each, CH3CO). 13C NMR (75 MHZ,CDCl3): δ(ppm): 170.5, 170.3, 
170.2 (3s, CO); 85.4 (d, C1); 71.6 (d, C5); 71.4 (d, C3); 69.9 (d, C2); 67.7 (d, C4), 61.8 (t, C6); 21.0, 
20.8, 20.7 (q, CH3CO). p.m.: 73-75°C [α]D = +39.3 (c=0.6, CHCl3). 
 
Synthesis of 2,3,4,6-tetra-O-acetyl-β-D-galactosyl-isothiocyanate 
 
O
OAc
OAc
AcO
OAc
NCS
 
 
To a solution of 2,3,4,6-tetra-O-acetyl-β-D-galactopyranosylamine (608 mg; 1.75 mmol) in CHCl3 
(13 ml) were  added water (5.5 ml), calcium carbonate (525 mg; 5.25 mmol) and thiophosgene 
(302.5 mg; 2.63 mmol). The reaction mixture was stirred at room temperature for 6h and followed 
by TLC (SiO2: eluent: toluene/ethyl acetate 6:4). Calcium carbonate was filtered off and the 
dichloromethane added. The organic phase was washed with water (4 x 20 ml), dried over sodium 
sulfate and the solvent evaporated under reduced pressure to obtain a yellow syrup . Yield: 90%. 
1H NMR (300 MHz,CDCl3) : δ(ppm): 5.39 (dd, 1H, J4,3= 3.3 Hz, J4,5= 1.1 Hz, H4); 5.31 (dd,1 H, 
J2,3= 10.2 Hz, J2,1= 8.6 Hz, H2); 5.01 (dd, 1H, J3,2= 10.2 Hz, J3,4= 3.3 Hz, H3); 4.97 (d, 1H, J1,2= 8.6 
Hz, H1); 4.13-4.11 (m, 2H, H6, H6’); 3.95 (ddd, 1H, J5,6= 6.4 Hz, J5,6’= 6.2 Hz, J5,4= 1.1 Hz, H5); 
2.16, 2.12, 2.04, 1.97 (4s, 3H of each CH3CO). 13C NMR (75 MHz,CDCl3) : δ(ppm): 170.2, 169.9, 
169.8, 169.0 (4s, CO); 143.7 (s, CS); 83.9 (d, C1), 72.9 (d, C5); 70.5 (d, C3); 69.2 (d, C2); 66.7 (d, 
C4); 61.1 ( t, C6); 20.54, 20.48, 20.39 (3q, CH3CO).  m.p. : 94°C [α]D  = +33.9 (c=1, CH2Cl2). 
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Synthesis of 25-(ethoxycarbonylmethoxy)calix[4]arene 16 
 
OH O
OH OH
O
O
 
 
To a suspension of tetrahydroxy calix[4]arene (3.0 g; 7.06 mmol) in dry DMF (120 ml) were added 
under nitrogen cesium fluoride (1.29 g, 8.47 mmol) and ethyl bromoacetate (7.86 ml, 7.06 mmol). 
The reaction mixture was stirred at 40°C for 24h and monitored by TLC (SiO2, eluent petroleum-
ether/dichloromethane 3:1). After completion of the reaction, water (100 ml) was added and the 
mixture extracted with ethyl acetate (3 x 100 ml). The combined organic layers were dried over 
sodium sulfate and the solvent was evaporated under reduced pressure to obtain compound xx as a 
white solid after flash chromatography (SiO2, eluent petroleum-ether/dichloromethane 3:1, 2:8, 
1:9). Yield: 68.5%. 
1H NMR (300 MHz,CDCl3) : δ(ppm): δ = 9.86 (s, 1H, OH); 9.14 (s, 2H, OH); 7.10 (d, 2H, J = 7.8 
Hz, Ar-H); 7.10 – 6.95 (m, 6H, Ar-H);  6.89 (dd, 1H, J = 7.6 Hz, Ar-H); 6.66 (q, 3H, Ar-H); 4.89 (s, 
2H, OCH2CO); 4.48 (d, 2H, J = 9.0 Hz, ArCH2axAr); 4.45 (q, 2H, J = 7.2 Hz, OCH2CH3); 4.30 (d, 
2H, J = 13.8 Hz, ArCH2axAr); 3.45 (d, 4H, J = 13.8 Hz, ArCH2eqAr); 1.43 (t, 3H, J = 6.9 Hz, CH3). 
13C NMR, see literature data (Sasaky, A. Murahashi, N. Yamada, H. Morikawa, A. Biol. Pharm. 
Bull., 1995, 18 (5), 740-746). 
ESI-MS (+) C32H30O6 m/z = 533.19 [M+Na]+. 
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Synthesis of 25-(ethoxycarbonylmethoxy)-26,27,28-tripropyloxycalix[4]arene 17 
 
O O
O O
O
O
 
 
To a solution of compound 16 (2.46 g; 4.81 mmol) in dry DMF (35 ml) at 0°C, sodium hydride 
(0.96 g; 24 mmol) and propyl iodide (4.1 g; 24 mmol) were added under nitrogen atmosphere. The 
suspension was stirred at room temperature for 24h and the reaction monitored by TLC (SiO2, 
eluent cycloexane/ ethyl acetate 8:2). The reaction was quenched with 0.1M HCl and extracted with 
ethyl acetate (3 x 100 ml). The combined organic layers were dried over sodium sulfate and the 
solvent was evaporated under reduced pressure to obtain compound 17 as a colourless oil after 
purification by cartridge Flashvach chromatography (SiO2, eluent cycloexane/ethyl acetate 98:2). 
Yield: 89%. 
1H NMR (300 MHz,CDCl3) : δ (ppm):  6.84 – 6.75 (m, 4H, Ar-H); 6.75 – 6.67 (m, 2H, Ar-H); 6.44 
(s, 6H, Ar-H); 4.74 (s, 2H, OCH2CO); 4.65 (d, 2H, J = 13.5 Hz, ArCH2axAr); 4.45 (d, 2H, J = 13.2 
Hz, ArCH2axAr); 4.20 (q, 2H, J = 7.2 Hz, OCH2CH3); 3.89 (t, 2H, J = 7.5 Hz, OCH2CH2CH3); 3.88 
– 3.76 (m, 4H, OCH2CH2CH3); 3.21 (d, 2H, J = 13.5 Hz, ArCH2eqAr); 3.16 (d, 2H, J = 13.5 Hz, 
ArCH2eqAr); 1.95-1.87 (m, 6H, CH2CH2CH3); 1.29 (t, 3H, J = 7.2 Hz, CH2CH3); 1.03 (t, 6H, J = 
7.5 Hz, OCH2CH2CH3); 0.97 (t, 3H, J = 7.5 Hz, OCH2CH2CH3). 13C NMR (75 MHz, CDCl3): δ 
(ppm): 170.3 (CO); 157.2, 156.1, 156.0 (Ar ipso); 135.9, 135.6, 134.4, 134.3 (Ar meta); 128.8, 
128.5, 128.8, 127.9 (Ar ortho); 122.6, 122.2, 122.1 (Ar para); 76.9 (OCH2CH2); 70.5 (OCH2CO); 
60.4 (COCH2CH3); 31.4, 31.0 (Ar-CH2-Ar); 23.4 (CH2CH2CH3); 14.3 (OCH2CH3);  10.7, 10.3 
(CH2CH2CH3); ESI-MS: (+) C30H38N6O7 m/z = 637.55 [M+Na]+. 
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Synthesis of 5,11,17,23-tetraiodo-25-(ethoxycarbonylmethoxy)-26,27,28-tripropyloxy-
calix[4]arene 18 
 
O O
O O
O
O
I
I
I
I
 
 
To a solution of compound 17 (200 mg, 0.31 mmol) in CHCl3 (30 ml) silver acetate (305 mg, 1.38 
mmol) was added. The reaction mixture was stirred at 60°C for 30 min and then iodine (351 mg, 
1.38 mmol) was added and the suspension stirred at 60°C for 1h. The reaction was monitored by 
TLC (SiO2, eluent cycloexane/ethyl acetate 99:1) and then quenched by filtration of the inorganic 
salts which were eliminated. The filtrate was washed with 20% sodium thiosulfate solution until the 
water colour turns to yellow. The organic phase was washed again with water (2 x 60 ml) and dried 
over sodium sulfate to obtain compound 18 as a yellow foam. Yield: 88%. 
1H NMR (300 MHz,CDCl3) : δ(ppm): 7.20 (s, 2H, Ar-H); 7.19 (s, 2H, Ar-H); 6.43 (s, 4H, Ar-H); 
4.70 (s, 2H, OCH2CO); 4.50 (d, 2H, J = 13.5 Hz, ArCH2axAr); 4.28 (d, 2H, J = 13.2 Hz, 
ArCH2axAr); 4.17 (q, 2H, J = 7.2 Hz, OCH2CH3); 3.86 (t, 2H, J = 7.8 Hz, OCH2CH2CH3); 3.82-
3.67 (m, 6H, OCH2CH2); 3.10 (d, 2H, J = 14.4 Hz, ArCH2eqAr); 3.05 (d, 2H, J = 13.8 Hz, 
ArCH2eqAr); 1.95 – 1.80 (m, 6H, CH2CH2CH3); 1.27 (t, 3H, J = 5.1 Hz, CH2CH3); 0.99 (t, 6H, J = 
7.2 Hz, CH2CH2CH3); 0.93 (t, 3H, J = 7.5 Hz, CH2CH2CH3). 13C NMR (75 MHz, CDCl3): δ 
(ppm): 169.4 (CO); 156.9, 156.0, 155.0 (Ar ipso); 140.8, 138.0, 137.4, 137.2, 137.1, 136.7, 133.4, 
128.3, 123.5 (Ar); 86.2, 85.7 (Ar para); 76.5 (OCH2CH2);  71.1 (OCH2CO); 60.6 (COCH2CH3); 
31.7, 30.2, 29.6 (ArCH2Ar); 23.1, 22.9 (CH2CH2CH3); 14.2 (OCH2CH3); 10.3, 10.2 (CH2CH2CH3). 
ESI-MS: (+) C30H58N6O7I4 m/z = 1163.07 [M+Na]+  
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Synthesis of 5,11,17,23-tetrakis[trimethylsilylacetylene]-25-(ethoxycarbonylmethoxy)-
26,27,28-tripropyloxycalix[4]arene 19 
 
O O
O O
O
O
Si Si
Si
Si
 
 
In a sealed tube under argon atmosphere, a solution of compound 18 (2.95 g, 2.6 mmol) in degassed 
TEA (80 ml) was added of PdCl2(PPh3)3 (3% mol; 0.055 g, 0.078 mmol), CuI (5% mol; 0.025 g, 
0.13 mmol) and trimethylsilylacetylene (1.52 g; 15.6 mmol). The solution was stirred at 80°C under 
argon atmosphere for 48h and monitored by TLC (SiO2; eluent petroleum ether/ethyl acetate 99:1). 
Then was quenched with 0.01M HCl until neutral pH. The organic phase was extracted with ethyl 
acetate (3 x 100 ml), washed with water until the pH is neutral, dried over sodium sulfate and the 
solvent evaporated under reduced pressure to obtain a brown foam. The crude product of reaction 
was purified by flash chromatography (SiO2; eluent petroleum ether/ethyl acetate 96:4, 9:1) to 
obtain compound 19 as yellow solid. Yield: 56%. 
1H NMR (300 MHz,CDCl3) : δ(ppm) = 7.08 (s, 2H, Ar-H); 7.07 (s, 2H, Ar-H); 6.80 (s, 4H, Ar-H); 
4.80 (s, 2H, OCH2CO); 4.54 (d, 2H, J = 13.2 Hz, ArCH2axAr); 4.34 (d, 2H, J = 12.9 Hz, 
ArCH2axAr); 4.15 (q, 2H, J = 5.4 Hz, OCH2CH3); 3.88 (t, 3H, J = 7.8 Hz, OCH2CH2); 3.88 – 3.68 
(m, 6H, OCH2CH2); 3.15 (d, 2H, J = 14.4 Hz, ArCH2eqAr); 3.10 (d, 2H, J = 13.2 Hz, ArCH2eqAr); 
1.94 - 1.80 (m, 6H, CH2CH2CH3); 1.26 (t, 3H, J = 5.7 Hz, OCH2CH3); 1.04 - 0.94 (m, 9H, 
CH2CH2CH3). 13C NMR (75 MHz, CDCl3): δ (ppm): 157.3 (CO); 156.3 (Ar ipso); 135.5, 134.6, 
133.5, 132.8, 132.6, 132.4, 132.3 (Ar); 117.2 (Ar para); 105.5, 105.3 (CCSi); 92.7 (CCSi); 77.3, 
77.2 (OCH2CH2); 70.5 (COCH2O); 60.5 (OCH2CH3); 31.2, 30.7 (ArCH2Ar); 23.1 (CH2CH2CH3); 
14.2 (OCH2CH3); 10.4, 10.0 (CH2CH2CH3);  0.2 (Si(CH3)3). ESI-MS: (+) C61H80O6Si4 m/z = 
1044.20 [M+Na]+. 
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Synthesis of 5,11,17,23-tetraacetylene-25-(ethoxycarbonylmethoxy)-26,27,28-
tripropyloxycalix[4]arene 20 
 
O O
O O
O
O
 
 
To a solution of compound 19 (0.153 g, 0.15 mmol) and dry DMF (15 ml) in a Schlenk tube under 
nitrogen atmosphere was added potassium fluoride (0.521 g, 8.98 mmol). The suspension was 
stirred at 60°C for 24h. The reaction was monitored by TLC (SiO2; eluent cycloexane/ethyl acetate 
8:2) and then quenched with 0.1M HCl (20 ml). The product was extracted with ethyl acetate (3 x 
20 ml), dried over sodium sulfate and solvent evaporated under reduced pressure to obtain 
compound 20 as brown foam. Yield: 98%. 
1H NMR (300 MHz,CDCl3) : δ(ppm): δ = 7.018, 7.013 (2s, 2H for each, Ar-H); 6.65 (s, 4H, Ar-H); 
4.71 (s, 2H, OCH2CO); 4.56 (d, 2H, J = 13.8 Hz, ArCH2axAr); 4.37 (d, 2H, J = 13.5 Hz, 
ArCH2axAr); 4.18 (q, 2H, J = 7.2 Hz, OCH2CH3); 3.88 (t, 2H, J = 7.5 Hz, OCH2CH2); 3.90 – 3.74 
(m, 6H, OCH2CH2); 3.15 (d, 2H, J = 14.7 Hz, ArCH2eqAr); 3.10 (d, 2H, J = 14.1 Hz, ArCH2eqAr); 
2.96, 2.81 (2s, 4 H, HCC); 2.00 - 1.90 (m, 6H, CH2CH2CH3); 1.27 (t, 3H, J = 7.2 Hz, CH2CH3); 
1.06-0.91 (m, 9H, CH2CH2CH3). 13C NMR (75 MHz, CDCl3): δ (ppm): δ = 172.9 (CO); 156.8 (Ar 
ipso); 135.0, 133.8, 132.7, 132.5, 132.0, 129.0, 128.2, 125.2 (Ar); 116.0 (Ar ortho); 83.8, 83.7 
(CCH); 77.1, 76.1 (CCH); 76.0, 75.7 (OCH2CH2); 70.3 (OCH2CO); 60.5 (OCH2CH3); 30.9, 29.6 
(ArCH2Ar); 23.1, 21.4 (CH2CH2CH3); 14.1 (OCH2CH3); 10.0, 9.3 (CH2CH2CH3). ESI-MS: (+) 
C58H72O6 m/z = 755.41 [M+Na]+. 
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Synthesis of 5,11,17,23-tetracetylene-25-(hydroxycarbonylmethoxy)-26,27,28-
tripropyloxycalix[4]arene 21 
 
O O
O O
OH
O
 
 
To a solution of compound 20 in THF/H2O (25 ml 5:1 v/v) was added a solution of potassium 
hydroxide (0.308 g, 0.61 mmol) in THF/H2O (10 ml 5:1 v/v). The reaction mixture was stirred at 
reflux for 12 h and the reaction monitored by TLC (SiO2; eluent cycloexane/ethyl acetate 8:2), then 
quenched with 1M HCl until the pH 3. The product was extracted with dichloromethane (3 x 30 
ml), the organic layer washed with water and dried over sodium sulfate. The solvent was evaporated 
under reduced pressure to obtain compound 21 as a brown foam. Yield: 80%. 
1H NMR (300 MHz,CDCl3): δ(ppm): 7.32 (s, 4H, Ar); 6.55 (d, 2H, J = 1.8 Hz, Ar); 6.50 (d, 2H, J 
= 1.8 Hz, Ar); 4.83 (s, 2H, OCH2CO); 4.38 (d, 2H, J = 13.2 Hz, ArCH2axAr); 4.24 (d, 2H, J = 13.8 
Hz, ArCH2axAr); 4.05 – 3.95 (m, 2H, OCH2CH2); 3.77-3.15 (m, 6H, OCH2CH2); 3.27 (d, 2H, J = 
13.8 Hz, ArCH2eqAr); 3.15 (d, 2H, J = 12.8 Hz, ArCH2eqAr); 3.10, 2.77 (2s, 4 H, HCC) 2.00 – 1.75 
(m, 6H, CH2CH2CH3); 1.00 (t, 6H, J = 7.2 Hz, CH2CH3); 0.85 (t, 3H, J = 7.5 Hz, CH2CH3). 13C 
NMR (75 MHz, CDCl3): δ (ppm): 170.1 (CO); 157.6, 156.6, 154.0 (Ar ipso); 136.2, 134.7, 133.5, 
133.2, 132.9, 132.4, 132.0, 131.9 (Ar); 118.8, 117.4, 116.6 (Ar para); 83.8, 83.0 (CCH); 78.5, 77.2 
(CCH);  76.3 (OCH2CH2); 71.4 (OCH2CO); 30.9, 30.2 (ArCH2Ar); 22.9, 22.6 (CH2CH2CH3); 10.3, 
9.7 (CH2CH2CH3). ESI-MS: (+) C58H72O6 m/z = 755.41  [M+Na]+ 
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Synthesis of tetra-O-acetyl-1-β-(2-bromoethyloxy)-galactose 22 
 
O
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OAc
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To a solution of peracetylated D-galactose (2.5 g, 6.40 mmol) and dry DCM (25 ml) in a two-
necked flask under nitrogen atmosphere, was added at 0° C 2-bromoethanol (8.7 mmol, 0.625 ml) 
and boron trifluoride (25.6 mmol, 3.2 ml). The solution was stirred at room temperature overnight. 
The reaction was monitored by TLC (SiO2, eluent toluen/ethyl acetate 7:3) and quenched with 
water (20 ml) and an aqueous solution of sodium chloride. The organic phase was separated, 
washed with water until neutral pH and dried over sodium sulfate. The solvent was evaporated 
under reduced pressure to obtain pure compound 22 as a yellow syrup. Yield: 99%. 
1H NMR (300 MHz,CDCl3) : δ(ppm): δ = 5.38 (dd, 1H, J = 3.2 Hz, J = 0.9 Hz, H4); 5.23 (dd, 1H, J 
=10.5 Hz, J = 7.8 Hz, H2); 5.01 (dd, 1H, J = 10.5 Hz, J = 3.3, H3); 4.51 (d, 1H, J = 7.8 Hz, H1); 4.21 
– 4.06 (m, 3H, H6ab and OCHHCH2); 3.91 (td, 1H, J = 6.6, J = 0.9 Hz, H5); 3.88 – 3.76 (m, 1H, 
OCHHCH2); 3.55 – 3.44 (m, 2H, CH2Br); 2.14, 2.07, 2.04, 1.99 (4s, 12 H, CH3CO2).  
ESI-MS: (+)C16H23O10Br  m/z = 479.13  [M+2Na]+, 477.13  [M+Na]+ 
For other physico-chemical data see: Sasaky, A. Murahashi, N. Yamada, H. Morikawa, A. Biol. 
Pharm. Bull., 1995, 18 (5), 740-746). 
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Synthesis of tetra-O-acetyl-1-β-(2-azidoethyloxy)-galactose 23 
 
O
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To a solution of compound 22 (2.94 g, 6.46 mmol) and dry DMF (40 ml) in a two-necked flask, was 
added sodium azide (0.855 g, 13.5 mmol) under nitrogen atmosphere. The suspension was stirred at 
60°C for 24h. The reaction was monitored by TLC (SiO2, eluent toluene/ethyl acetate 7:3) was and 
then quenched with water (50 ml). The product was extracted with ethyl acetate (3 x 30 ml), the 
combined organic layers dried over sodium sulfate and the solvent evaporated under reduced 
pressure to obtain compound 23 as yellow oil. Yield: 90%. 
1H NMR (300 MHz, CDCl3) : δ(ppm): 5.39 (dd, 1H, J= 3.3 Hz, J = 0.9 Hz, H4); 5.24 (dd, 1H, J = 
10.5 Hz, J = 7.8 Hz, H2); 5.01 (dd, 1H, J = 10.5 Hz, J = 3.3, H3); 4.55 (d, 1H, J = 8.4 Hz, H1); 4.25 
– 3.98 (m, 3H, H6ab and OCHHCH2); 3.91 (td, 1H, J = 6.6 Hz, J = 0.9 Hz, H5); 3.72 – 3.64 (m, 1H, 
OCHHCH2); 3.55 – 3.44 (m, 1H, CHHBr); 2.14, 2.07, 2.04, 1.97 (4s, 12 H, CH3CO2). 
For other physico-chemical data see: Sasaky, A. Murahashi, N. Yamada, H. Morikawa, A. Biol. 
Pharm. Bull., 1995, 18 (5), 740-746). 
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Synthesis of compound 24 
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To a mixture of compound 21 calix (77.3 mg, 0.11 mmol) and compound 23 azide (100.6 mg, 0.24 
mmol) in THF/H2O (4 ml 2:1) copper sulfate (5% mol) and sodium ascorbate (50% mol) were 
added. The reaction mixture was sonicated in an ultrasound cleaning bath for two minutes, then 
magnetically stirred in the dark at room temperature for 72h. The reaction was monitored by TLC 
(SiO2, eluent DCM/MeOH, 94:6). The reaction was quenched with water (10 ml), the product 
extracted with ethyl acetate (3 x 15 ml) and the organic layers washed with 1M phosphate buffer at 
pH 7 (2 x 10 ml), dried over sodium sulfate and concentrated under vacuum. The residue was 
triturateed with ethyl ether to obtain a compound 24 as white solid (to eliminate Yield: 34% not 
pure) 
Selected physico-chemical data  
 
1H NMR (300 MHz,CDCl3) : δ(ppm): 11.70 (bs, 1H, COOH); 7.91 (d, 2H, J = 7.8 Hz, NCHC); 
7.81 (d, 2H, J = 10.8 Hz, NCHC); 3.45 (d, 2H, J = 13.8 Hz, ArCH2eqAr); 3.33 (d, 2H, J = 13.2 Hz, 
ArCH2eqAr); 2.14, 2.05, 2.00, 1.96 (4s, 48 H, COCH3); 1.03, 0.87 (2m, 12 H, CH2CH2CH3). 
ESI-MS: (+) C111H136O46N12 m/z = 1209.91 [M+2Na]2+ 
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Synthesis of 25,26,27,28-tetrakis(ethoxycarbonylmethoxy)-5,11,17,23-tetra-tert-butyl 
calix[4]arene 25 
 
O O OO
O
O
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C(CH3)3
C(CH3)3
C(CH3)3
(CH3)3C
 
 
To a solution of para-tert-butyl-calix[4]arene (5 g, 7.7 mmol ) and dry THF (100 ml) in a three-
necked flask was added NaH at 55% (5.39 g, 123 mmol) under nitrogen atmosphere. The solution 
was stirred at room temperature for 20 minutes. Ethyl bromoacetate (7.13 ml, 61.6 mmol ) was then 
added and the reaction mixture stirred at 70° C for two hours. The reaction was monitored by TLC 
(SiO2, eluent: DCM/hexane 1:1). The reaction was quenched with 1N HCl (100 ml) and the 
separated organic phase was washed with water until neutral pH. The solvent was evaporated under 
reduced pressure to obtain compound 25 as beige solid. Yield 87 %. 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 6.77 (s, 8H, Ar); 4.85 (d, J= 12 Hz, 4H, Ar-CH2-Ar ax); 
4.8 (s, 8H, Ar-OCH2); 4.2 (q, J= 6 Hz, 8H, OCH2); 3.18 (d, J=12 Hz, 4H, Ar-CH2-Ar eq); 1.28 (m, 
12H, CH3); 1.07(s, 36H, CH3 del t-Bu). 
For other physico-chemical data see: Iwamoto, K. Shinkai, S. J. Org. Chem. 1992, 57, 7066-7073. 
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Synthesis of 25,26,27,28-tetrakis(ethoxycarbonylmethoxy)-5,11,17,23-tetranitrocalix[4]arene 
26 
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To a cooled (0°C) solution of compound 25 (3 g, 3.02 mmol) and DCM (30 ml) in a round-
bottomed flask, were added acetic acid (100 ml) and concentrated HNO3 (19 ml, 301 mmol). The 
solution was stirred at room temperature for 5 h and monitored by TLC (SiO2, eluent: ethyl 
acetate/hexane 6:4). Then it was quenched with water (100 ml) and the product extracted in the 
organic phase with DCM (2 x 50 ml) and then washed with water until neutral pH. The solvent was 
evaporated under reduced pressure to obtain a brown solid. Yield 45%. 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 7.62 (s, 8H, Ar); 5.05 (d, J=15 Hz, 4H, Ar-CH2-Ar ax); 
4,77 (s, 8H, Ar-OCH2); 4.24 (q, J = 6 Hz, 8H, OCH2); 3.52 (d, J=15 Hz, 4H, Ar-CH2-Ar eq); 1.31 
(t, J=3 Hz, 12H, CH3). ESI-MS: (+) C44H44N4O20 m/z= 971.39 [M+Na]+ . 
For other physico-chemical data see: Verboom, W. Durie, A. Egberink, R. J. M. Asfari, Z. 
Reinhoudt, D. N. J. Org. Chem. 1992, 57, 1313-1316. 
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Synthesis of 25,26,27,28-tetrakis(ethoxycarbonylmethoxy)-5,11,17,23-tetraaminocalix[4]arene 
27 
O O OO
O
O
O
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H2N NH2
NH2 NH2
 
 
In a two necked round bottomed flask, under nitrogen atmosphere, compound 26 (1.29 g, 1.34 
mmol) was dissolved in methanol (64.68 ml). Then Co(II) chloride hexahydrate (2.14 g, 9 mmol) 
and NaBH4 (1.68 g, 44.4 mmol) were added in small aliquots. The suspension was stirred at room 
temperature overnight. The reaction was monitored by TLC (SiO2, eluent: ethyl acetate/methanol 
9:1). After disappearance of the starting material, the reaction was quenched by addition of 
dichloromethane (20 ml). The organic phase was separated and washed with 1N HCl (30 ml) and 
NH4OH (28%, 40 ml) until pH 10. The solvent was evaporated under reduced pressure to obtain 27 
as brown solid. Yield 55%. 
1H-NMR (300 MHz, CDCl3 drops of CD3OD): 
δ (ppm)= 5.95 (bs, 8H, Ar); 4.57-4,54 (bs, 12H, Ar-CH2-Ar Ax and Ar-OCH2); 4.14-4.12 (bs, 8H, 
CH2); 2.94 (bs, 4H, Ar-CH2-Ar eq); 1.21 (bs, 12H, CH3). 
 
 142
Synthesis of 25,26,27,28-tetrakis(ethoxycarbonylmethoxy)-5,11,17,23-tetrakis(N-2-
chloroacetamide)calix[4]arene 28 
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To a solution of 27 (0.71 g, 0.74 mmol) and diisopropylamine (DIPEA, 1.3 ml, 7.37 mmol) in dry 
dichloromethane (35 ml), was added 2-chloro-acetyl chloride (0.59 ml, 7.37 mmol) under nitrogen 
atmosphere. The solution was stirred at room temperature for 1 h. The reaction was monitored by 
TLC (SiO2, eluent: THF/DCM 7:3) and then quenched with 0.5 M HCl (15 ml). The reaction was 
diluted with DCM (20 ml) and washed with water (4 x 10 ml) until neutral pH. The solvent was 
evaporated under reduced pressure to obtain product 28 as dark solid after preparative layer 
chromatography (SiO2, eluent: THF/DCM 1:1). Yield 95%. 
1H-NMR (300 MHz, CDCl3 drops of CD3OD): δ (ppm) = 6.71 (s, 8H, Ar); 4.63 (d, J=15 Hz, 4H, 
Ar-CH2-Ar ax); 4.51 (s, 8H, Ar-OCH2); 3.98 (q, J = 6 Hz, 8H, OCH2); 3.82 (s, 8H, CH2Cl); 3.01 (d, 
J=15 Hz, 4H, Ar-CH2-Ar eq); 1.07 (t, J = 6 Hz, 12H, CH3). 
13C-NMR (300 MHz, CDCl3 drops of CD3OD): δ (ppm) = 169.8 (COOEt), 167.8 (COCH2Cl); 
152.8 (Ar-ipso); 134.6 (Ar-para); 131.7 (Ar-ortho); 121.1 (Ar-meta); 71.2 (Ar-OCH2); 60.6 
(OCH2CH3); 42.8 (COCH2Cl); 31.4 (Ar-CH2-Ar); 14.0 (CH2CH3). 
m. p. = 96-99°C 
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Synthesis of 25,26,27,28-tetrakis(ethoxycarbonylmethoxy)-5,11,17,23-tetrakis(N-2-
azidoacetamide)calix[4]arene 29 
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To a solution of compound 28 (1.16 g, 1.03 mmol) in DCM (30 ml) were added tetrabutyl 
ammonium hydrogen sulfate (TBAHS, 1.39 g, 4.10 mmol), sodium azide (2.67 g, 41 mmol) and a 
saturated aqueous NaHCO3 solution (30 ml). The suspension was stirred at room temperature for 2 
days. The reaction was monitored by ESI-MS analysis and quenched with water (15 ml). The 
organic phase was separated and washed with a saturated NaHCO3 solution (3 x 10 ml), HCl 1M (4 
x 15 ml) and again water until neutral pH. The solvent was evaporated under reduced pressure to 
obtain a beige solid compound 29 after crystallization by ethanol. Yield 52%. 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 6.84 (s, 8H, Ar); 4.87 (d, J = 12 Hz, 4H, Ar-CH2-Ar ax); 
4.71 (s, 8H, Ar-OCH2); 4.19 (q, J = 9 Hz, 8H, OCH2); 4.04 (s, 8H, CH2N3); 3.27 (d, J = 12 Hz, 4H, 
Ar-CH2Ar eq); 1.23 (t, J = 9 Hz, 12H, CH3). 13C-NMR (300 MHz, CDCl3): δ (ppm)= 169.8 
(COOEt); 164.8 (COCH2N3); 153.1 (Ar-ipso); 134.8 (Ar-para), 131.4 (Ar-ortho); 121.5 (Ar-meta); 
71.3 (Ar-OCH2CO); 60.5 (OCH2); 52.7 (CH2N3); 31.5 (Ar-CH2-Ar); 14.1 (CH2CH3). ESI-MS: (+) 
C52H56N16O16 m/z = 1183.66 [M+Na] +, 1200.07 [M+K] +. m. p. = 144-147 °C 
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Synthesis of compound 30 
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In a test tube were added compound 29 (0.05 g, 0.0043 mmol), peracetylated 2-propynil-β-D-
glucose (0.099 mg, 0.258 mmol), copper sulfate pentahydrate (6.5 mg, 0.026 mmol), sodium 
ascorbate (10.3 mg, 0.052 mmol) and DMF with 10 drops of water. The suspension was stirred 
under microwave irradiation in the dark at 80°C, 150 W for 20 minutes. The reaction was 
monitored by TLC (SiO2, eluent: ethyl acetate 100% plus 4 drops of glacial acetic acid). The 
reaction was quenched with water (10 ml), the product extracted in ethyl acetate (4 x 20 ml),the 
organic phase dried over sodium sulfate and the solvent evaporated under reduced pressure. The 
carbohydrate excess was recovered by trituration of the crude product with ethyl ether to obtain the 
compound 30 as brown solid. Yield 84%. 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 8.03 (bs, 4H, CH tr); 6.94 (bs, 8H, Ar); 5.24-5.21 (m, 20H, 
OCH2CO, OCCH2N, H-3); 5.04 (t, J=18 Hz, 4H, H-4); 4.95-4.70 (m, 16H, H-2, H-1, Ar-CH2-Ar 
ax); 4.72 (bs, 8H, OCH2-tr); 4.34-4.15 (m, 16H, H-6, H-6’ and OCH2CH3); 3.95-3.85 (m, 4H, H-5); 
3.20-3.09 (bs, 4H, Ar-CH2-Ar eq); 2.02, 1.99, 1.95 and 1.94 (4s, 12H each, CH3CO); 1.27 (bs, 12H, 
CH2CH3). ESI-MS: (+) C120H144N16O56 m/z = 1376.8 [M+Na] ++, 925 [M+Na] +++ 
m. p. = 99-103 °C 
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Synthesis of methyl-3,4,5-trihydroxybenzoate 31 
 
OH
OHOH
O O  
 
To a solution of gallic acid (0.500 g, 2.9 mmol) in methanol (15 ml) was added a catalytic amount 
of conc. sulfuric acid (two drops) and the stirring mixture was refluxed overnight. The reaction was 
quenched with 2N NaOH till neutral pH. Methanol was distilled off and the residue dissolved in 
ethyl acetate, washed with brine (3 x 20 ml) and water until the pH is neutral. The organic phase 
was dried over sodium sulfate, the solvent was evaporated under reduced pressure to obtain 
compound 31 as white solid. Yield: 86%. 
Physic-chemistry date see: Brouwer, A. J. Mulders, S. J. E. Liskamp, R. M. J. Eur. J. Org. Chem. 
2001,1903-1915. 
 
Synthesis of methyl-3,4,5-tripropargyloxybenzoate 32 
 
O
OO
O O  
 
Methyl 3,4,5-trihydroxy benzoate (0.457 g, 2.48 mmol) was dissolved in dry DMF (5 ml) and 
anhydrous K2CO3 (1.30 g, 9.30 mmol) was added under nitrogen atmosphere. To this suspension 
was added dropwise a solution of propargylbromide (0.831 ml, 9.30 mmol). The mixture  was 
stirred at room temperature for 24h. The reaction was monitored by TLC (SiO2; eluent 
cyclohexane/ethyl acetate 2:8). Then, DMF was distilled off under vacuum and the brown solid was 
solubilised in ethyl acetate (20 ml) and washed with water (3 x 20 ml), 1M KHSO4 (3 x 20 ml) and 
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brine (3 x 20 ml). The organic phase was dried over sodium sulfate, the solvent was removed under 
reduce pressure to obtain compound 32 as white solid. Yield 91%. 
1H NMR (300 MHz,CDCl3) : δ (ppm):  7.46 (s, 2H, H-Ar); 4.82 (d, 2H, J = 2.45 Hz, CH2-
propargyl); 4.79 (d, 4H, J = 2.40 Hz, CH2-propargyl); 3.90 (s, 3H, COOCH3); 2.53 (t, 2H, J = 2.39, 
CH2C≡CH); 2.45 (t, 1H, J = 2.40 Hz CH2C≡CH);  
13C NMR (75 MHz, CDCl3): δ (ppm): 166.2 (C=O); 151.2, 141.0, 125.7, 109.8 (Ar); 78.6 77.9 
(OCH2C≡CH); 76.13, 75.5 (C≡CH); 60.3, 56.9 (OCH2); 52.3 (OCH3). 
ESI-MS: (+)C17H14O5 m/z = 321.2 [M+Na]+. 
 
Synthesis of 3,4,5-tripropargyloxybenzoate 33 
 
O
OO
O OH  
 
To a solution of compound 32 (672.6 mg 2.25 mmol) in a dioxane/methanol 15:1 mixture (4 ml) 
was added an aqueous 4M NaOH solution (2 ml). The solution was stirred to room temperature 
overnight and monitored by TLC (SiO2; eluent cycloexane /ethyl acetate 4:6). After complete 
conversion of starting material, the reaction was quenched with 1N HCl until neutral pH. The 
solution was evaporated to obtain a solid that was dissolved in ethyl acetate. The solution was 
washed with 1M KHSO4 solution (3 x 50 ml) and brine (3 x 50 ml). The organic phase was 
separated and dried over sodium sulfate, the solvent was evaporated under reduced pressure to 
obtain a white solid pure. Yield: 96%. 
1H NMR (300 MHz,CD6CO): δ(ppm): 7.53 (s, 2H, H-Ar); 4.93 (d, 4H, J = 2.42 Hz OCH2C≡CH); 
4.82 (d, 2H, J = 2.49 Hz OCH2C≡CH); 3.13 (t, 2H, J = 2.38 Hz OCH2C≡CH); 3.00 (t, 1H, J = 2.42 
Hz OCH2C≡CH); 13C NMR (75 MHz, acetone-d6): δ (ppm): 166.9 (CO); 152.4, 141.8, 126.8, 
110.6 (Ar); 79.8, 79.3 (OCH2C≡CH); 77.5, 76.9 (OCH2C≡CH); 60.5, 57.5 (OCH2C≡CH). 
ESI-MS: (+)C16H12O5 m/z = 284 [M+Na]+ 
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Synthesis of compound 34a 
 
O
OO
O
N
N
N
ONN
N
O
N
N
N
O
O
OAc
OAc
AcO
OAc
OAcO
OAc
OAc
OAc
OAcO
OAc
OAc
OAc
OH  
 
 
To a suspension of 33 (300 mg, 1.06 mmol) and 23 (1.72 g, 4.13 mmol) in DMF/H2O 1:1, was 
added copper sulfate pentahydrate (13.23 mg, 0.05 mmol) and sodium ascorbate (105 mg, 0.53 
mmol). The mixture was allowed to react in the dark under vigorously stirring. The reaction was 
monitored by TLC (SiO2 ; eluent: cycloexane/ethyl acetate 1:9). After complete conversion of 
starting material the reaction was quenched with water (20 ml) to obtain a white solid that was 
purified by flash chromatography (SiO2 ; eluent: cycloexane/ethyl acetate 3:7, 2:8, 100% acetone) 
to obtain compound 34a as white foam. Yield 56%. 
1H NMR (300 MHz,CDCl3): δ(ppm): 7.86 (bs, 3H, H-Tr); 7.47 (bs, 2H, H-Ar); 5.37 (d, J = 3.0 Hz, 
H-4); 5.23 (bs, 6H, OCH2Tr); 5.20-5.10 (m, 3H, H-2); 5.00-4.96 (m, 3H, H-3); 4.60-4.52 (m, 6H, 
NCH2CH2O); 4.50 (d, 1H, J = 7.8 Hz, H-1); 4.49 (d, 2H, J = 8.1 Hz, H-1); 4.35-4.20 (m, 3H, 
NCH2CH2O); 4.20-4.04 (m, 6H, H-6, H-6’); 4.04-3.84 (m, 6H, NCH2CH2O, H-5); 2.14, 2.04, 1.96, 
1.94 (4s, 9H, each, COCH3). 13C NMR (75 MHz, CDCl3): δ(ppm) 170.3, 170.1, 169.9, 169.6, 
151.9, 144.0, 143.2, 141.9, 125.0, 124.6, 109.6, 100.9, 100.8, 70.8, 70.5, 68.3, 67.8, 67.4, 66.9, 
66.2, 62.8, 61.6, 61.1, 50.0, 49.7, 20.6. ESI-MS: (+) C64H81N9O35 m/z = 1581.0 [MNa + Na]+. 
 
 
 
 
 
 
 
 148
Synthesis of compound 35a 
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OAc
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To a stirring solution of compound 34a (200 mg, 0.13 mmol) and DCM (10 ml) in a two-necked 
flask under nitrogen atmosphere, was added HBTU (74 mg; 0.19 mmol), DOTA amino derivative 
12 (80 mg, 0.13 mmol) and TEA (0.036 ml 0.26 mmol,). The reaction mixture was stirred at room 
temperature for 24h. The reaction was monitored by TLC (SiO2, eluent dichloromethane/methanol 
9:1). The reaction was quenched with water (15 ml) the organic phase extracted with 
dichloromethane (3 x 10 ml), and dried on sodium sulphate. The solvent was evaporated under 
reduced pressure to obtain a crude product as orange. Compound 35a was obtained pure by flash-
chromatography (SiO2, eluent dichloromethane/methanol 96:4) as an white solid. Yield: 84%. 
1H NMR (300 MHz, DMSO-d6): δ(ppm): 8.42 (bs, 1H, CONH); 8.21 (bs, 1H, CONH); 8.11 (s, 2H, 
H-Tr); 7.92 (s, 1H, H-Tr); 7.37 (s, 2H, H-Ar); 5.25 (d, J = 3.3 Hz, 3H, H-4); 5.17 (bs, 4H, OCH2Tr); 
5.15-5.07 (m, 3H, H-3); 5.05 (bs, 2H, OCH2Tr); 4.96-4.83 (m, 3H, H-2); 4.73 (d, J = 8.1 Hz, 2H, H-
1); 4.71 (d, J = 8.1, Hz, 1H, H-1); 4.64-4.55 (m, 3H, NCHHCH2O); 4.55-4.41 (m, 3H, 
NCHHCH2O); 4.30-4.15 (m, 3H, H-5); 4.16-4.08 (m, 3H, NCH2CHHO); 4.08-4.01 (m, 6H, H-6 H-
6’); 4.00-3.81 (m, 3H, NCH2CHHO); 2.09, 2.00, 1.89, 1.88 (4s, 9H each, OCOCH3); 1.44 (s, 9H, 
COOC(CH3)3); 1.43 (s, 18H, COOC(CH3)3). 13C NMR (75 MHz, DMSO-d6): δ(ppm) 172.3, 172.0, 
171.4, 169.7, 169.3, 168.9, 151.4, 143.1, 142.3, 129.8, 124.5, 106.8, 99.5, 80.9, 80.8, 69.9, 69.8, 
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68.1, 67.1, 65.5, 62.3, 61.1, 55.8, 55.2, 49.2, 49.0, 38.1, 27.5, 27.4, 27.3, 20.3, 20.2, 20.1, 20.0. 
ESI-MS: (+) C94H137N15O41 m/z = 1089.6 [M + 2Na]2+, 2155.8 [M + Na]+. 
 
Synthesis of compound 36a 
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OAc
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To a solution of compound 35a (232.8 mg 0.11 mmol) in dichloromethane (1.5 ml) was added, at 
0°C, triethylsilane (0.088 ml 0.55 mmol,) and trifluoroacetic acid (0.111 ml, 1.49 mmol) The 
mixture was stirred at room temperature for 24 h and monitored by TLC (SiO2; eluent 
dichloromethane/methanol 9:1). After complete conversion of starting material, the solvent was 
evaporated under reduced pressure and the crude was washed several times with chloroform and 
ethyl ether until to obtained compound 36a as white solid without further purification. Yield 92%. 
1H NMR (300 MHz, CDCl3): δ(ppm): 11.40 (bs, 3H, COOH); 7.95 (bs, 3H, H-Tr); 7.30 (bs, 2H, H-
Ar); 5.38 (bs, 3H, H-4); 5.28-5.16 (m, 6H, OCH2Tr); 5.16-5.09 (m, 3H, H-2); 5.04-4.91 (m, 3H, H-
3); 4.63 (bs, 6H, NCH2CH2O); 4.50 (d, 3H, J = 7.8 Hz, H-1); 4.34-3.76 (m, 15H, NCH2CH2O, H-6, 
H-6’, H-5); 3.68-2.48 (multiplets and bs, 28H, NCH2CH2N, NCH2CONH, NCH2CH2-crown, 
NCH2COOH); 2.13, 2.02, 1.95, 1.91 (4s, 9H each, OCOCH3). 13C NMR (75 MHz, CDCl3): δ(ppm) 
170.5, 170.2, 170.0, 169.8, 160.6, 160.1, 159.6, 152.7, 125.2, 117.1, 113.3,100.7, 70.8, 70.5, 68.4, 
66.9, 61.8, 61.1, 50.7, 38.7, 29.6, 20.5. ESI-MS: (+) C82H113N15O41 m/z = 1035.1 [MNaK+2Na]2+, 
1014 [MNa+2Na]2+. 
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Synthesis of compound 37a 
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To a solution of compound 36a (199 mg 0.10 mmol) in methanol (25 ml) was added, a solution of 
sodium methoxide until pH is 8-9. The solution was stirred at room temperature for 2h. The reaction 
was monitored by TLC (SiO2; eluent ethyl acetate/iso-propanol/water 5:2:1. After complete 
conversion of starting material, the reaction was quenched by addition of AMBERLITE IR 120 H+ 
resin until neutral pH. The resin was filtered, washing with methanol and the solvent was 
evaporated under reduced pressure to obtained product as beige solid without further purification. 
Yield 98%. 
1H NMR (300 MHz, D2O): δ(ppm): 8.20 (bs, 2H, H-Tr); 7.88 (bs, 1H, H-Tr); 7.34 (bs, 2H, H-Ar); 
5.26 (bs, 4H, OCH2Tr); 5.13 (bs, 2H, OCH2Tr); 4.80-4.67 (m, 4H, NCH2CH2O); 4.67-4.52 (m, 2H, 
NCH2CH2O); 4.43-4.29 (m, 5H, H-1, NCH2CH2O); 4.29-3.95 (m, 4H, NCH2CH2O); 3.92 (d, J = 
3.2 Hz, H-4); 3.82-2.62 (multiplets and bs, 43H, H-5, H-3, H-6, H-6’, H-2, NHCH2CH2NH, 
NCH2CO, NCH2COOH, NCH2CH2N-crown). 13C NMR (75 MHz, D2O): δ(ppm) 172.6, 155.0, 
146.1, 129.4, 110.6, 106.4, 78.4, 75.9, 74.2, 73.9, 72.6, 72.3, 71.8, 71.3, 68.5, 65.4, 64.2, 54.5, 53.8, 
53.6, 42.9, 41.6. ESI-MS: (+) C58H89N15O29 m/z = 753.01 [M+2Na]2+ , 731.05 [M+2H]2+ , 1482.7 
[M+Na]+. 
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Synthesis of compound 34b 
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To a suspension of 33 (300 mg, 1.06 mmol) and peracetylated glucose-O-2-azido 23a (1.46 g, 3.49 
mmol) in DMF/H2O 1:1, was added copper sulfate pentahydrate (25 mg, 0.10 mmol) and sodium 
ascorbate (105 mg, 0.53 mmol). The mixture was allowed to react in the dark under vigorously 
stirring. The reaction was monitored by TLC (SiO2 ; eluent: cycloexane/acetone 2:8, 0.1% of acetic 
acid). After complete conversion of starting material the reaction was quenched with water (20 ml) 
to obtain a white solid that was purified by flash chromatography (SiO2 ; eluent: cycloexane/ethyl 
acetate 3:7, 2:8, 100% acetone) to obtain compound 34b as white foam. Yield 56%. 
1H NMR (300 MHz, CDCl3): δ(ppm):7.87 (bs, 2H, H-Tr); 7.82 (bs. 1H, H-Tr); 7.47 (bs, 2H, H-Ar); 
5.28 (bs, 6H, OCH2Tr); 5.23-4.93 (m, 9H, H-3, H-4, H-2); 4.65-4.48 (m, 6H, NCH2CH2O); 4.53 (d, 
J = 8.1 Hz, 3H, H-1); 4.45-3.85 (m, 12H, NCH2CHHO, H-6, H-6’) 3.80-3.60 (m, 3H, H-5); 2.06, 
2.00, 1.97, 1.92 (4s, 9H each, OCOCH3). 13C NMR (75 MHz, CDCl3): δ(ppm) 170.6, 170.1, 169.4, 
151.9, 144.0, 143.2, 141.7, 125.1, 124.6, 109.5, 100.5, 100.4, 72.4, 71.8, 70.8, 70.7, 68.1, 67.6, 
66.1, 62.8, 61.7, 50.0, 49.7, 20.7, 20.5. ESI-MS: (+) C64H81N9O35 m/z = 790.2 [M+2Na]2+, 801.7 
[MNa+2Na]2+, 1558.4 [M+Na] +. 
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Synthesis of compound 35b 
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To a stirring solution of compound 34b (400 mg, 0.26 mmol) and DCM (20 ml) in a two-necked 
flask under nitrogen atmosphere, was added HBTU (148 mg; 0.39 mmol), DOTA amino derivative 
12 (160 mg, 0.26 mmol) and TEA (0.072 ml 0.52 mmol,). The reaction mixture was stirred at room 
temperature for 24h. The reaction was monitored by TLC (SiO2, eluent dichloromethane/methanol 
9:1). The reaction was quenched with water (20 ml) the organic phase extracted with 
dichloromethane (3 x 10 ml), and dried on sodium sulphate. The solvent was evaporated under 
reduced pressure to obtain a crude product as orange. Compound 35b was obtained pure by flash-
chromatography (SiO2, eluent dichloromethane/methanol 96:4) as an white solid. Yield: 55%. 
1H NMR (300 MHz, CDCl3): δ(ppm): 7.95 (bs, 1H, H-Tr); 7.90 (bs, 2H, H-Tr); 7.28 (bs, 2H, H-
Ar); 7.09 (bs, 1H, NHCO) 6.71 (bs, 1H, NHCO) 5.23 (bs, 4H, OCH2Tr); 5.20 (bs, 2H, OCH2Tr); 
5.18-4.90 (m, 9H, H-3, H-4, H-2); 4.63-4.50 (m, 6H, NCH2CH2O, H-1); 4.32-3.92 (m, 12H, 
NCH2CH2O, H-6, H-6’); 3.80-3.68 (m, 3H, H-5); 2.08, 2.00, 1.97, 1.93 (4s, 9H each, OCOCH3); 
1.45 (s, 18H, OC(CH3)3); 1.44 (s, 9H, OC(CH3)3). 13C NMR (75 MHz, CDCl3): δ(ppm): 172.3, 
171.8, 170.7, 170.0, 169.5, 169.4, 152.0, 144.3, 143.5, 129.9, 124.9, 124.5, 107.1, 100.5, 100.3, 
82.0, 72.6, 71.8, 71.7, 70.7, 68.2, 67.5, 66.4, 62.9, 61.7, 55.8, 55.6, 49.8, 49.5, 38.6, 27.9, 20.7, 
20.6. ESI-MS: (+) C94H137N15O41 m/z = 1089.4 [M + 2Na]2+. 
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Synthesis of compound 36b 
 
O
OO
O
N
N
N
O
NN
N
O
N
N
N
O
N
N
N
N
O
NH
O
OH
O OH
OHO
O
OAc
OAc
AcO
AcO
OAcO
OAc
OAc
AcO
OAcO
OAc
OAc
AcO
NH
 
 
To a solution of compound 35b (300 mg 0.14 mmol) in dichloromethane (3 ml) was added, at 0°C, 
triethylsilane (0.112 ml 0.70 mmol,) and trifluoroacetic acid (0.470 ml, 5.74 mmol) The mixture 
was stirred at room temperature for 24 h and monitored by TLC (SiO2; eluent 
dichloromethane/methanol 9:1). After complete conversion of starting material, the solvent was 
evaporated under reduced pressure and the crude was washed several times with chloroform and 
ethyl ether until to obtained compound 36b as white solid without further purification. Yield 78%. 
1H NMR (300 MHz, CDCl3): δ(ppm): 7.93 (bs, 3H, H-Tr); 7.30 (bs, 2H, H-Ar); 5.25-4.80 (m, 15H, 
OCH2Tr, H-4, H-3, H-2); 4.80-4.45 (m, 9H, NCH2CH2O, H-1); 4.40-2.35 (multiplets and bs, 43H, 
H-5, NCH2CH2O, CONHCH2CH2NHCO, NCH2CO, NCH2COOH, NCH2CH2N-crown); 2.05, 2.00, 
1.97, 1.89 (4s, 9H each, OCOCH3). 13C NMR (75 MHz, CDCl3): δ(ppm): 170.7, 170.1, 169.5, 
165.8, 100.4, 72.4, 71.8, 70.8, 68.3, 65.8, 61.7, 40.1, 38.6, 20.7, 20.5. ESI-MS: (+) C82H113N15O41 
m/z = 1035.2 [MNaK+2Na]2+, 1013.3 [MNa+2Na]2+ 1005.3 [M+2Na]2+. 
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Synthesis of compound 37b 
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To a solution of compound 36b (215.6 mg 0.11 mmol) in methanol (30 ml) was added, a solution of 
sodium methoxide until pH is 8-9. The solution was stirred at room temperature for 2h. The reaction 
was monitored by TLC (SiO2; eluent ethyl acetate/iso-propanol/water 5:2:1. After complete 
conversion of starting material, the reaction was quenched by addition of AMBERLITE IR 120 H+ 
resin until neutral pH. The resin was filtered, washing with methanol and the solvent was 
evaporated under reduced pressure to obtained product as beige solid without further purification. 
Yield 81%. 
1H NMR (300 MHz, D2O): δ(ppm): 8.17 (bs, 2H, H-Tr); 7.83 (bs, 1H, H-Tr); 7.30 (bs, 2H, H-Ar); 
5.25 (bs, 4H, OCH2Tr); 5.09 (bs, 2H, OCH2Tr); 4.69 (bs, 4H, NCH2CH2O); 4.56 (bs, 2H, 
NCH2CH2O); 4.45-4.35 (m, 3H, H-1); 4.30-3.93 (m, 6H, NCH2CH2O); 3.90-3.75 (m. 3H, H-6’); 
3.68-2.68 (multiplrts and bs, 43H, H-5, H-3, H-6, H-4, H-2, CONHCH2CH2NHCO, NHCOCH2N, 
CH2COOH NHCH2CH2NH-crown). 13C NMR (75 MHz, D2O): δ(ppm); 172.4, 154.9, 146.0, 141.7, 
133.6, 129.5, 129.4, 110.5, 105.7, 79.2, 78.8, 76.2, 72.9, 71.3, 65.3, 64.0, 53.7, 53.5, 42.9, 41.6, 
33.5. ESI-MS: (+) C58H89N15O29 m/z = 760.9 [M+K+Na]2+, 783.3 [MNa+Na+K]2+. 
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